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Cardiometabolic diseases (CMD) such as cardiovascular disease (CVD) and type 2 diabetes 
mellitus (T2DM), pose a major health burden on the world’s population. Moreover, 
cardiometabolic morbidity and mortality rates are expected to increase over the following decades. 
Sleep duration, sleep fragmentation, sleep timing and sleep architecture have been associated with 
cardiometabolic health and obesity, and warrant exploration as targets for reducing CMD risk.  
Aim and Objectives 
The purpose of this thesis was to evaluate the efficacy of a sleep behaviour intervention and 
consequent effect on cardiometabolic health. A commercial lifestyle intervention programme in 
the Cape Town metropole served as the setting in which the sleep behaviour intervention was 
applied. The participants of this lifestyle intervention programme received psychological support, 
dietary advice and regular group exercise sessions, which, at least in part, controlled for those 
factors, making this a suitable setting for the sleep behaviour intervention study.  
The purpose of this thesis was achieved by the following aims: 
1. To systematically review the effects of sleep extension interventions on cardiometabolic 
risk factors in adults. 
2. To describe and compare the sleep characteristics of adults who are lean, overweight and 
class I obese, and class II obese and to determine the extent to which sleep characteristics 
were associated with cardiometabolic health.  
3. To determine whether the sleep characteristics of individuals with overweight and obesity 
were altered as a result of participation in an eight-week diet and exercise lifestyle 
intervention programme.  
4. To measure the effects of a sleep behaviour intervention within an eight-week diet and 
exercise lifestyle intervention programme on sleep and cardiometabolic health in 
individuals with overweight and obesity, and to determine whether changes in sleep were 
associated with changes in cardiometabolic health.  
Methods 
For the first aim, the PubMed and Scopus databases were searched for relevant, English, peer-
reviewed scientific publications that described the effects of sleep extension on cardiometabolic 
health outcomes in adults (until August 2018). For the second aim, the body mass index (BMI), 
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waist circumference (WC), waist-to-height ratio (WHtr), blood pressure (BP), fasting glucose and 
total cholesterol (TC) levels, Cohen’s perceived stress scale (CPSS) score, and habitual sleep 
characteristics (questionnaire, actigraphy and polysomnography; PSG) of individuals who were 
lean (LEAN), overweight or class I obese (OW-OBI) and class II obese (OBII) were assessed and 
compared. For the third aim, the BMI, WC, WHtr, BP, fasting glucose and TC levels, CPSS score, 
and habitual sleep characteristics (questionnaire and actigraphy) of participants of a diet and 
exercise lifestyle intervention programme who were overweight or obese (HWP) and of individuals 
who did not participate in a lifestyle intervention programme (CON) were assessed and compared 
at baseline and eight weeks later at follow-up. For the fourth and final aim, BMI, WC, WHtr, total 
body fat, lean mass, BP, fasting measures of insulin resistance, lipids, resting metabolic rate (RMR) 
and habitual sleep characteristics (questionnaire and actigraphy) of participants of a lifestyle 
intervention programme with overweight or obesity who were randomly assigned to undergo a 
sleep behaviour intervention (SBI) or not (CON), were assessed and compared at baseline and 
eight weeks later at follow-up.  
Results and Discussion 
The systematic review observed that sleep extension is a viable, implementable intervention which 
may improve measures of insulin sensitivity, appetite and dietary intake. The review provides 
preliminary evidence for a role of sleep extension to improve cardiometabolic outcomes, but also 
highlights the need for studies assessing sleep improvement strategies in larger and more diverse 
cohorts, as well as the long-term sustainability of these interventions.  
In the second study, it was found that the OBII individuals in the intervention component of this 
thesis (n=63) had shorter actigraphy-measured time-in-bed (TiB), shorter total sleep time (TST) 
and lower sleep efficiency (SE) than the OW-OBI group (n=50, TiB: p=0.033; TST: p=0.002; SE: 
p=0.002) and the LEAN group (n=39, TiB: p=0.003; TST: p<0.001; SE: p=0.003). In addition, the 
OBII group had more awakenings >5 min (p=0.028), later bedtimes (p=0.019), less regular sleep 
(p=0.004), and less non-rapid eye movement stage 3 (NREM3) sleep (p=0.006) than the LEAN 
group. Finally, the OW-OBI and OBII groups had higher Pittsburgh Sleep Quality Index (PSQI, 
OW-OBI: p=0.003; OBII: p<0.001) and Epworth Sleepiness Scale (ESS, OW-OBI: p=0.003; 
OBII: p=0.008) scores than the LEAN group. Thus, individuals with class II obesity had more 
fragmented and irregular sleep, shorter sleep durations, less NREM3 sleep, worse subjective sleep 
quality, and more daytime sleepiness than their counterparts with overweight and class I obesity 
and those who are lean. This sleep impairment may put them at risk for future cardiometabolic 
complications, which in turn may perpetuate sleep impairment.  
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In the third study, the HWP group (n=31) reduced their BMI (effect size (ES): 1.015, p<0.001), 
WC (ES: 1.075, p<0.001) WHtr (ES: 1.073, p<0.001) and CPSS score (ES: 0.530, p=0.009) 
compared to the CON group (n=23), while no measurable changes in their sleep characteristics 
were observed. It was thus concluded that the eight-week lifestyle intervention programme does 
not per se cause changes in sleep, despite improvements in anthropometric measures. Since these 
findings suggest that participation in a diet and exercise lifestyle intervention programme alone 
does not halt or reverse the vicious cycle between poor sleep and cardiometabolic impairment, it 
must be explored whether the inclusion of a sleep behaviour intervention may confer additional 
benefits.  
In the final study, the SBI group (n=15) demonstrated earlier get-up times (ES: -0.811, p=0.035) 
and midpoints of sleep (ES: -0.815, p=0.034) than the CON group (n=15) in response to the 
intervention. Changes in sleep duration, sleep fragmentation or sleep timing were not different 
between the SBI and CON groups. SBP (ES: 0.627, p=0.039) and RMR (ES: 1.110, p=0.007) 
increased, and glycated haemoglobin (HbA1c) decreased (ES: -0.784, p=0.049) in the SBI group 
over the course of the programme. Furthermore, with the SBI and CON groups combined, change 
in TC and change in RMR correlated with change in SRI (TC: ⍴=0.565, p=0.002, n=27; RMR: 
⍴=0.612, p<0.001, n=27). These findings suggest that sleep modulation in individuals with 
overweight and obesity may result in cardiometabolic benefits, and that HbA1c, RMR and SBP 
may be more sensitive to changes in sleep timing than anthropometric measures and lipids.  
Conclusion 
The findings in this thesis support a role for sleep improvement strategies to improve 
cardiometabolic health. Before implementing a sleep behaviour intervention in new or existing 
lifestyle, wellness or incentive programmes, aspects such as format and content, participant 
selection, and screening for underlying sleep disorders and psychological conditions must be 
considered in order to maximise the efficacy of the sleep intervention. Further research is needed 
to confirm the findings of the present study in alternative settings, and to determine how 
participants who may benefit from a sleep behaviour intervention for the betterment of 















1.1 Introduction and scope of the thesis 
Cardiometabolic diseases (CMD) such as cardiovascular disease (CVD) and type 2 diabetes 
mellitus (T2DM), pose a major health burden on the world’s population. Recent global statistics 
indicate that 17.9 million and 5.0 million people die annually from CVD and T2DM respectively. 
CMD morbidity and mortality are expected to increase globally in the next few decades due to 
changes towards a more sedentary lifestyle and higher rates of urbanisation. These numbers of 
CMD morbidity are also expected to increase due to increasing life expectancy of individuals with 
CMD, and availability of more accurate and complete data (Cho et al., 2018). An important risk 
factor for these and other non-communicable diseases (NCD) is obesity, which is estimated to 
account for 3.4 million deaths annually world-wide (World Health Organization, 2015).  
An overwhelming amount of evidence has been published to suggest that cardiometabolic health 
is associated with sleep health (Rangaraj and Knutson, 2016). Generally, these studies show that 
individuals with poor cardiometabolic health and CMD are more likely to have impaired sleep, 
which may lead to further deterioration of their cardiometabolic health, thus perpetuating the 
vicious cycle between cardiometabolic health and poor sleep (Lucassen et al., 2012). This thesis 
focused on the improvement of sleep for the betterment of cardiometabolic health. Despite sleep 
encompassing a wide range of measures, this thesis will predominantly focus on measures that 
directly relate to cardiometabolic health, specifically sleep duration, fragmentation, timing, and 
architecture. 
1.2 An introduction to sleep and sleep health 
Carskadon and Dement (2011) defined sleep as “a reversible behavioural state of perceptual 
disengagement from and unresponsiveness to the environment” (Carskadon and Dement, 2011). 
Sleep is recurring, essential and covers approximately one-third of the human life span. One 
explanation for why we sleep may be to undertake essential biological activities to allow for optimal 
performance during the period we are best adapted to, namely daytime (Foster, 2018). These 
activities may be more efficient, or only possible, when the body is at rest, the sensory input is low, 
and the energy-requirement for other activities is decreased, which is the case during sleep. It 
makes sense that these activities occur at the time-of-day to which we are poorly adapted, namely 
night-time, and that we are thus adapted to sleep during this period.  
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1.2.1 Function of sleep 
Because the effects of insufficient sleep may manifest in multiple ways, it is likely that sleep does 
not serve one, but several different functions (Krueger et al., 2016). Our current understanding 
about functions of sleep have been reviewed by Krueger et al. (2017) and include ensuring proper 
immune function, reducing caloric use, replenishing energy stores in the brain, clearing waste 
products of neural metabolism from the brain, restoring cognitive and behavioural performance 
degradation induced by wakefulness, and allowing brain plasticity and memory consolidation 
(Krueger et al., 2016). Insufficient and poor quality sleep have also been associated with 
cardiometabolic impairments, which are discussed in Section 1.5. 
1.2.2 Regulation of sleep 
The regulation of normal sleep has been described as the product of two interacting mechanisms, 
the homeostatic process and the circadian process, and is referred to as the two-process model of 
sleep regulation (Borbely et al., 2016). The homeostatic process represents an increasing propensity 
to sleep during wakefulness. This sleep propensity then decreases during sleep. The circadian 
process counteracts the sleep homeostat by regulating alertness in a time-of-day-based sinusoidal 
matter. For most individuals, sleepiness sets in during the evening, when the homeostatic sleep 
propensity is at its highest, and the circadian alerting is diminished, which will lead to the 
preparation for bedtime and ultimately sleep (Borbely et al., 2016). Together, these two processes 
ensure that sleep occurs at approximately the same time-of-day, which is referred to as the 
regularity of sleep timing, which may be measured with the sleep regularity index (SRI) (Phillips et 
al., 2017). The interaction of the circadian and homeostatic processes also decreases the chance 
that sleep is interrupted. This unintentional discontinuation of sleep may be referred to as sleep 
fragmentation, and is often measured through sleep efficiency (SE, percentage of time-in-bed 
(TiB) spent sleeping), wake after sleep onset (WASO, time spent awake between initial sleep onset 
and final awakening), and the number of awakenings (expressed in duration or in occurrences per 
hour of sleep time) (Berry et al., 2018). 
1.2.3 Sleep architecture 
During a typical night, human adults cycle through different types of sleep with distinguishable 
electroencephalographic (EEG) patterns called sleep stages. The distribution and duration of these 
sleep stages within each sleep period is called sleep architecture. These sleep stages can be 
categorized into rapid eye movement (REM) and non-rapid eye movement (NREM) sleep stages 
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(McCarley, 2007). NREM sleep may be further divided in three sleep stages with increasing arousal 
thresholds (i.e. the intensity of stimuli required to wake up), namely NREM1, NREM2, and 
NREM3 sleep.  
NREM1 sleep is characterised by low-amplitude, mixed frequency (predominantly 4-7 Hz) EEG 
activity, and slow eye movements. Upon progression into NREM2 sleep, short bursts of fast 
oscillations (11-16 Hz) called sleep spindles, and single slow wave forms, called K-complexes, 
become visible on the EEG channel, specifically over the frontal and central brain regions. These 
K-complexes become more common as sleep progresses into NREM3 sleep, until slow wave 
activity (0.5-2 Hz) predominates the EEG channel. Due to these slow oscillations, NREM3 sleep 
is also referred to as slow wave sleep (Berry et al., 2018). The last sleep stage is REM sleep, which 
is not only characterized by rapid movements of the eye, but also by muscle atonia.  
Transitions to a lighter sleep stage, or to wakefulness, can occur from any sleep stage. When such 
transitions are paired with a sudden increase in EEG frequency, and, if a transition from REM 
sleep occurs, a concurrent increase in chin electromyography (EMG) activity, they are called 
‘arousals’ (Berry et al., 2018). 
1.2.4 Sleep health 
To ensure optimal mental and physical health, good sleep health is essential. While it is 
recommended that human adults sleep for 7–9 h in a 24-h period (Hirshkowitz et al., 2015), sleep 
duration alone is not sufficient to define good sleep health. Other dimensions of sleep are 
important too. While a global definition of sleep health is work in progress, it was suggested that 
such measure should incorporate sleep satisfaction, alertness/sleepiness, sleep timing, sleep 
continuity (a measure of how interrupted sleep is), and duration (Buysse, 2014). The American 
National Sleep Foundation recommends criteria that constitute good sleep quality, which may be 
used to determine sleep health (Ohayon et al., 2017). The difference between sleep quality and 
sleep health is that the first describes how good or bad sleep itself is, whereas the latter takes into 
account the effects of sleep on health and daytime functioning, such as satisfaction and sleepiness. 
As such, sleep quality is an important component of sleep health.  
Sleep is mainly an unconscious process, meaning that individuals have no direct control over the 
onset of sleep, the depth of sleep, or unwanted awakenings. However, certain behaviours may 
positively influence these aspects of sleep, and are called sleep hygiene. Common sleep hygiene 
recommendations include: avoiding or minimizing caffeine, nicotine and alcohol intake at specific 
times-of-day; exercising regularly, but not too close to bedtime; managing and avoid stress during 
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the day, so it can be kept out of the bedroom; minimizing noise in the bedroom; ensuring regular 
bedtimes and get-up times; and avoiding daytime napping (Irish et al., 2015).  
1.3 Measurement of sleep 
Because of the complexity of sleep, no single measure of sleep exists. Instead, various behavioural, 
neurological and subjective measures may be used to describe aspects of sleep.  
1.3.1 Polysomnography 
The gold standard method for determining sleep architecture is polysomnography (PSG), which, 
relies on EEG to detect brain activity, electrooculography (EOG) to detect eye-movements and 
EMG to detect muscle activity during sleep. The PSG recording of the entire sleep period is 
divided into epochs (usually 30 s in duration), which are scored individually based on rules 
originally set by Rechtschaffen and Kales (Rechtschaffen et al., 1968) or varieties thereof. The 
most commonly-used set of rules to score sleep, especially in sleep medicine, are those by the 
American Academy of Sleep Medicine (Berry et al., 2018). In additional to EEG, EOG, and EMG, 
other channels such as electrocardiography (ECG), pulse oximetry, nasal and oral airflow, thorax 
and abdominal respiration, may be included in PSG depending on the test requirements. These 
additional channels are usually included to detect sleep disorders such as sleep-disordered 
breathing. Although PSG is the gold standard for assessing sleep, PSG is invasive, costly, and not 
representative of habitual sleep, especially when done in the clinical environment of a sleep 
laboratory, which is often the case.  
1.3.2 Actigraphy 
A common tool for the assessment of habitual sleep is actigraphy, which involves the detection of 
movements, usually via a wrist-worn accelerometer. Since actigraphy is cost-effective and non-
invasive, it can be used to monitor several days or weeks of sleep. This makes actigraphy superior 
for assessing habitual sleep patterns, including timing and regularity. Actigraphy relies only on 
body movement, and since the absence of movement does not always imply sleep, actigraphy-
assessed sleep duration is usually over-predicted compared to PSG-assessed sleep duration 
(Jackson et al., 2018). On-device annotation and sleep diaries are often used to increase accuracy 
of defining bedtimes and get-up times of the main sleep period. Actigraphy is not suitable to 
measure or predict sleep architecture as sleep stages cannot be accurately distinguished by 
movements alone.  
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1.3.3 Subjective sleep measures 
In addition to the objective aspects of sleep, sleep can also be assessed subjectively. Subjective 
sleep measures may relate to the perceived quality of sleep, daytime sleepiness or fatigue, risk for 
sleep disorders, or self-reported measures of sleep timing, duration, latency or disturbances. While 
many subjective tools have been developed, it is beyond the scope of this thesis to present tools 
other than those used in the experimental chapters. 
Subjective sleep quality is difficult to define as many elements contribute to “good” sleep. A 
widely-used tool for the assessment of subjective sleep quality is the Pittsburgh Sleep Quality Index 
(PSQI) questionnaire, which comprises 19 questions relating to sleep habits and provides scores 
on seven components, as well as a global sleep quality score (sum of the component scores) and 
self-reported bedtime, get-up time, sleep onset latency (SOL), and sleep duration (Buysse et al., 
2002). Another subjective measure, which is used to assess the effect of habitual sleep on daytime 
sleepiness, is the Epworth Sleepiness Scale (ESS) (Johns, 1991). Based on the likeliness of dozing 
off in eight different scenarios, the ESS assigns each individual a ‘sleepiness score’ between 0 and 
24, with higher scores indicating greater levels of daytime sleepiness. 
Lastly, subjective sleep measures may be used to assess an individual’s sleep duration, SOL, or 
number and duration of awakenings, usually in response to a single question. Although self-
reported sleep assessments are cost-efficient and simple to use, they may overestimate sleep 
duration compared to objectively measured sleep duration, especially when sleep fragmentation is 
high (Cespedes et al., 2016, Jackson et al., 2018).  
1.4 An introduction to circadian rhythms 
Most physiological processes including metabolism (Huang et al., 2011), bowel movement 
(Hoogerwerf, 2006), cell regeneration (Huang et al., 2011), and hormone secretion (Moore and 
Klein, 1974, Moore and Eichler, 1972) exhibit circadian (i.e. approximately 24 h) variation. These 
so-called circadian rhythms are controlled by a system of molecular clocks, which can be found in 
virtually all cells (Patke et al., 2020), and which oscillate with a period of about 24 h. The circadian 
clocks in cells that share a common function (e.g. liver cells, heart cells) oscillate in unison, which 
allows the time-dependent physiological processes in organs to be aligned (Rietveld, 1992). The 
rhythms of these peripheral clocks are orchestrated by two clusters of cells in the hypothalamus, 
called the suprachiasmatic nuclei (SCN), which allows for the alignment between the circadian 
rhythms in organs (Rietveld, 1992) and synchronisation to the external light environment. The 
function of the system of circadian clocks is to anticipate time-of-day-related changes to the 
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environment, and to regulate physiological processes on a molecular, cellular, organ and organism 
level. For example, circadian rhythms make the suppression of bowel movement and urine 
secretion at night possible to allow uninterrupted nocturnal sleep (Hoogerwerf, 2006, Cho et al., 
2011). Circadian rhythms also allow an increase in metabolic activity during the day in anticipation 
of food intake (Huang et al., 2011).  
The circadian clocks oscillate endogenously and can be synchronised or entrained to the 
environment through external time cues, commonly referred to as zeitgebers. The most important 
time cue for the SCN is light, which is captured by the photopigment melanopsin found in the 
intrinsically photosensitive retinal ganglion cells in the retina (Berson, 2007). Information about 
light exposure is then projected to the SCN via the retinohypothalamic tract, where it may delay 
or advance the phase (i.e. timing) of the SCN’s circadian rhythm, allowing alignment with the light-
dark cycle resulting from the Earth’s rotation around its own axis. Other time cues include food 
intake (Feillet et al., 2006), exercise (Mrosovsky, 1996), and possibly social interactions (Grandin 
et al., 2006).  
Naturally, some variation in the timing of circadian clocks relative to environmental and social 
time exists between individuals (Roenneberg et al., 2003). This characteristic is observed 
behaviourally as one’s chronotype, or diurnal preference. Those with a strong preference for 
mornings (i.e. retiring and rising earlier) are on one end of the chronotype spectrum, those without 
a strong preference for either mornings or evenings are in the middle of the spectrum, while those 
with a strong preference for evenings (i.e. retiring and rising later) are on the other end of the 
spectrum. Various tools have been developed to asses a person’s chronotype, such as the Horne-
Östberg morningness-eveningness personality questionnaire (HÖ-MEQ) (Horne and Ostberg, 
1976), and the Munich chronotype questionnaire (Roenneberg et al., 2003).  
1.4.1 Circadian disruption 
When an individual’s system of circadian clocks does not appropriately anticipate time-of-day, 
resulting in impaired daytime functioning or health, we speak of circadian disruption. One form 
of circadian disruption may be caused by an extremely late or early chronotype, such that an 
individual’s circadian clock is anticipating night-time during daytime and vice versa. In more extreme 
cases, an individual may be diagnosed with a circadian rhythm disorder, such as advanced or 
delayed sleep phase disorder. Individuals with later chronotypes are more likely to develop 
cardiometabolic impairment (Merikanto et al., 2013), which is further discussed in Section 1.5.4. 
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Another form of circadian disruption is social jet lag, which is the misalignment between the 
circadian clock time, or chronotype, and social time (related to social obligations such as work and 
family) (Wittmann et al., 2006). Social jet lag is the difference between the time of the midpoint of 
sleep on working days, mainly driven by the social clock, and the time of the midpoint of sleep on 
free days, mainly driven by the circadian clock. The larger social jet lag is, the higher the 
misalignment between circadian and social time, and the higher the risk of daytime sleepiness and 
sleep deprivation. Social jet lag has been associated with obesity (Roenneberg et al., 2012) and 
other aspects of cardiometabolic health, which are also further discussed in Section 1.5.4.  
To ensure proper circadian functioning, circadian rhythms must be of sufficient amplitude, so that 
differences between the peak and trough of the circadian rhythm of any physiological process or 
behaviour is prominent. For example, when the circadian amplitude of alertness is attenuated, not 
only could the individual be less alert during the day but also more alert during night-time, which 
may impair nocturnal sleep. Indeed, sleep disturbances have been associated with a decreased 
circadian amplitude of melatonin (Pandi-Perumal et al., 2009). Moreover, attenuated circadian 
amplitudes of body temperature and heart rate have been associated with T2DM (Gubin et al., 
2017).  
Circadian disruption may have an external origin, related to zeitgebers, or have an internal origin, 
related to the zeitgeber reception or circadian clock. For example, circadian disruption may be 
caused by exposure to zeitgebers at the wrong time-of-day (e.g. exposure to bright light in the 
middle of the night) or by weak zeitgebers (e.g. working in an office with low-intensity lights), 
which makes the synchronisation of the circadian clock to the Earth’s light-dark cycle difficult. On 
the other hand, independent of zeitgebers, blindness (Sack et al., 1992), eye lens opacity (Kessel et 
al., 2010), neurodegeneration (Videnovic et al., 2014), and mutations in the genes involved in 
circadian regulation (Barnard and Nolan, 2008), may also result in circadian disruption. Where 
circadian disruption has an external origin, behavioural factors such as night-time bright-light 
exposure, caffeine consumption, and irregular bedtimes may be addressed to improve circadian 
health (Swanson and Burgess, 2017).  
1.5 Cardiometabolic impairment and poor sleep: a vicious cycle 
1.5.1 Cardiometabolic health 
Risk factors that predispose an individual to CMD include abdominal obesity, hypertension, 
hyperglycaemia, hyperlipidaemia, and hypertriglyceridaemia (Eckel et al., 2005). The co-occurrence 
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of three or more of these CMD risk factors considerably increases an individual’s risk of 
developing CMD, and is historically referred to as the metabolic syndrome (MetS), or simply ‘high 
cardiometabolic risk’ (Grundy et al., 2005). The associations between CMD and risk factors thereof 
for four aspects of sleep; sleep duration, sleep fragmentation, sleep timing, and sleep architecture, 
will be summarized in the sections below.  
1.5.2 Cardiometabolic health and sleep duration 
Studies that report on the associations between short sleep duration and cardiometabolic outcomes 
may either refer to chronic (i.e. habitual) or acute (i.e. sleep restriction) short sleep duration. With 
regards to the association between habitual short sleep duration and cardiometabolic health, 
evidence from both cross-sectional and prospective studies are available.  
In cross-sectional studies, both self-reported and objective short sleep duration have been 
associated with metabolic disturbances, including the development of obesity, hypertension, 
diabetes and cardiovascular disease (Taheri et al., 2004, Lauderdale et al., 2009, Buxton and 
Marcelli, 2010). Higher levels of glycated haemoglobin (HbA1c) were associated with self-reported 
short sleep duration (<6 h) in T2DM outpatients, independent of known confounding factors 
(Martorina and Tavares, 2019). Another study found that the association between self-reported 
short sleep duration and increased adiposity was stronger in women than in men (St-Onge et al., 
2010). Likewise, women, but not men, who reported sleeping ≤5 h per night were at a greater risk 
for hypertension (blood pressure (BP) ≥140/90 mmHg) or using hypertensive medication than 
those who reported sleeping for 7 h per night (Cappuccio et al., 2007). This increased hypertensive 
risk was also found in women who reported sleeping <6 h per night compared to women who 
reported sleeping ≥6 h per night, and this association was stronger in premenopausal than 
postmenopausal women (Stranges et al., 2010). Lastly, women who reported short sleep durations 
(≤5 h) had elevated levels of high-sensitivity C-reactive protein (CRP) a marker of acute-phase 
inflammation (Miller et al., 2009).  
Prospective cohort studies have shown that a self-reported short sleep duration (≤5 h (Yeo et al., 
2013) or <6 h (Magee et al., 2013) per night) was associated with higher all-cause and CVD 
mortality. Moreover, women who reported sleeping ≤5 h or <6 h per night, had an increased risk 
of developing hypertension within the following 5 years, compared to women who reported 
sleeping 7 h per night (Cappuccio et al., 2007).  
Acute short sleep duration, or sleep restriction, has also been associated with cardiometabolic 
impairment in various experimental design studies. For example, sleep deprivation for only one 
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night was associated with elevated afternoon/evening cortisol levels, which in turn was associated 
with abdominal obesity and insulin resistance, both major risk factors for T2DM (Omisade et al., 
2010). Moreover, two nights of sleep restriction (4 h TiB) in twelve healthy men resulted in a 
reduction in leptin (appetite-supressing hormone), an increase in ghrelin (appetite-stimulating 
hormone), and an increase in hunger and appetite (Spiegel et al., 2004c), which may increase food 
intake, and subsequently increase risk for weight-gain and obesity. Lastly, five nights of sleep 
restriction (4 h TiB) decreased whole-body and skeletal muscle and adipose tissue-specific insulin 
resistance in 14 healthy men and women (Rao et al., 2015).  
Knutson and Van Cauter (2008) and Lucassen et al. (2012) have proposed similar models to explain 
how short sleep duration may be related to the development of obesity and T2DM. The authors 
suggested that on one hand, short sleep duration could result in an increase in sympathetic nervous 
system activity as well as an increase in evening cortisol, night time growth hormone levels and 
pro-inflammatory cytokines, all of which may contribute to increasing insulin resistance and 
decreasing glucose tolerance, which in turn may lead to T2DM. On the other hand, short sleep 
duration has been associated with increased orexin and ghrelin levels (Taheri et al., 2004), and 
decreased leptin levels (Mullington et al., 2003). This may increase appetite, which, in addition to 
short sleep duration leaving a person more time to eat, could potentially increase food intake, 
which contributes to the development of obesity if energy expenditure remains low (Knutson & 
Van Cauter, 2008; Lucassen et al., 2012).  
1.5.3 Cardiometabolic health and sleep fragmentation 
Sleep fragmentation has been associated with anthropometric measures and other aspects of 
cardiometabolic health. For example, various studies have shown that obesity and a higher body 
mass index (BMI) are associated with measures of sleep fragmentation, such as the fragmentation 
index (amount of interruption of sleep measured by physical movement)(van den Berg et al., 2008, 
Lauderdale et al., 2009) and frequency of awakenings (Corbalan-Tutau et al., 2012). Moreover, 
middle-aged women, but not men, who reported waking up several times per night were more 
likely to experience major weight gain (>5 kg) over the following five to seven years than those 
who did not report any frequent sleep problems (Lyytikäinen et al., 2010). Sleep fragmentation 
may not only be associated with weight gain, it may also make weight-loss more difficult. For 
example, women with overweight and obesity who had five or more wake episodes per night (from 
actigraphy) experienced less weight loss in response to a seven-month weight-loss intervention 
compared to those with less than five wake episodes per night (Sawamoto et al., 2014). 
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Interestingly, sleep fragmentation seems to be associated with waist circumference (WC), 
independent of BMI, suggesting that different mechanisms link sleep fragmentation with general 
and abdominal adiposity (Mezick et al., 2014). This association was only found in women, 
however, and there may be important sex differences in the association between sleep 
fragmentation and adiposity. Higher SE, a measure that correlates with sleep fragmentation, has 
also been associated with adverse cardiometabolic health, namely obesity and higher diastolic BP 
(DBP) (Resta et al., 2003, Corbalan-Tutau et al., 2012). 
Moreover, two days of experimentally induced sleep fragmentation in individuals who were healthy 
decreased insulin sensitivity and glucose effectiveness (the insulin-independent and glucose-
dependent uptake of glucose and suppression of glucose production), while morning cortisol levels 
and sympathetic nervous system activity increased (Stamatakis and Punjabi, 2010). Furthermore, 
experimentally-induced sleep fragmentation increased insulin secretion, decreased glucagon-like 
peptide 1 (stimulates insulin secretion, reduces appetite (Holst, 2007)), reduced fat oxidation and 
increased carbohydrate oxidation in healthy males (Gonnissen et al., 2013, Hursel et al., 2011). 
An important cause of sleep fragmentation is obstructive sleep apnoea (OSA) which may be found 
in 9 to 38% of individuals in populations of many industrialised regions around the globe excluding 
Africa (Senaratna et al., 2017). OSA is a condition where the flow of air into the lungs repeatedly 
decreases or ceases completely as a result of narrowing of the upper airway. This cessation in 
airflow results in frequent oxygen desaturation, followed by an arousal from sleep, often 
accompanied with gasps for air. OSA has been associated with obesity (Punjabi, 2008), 
hypertension (Kapa et al., 2008), cardiovascular disease (Newman et al., 2001), insulin resistance 
(Ip et al., 2002), and all-cause mortality (Marshall et al., 2008). It remains unknown whether 
intermittent hypoxia, sleep fragmentation, or both drive cardiovascular impairment in OSA. On 
one hand, sleep fragmentation was found to be independently associated with dyslipidaemia in 
patients with OSA (Qian et al., 2016), suggesting that sleep fragmentation alone may impair the 
lipid profile. Moreover, experimentally induced sleep fragmentation in mice, without intermittent 
hypoxia, resulted in higher counts of monocytes and neutrophils, which suggests an increased pro-
inflammatory state, and more severe atherosclerosis (McAlpine et al., 2019). Indeed, sleep 
fragmentation in humans was linked to a higher neutrophil count and higher coronary artery 
calcification (Vallat et al., 2020). Sleep fragmentation without intermittent hypoxia has also been 
shown to increase sympathetic nervous system activation (Ferreira et al., 2020), vascular 
endothelial dysfunction and BP (Carreras et al., 2014). On the other hand, however, 30 days of 
experimentally induced sleep fragmentation did not alter structural or functional 
echocardiographic outcomes in mice (Cabrera-Aguilera et al., 2019). Moreover, the pathway for 
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intermittent hypoxia-driven cardiometabolic impairment is evident and well understood (Levy et 
al., 2015). In conclusion, the contribution of intermittent hypoxia and sleep fragmentation to 
cardiometabolic impairment in OSA is complex and may differ between specific types of 
cardiovascular and metabolic impairment, between different levels of hypoxia and sleep 
fragmentation severity, and between different durations of the presence of hypoxia and sleep 
fragmentation (e.g. months or years).  
While extensive work has been carried out on the association between cardiometabolic health and 
OSA, more research is needed on the association between cardiometabolic health and other 
dimensions of sleep. Therefore, this thesis will focus on sleep duration, sleep fragmentation, sleep 
architecture, and sleep timing separately from OSA.   
1.5.4 Cardiometabolic health and sleep timing 
Another important factor in the relationship between cardiometabolic health and sleep is sleep 
timing and derivatives thereof. For example, one study showed that individuals who prefer later 
bedtimes are more likely to have T2DM and arterial hypertension than individuals who prefer 
earlier bedtimes, independent of sleep duration (Merikanto et al., 2013). Another study found that 
later sleep timing (midpoint of sleep ≥5:30) was associated with more calories consumed after 
20:00, but not with BMI, after adjusting for sleep duration (Baron et al., 2011). On the other hand, 
advancing bedtime resulted in an increased intake of low glycaemic index foods, fruit and dairy in 
adolescents (Asarnow et al., 2017).  
Moreover, sleep/wake pattern regularity has also been associated with measures of 
cardiometabolic health. For example, a larger variability in bedtime was associated with an higher 
BMI and insulin resistance in middle-aged women (Taylor et al., 2016), and a lower SRI in older 
adults was associated with an increased ten-year risk of CVD, T2DM, obesity, hypertension, and 
higher levels of fasting glucose and HbA1c (Lunsford-Avery et al., 2018).  
Lastly, social jet lag has been identified as a contributor to poor cardiometabolic health as well. 
This circadian misalignment has been associated with a higher BMI (Roenneberg et al., 2012), 
higher prevalence of being overweight or obese (Mota et al., 2017, Parsons et al., 2015), higher 
fasting glucose levels (Mota et al., 2017), the metabolic syndrome (Parsons et al., 2015), and the 
presence of more cardiometabolic risk factors (Wong et al., 2015).  
Sleep timing, sleep regularity and social jet lag are associated with cardiometabolic health because 
they relate to circadian health, which has been shown to be associated with adverse 
cardiometabolic health. For example, a simulated shift work protocol, leading to circadian 
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misalignment, resulted in increased waketime BP and 24 h average SBP and DBP, and increased 
inflammatory markers interleukin (IL)-6, C-reactive protein (CRP), resistin, and tumour necrosis 
factor (TNF)-ɑ (Morris et al., 2016, Morris et al., 2017). Other endocrinologic consequences of 
circadian disruption includes decreased leptin levels, which has been shown in 14 healthy 
participants following 25 light-dark cycles of 24.6 h (the duration of a day on Mars) (Nguyen and 
Wright, 2010). Forced-desynchrony, a method of inducing circadian disruption by exposing 
individuals to a non-24 h light-dark cycle, thus preventing circadian alignment, resulted in increased 
blood glucose and insulin levels, reversed daily cortisol rhythm, and increased arterial pressure in 
a study with ten adults (Scheer et al., 2009). Circadian misalignment may also impair autonomic 
nervous system function, which has also been associated with CVD risk (Grimaldi et al., 2016). 
Experimentally-induced circadian disruption in humans and mice has also been associated with 
altered rhythms of composition and function of the intestinal microbiota, resulting in glucose 
intolerance and obesity (Thaiss et al., 2014). Furthermore, polymorphisms within the genes that 
are involved in circadian rhythmicity (CLOCK, BMAL1 and PER2) have been associated with 
obesity, metabolic syndrome, eating disorders and T2DM (Garaulet and Madrid, 2009, Garaulet 
et al., 2010, Garaulet et al., 2011, Sookoian et al., 2008).  
Lifestyle-driven circadian disruption, such as that seen in shift workers and those with social jet 
lag, has also been associated with poor cardiometabolic health. For example, shift work has been 
associated with an increased risk for obesity and cardiometabolic impairment (Di Lorenzo et al., 
2003, Karlsson et al., 2001), and coronary heart disease (Vetter et al., 2016). An additional effect 
of circadian disruption, however, is disrupted sleep, which, as has been discussed in the previous 
sections and following section, may further contribute to cardiometabolic impairment (Dijk and 
von Schantz, 2005). Moreover, circadian disruption in combination with sleep restriction, which 
often occurs in shift workers, decreases resting metabolic rate (RMR) and pancreatic insulin 
secretion after a meal, which lead to increased blood glucose level (Buxton et al., 2012). In addition, 
individuals with social jet lag have an increased risk for obesity and CMD (Roenneberg et al., 2012, 
Wong et al., 2015). Thus, sleep timing and derivatives thereof, as they relate to circadian disruption 
are directly linked to cardiometabolic health.  
1.5.5 Cardiometabolic health and sleep architecture 
Sleep architecture has been associated with cardiometabolic health in cross-sectional studies. For 
example, community-dwelling older (≥65 y) men with the least time spent in NREM3 sleep had 
increased odds for obesity compared to those with the most time spent in NREM3 sleep (Rao et 
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al., 2009). Moreover, in obese adolescents, less NREM3 was associated with decreased insulin 
secretion following an intravenous glucose tolerance test, even after correcting for degree of 
obesity, pubertal stage, sex and obstructive sleep apnoea (Koren et al., 2011).  
Experimental studies have also shown associations between cardiometabolic health and sleep 
architecture. For example, in a cross-over trial, Tasali et al. (2008) demonstrated that NREM3 sleep 
suppression lead to decreased insulin sensitivity in healthy adults, suggesting that NREM3 sleep is 
important for maintaining normal glucose homeostasis (Tasali et al., 2008). Furthermore, 
experimental reductions in NREM3 and REM sleep have been shown to increase appetite, 
carbohydrate and fat consumption, and energy intake in apparently healthy adults (Shechter et al., 
2012). Experimental NREM3 suppression in healthy men resulted in reduced insulin sensitivity, 
while experimental REM sleep disturbance did not affect glucose tolerance (Herzog et al., 2013). 
Combined, these cross-sectional and experimental studies suggest that compromised sleep 
architecture, specifically decreased NREM3 sleep, may increase risk for obesity and T2DM. 
1.6 Lifestyle intervention programmes 
A range of interventions have been explored to curb the rise of obesity and ultimately reduce risk 
for CMD, of which nutrition and exercise modulation are possibly the most common (Fontana et 
al., 2007). Both interventions aim to induce an energy deficit via strategies such as calorie 
restriction, increased energy expenditure and boosting of metabolic rate, and have been shown to 
be successful in improving body composition, blood lipids and insulin sensitivity in healthy 
(Fontana et al., 2007, Wu et al., 2009), and diabetic populations (Kelley et al., 1993). Despite 
effective short-term improvements in weight loss and cardiometabolic health, adherence and 
partial weight regain are common challenges in both nutrition and exercise interventions, and 
necessitate exploring alternative or additional interventions (Wu et al., 2009).  
Given the associations between short sleep duration, sleep fragmentation, delayed and irregular 
sleep timing and decreased NREM3 sleep with an increased likelihood for developing obesity and 
CMD, an intriguing question is whether or not improving these aspects of sleep might reverse 
some of the associated cardiometabolic risk factors. Surprisingly few studies have studied the 
effects of sleep modulation on reducing risk for developing obesity and CMD (Haack et al., 2013, 
Leproult et al., 2015, Al Khatib et al., 2018, Tasali et al., 2014, Reynold et al., 2014, Kubo et al., 
2011). In one study, experimental extension of sleep duration by almost 3 h per night, lead to an 
increase in insulin sensitivity, assessed with the oral glucose tolerance test, in short-sleeping (<6.5 
h) healthy male adults (Killick et al., 2015). Others found that advancing the bedtime of adolescents 
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resulted in increased intake of low glycaemic index foods, fruit and dairy (Asarnow et al., 2017). 
While this topic is discussed in more detail in Chapter 2, more research is needed to assess whether 
improving sleep in individuals who are at risk for developing CMD could improve their 
cardiometabolic health.  
1.7 Purpose of thesis 
The aim of this thesis is to investigate whether a sleep behaviour intervention, aimed at improving 
nocturnal sleep over a period of eight weeks, can improve anthropometric measures of BMI, WC, 
waist-to-height ratio (WHtr), total body fat and lean mass, and improve cardiometabolic health 
outcomes in individuals with overweight and obesity (Chapter 5). This aim will be achieved by 
first systematically reviewing the literature about sleep extension interventions to improve 
cardiometabolic health, by describing their strengths and weaknesses and identifying knowledge 
gaps (Chapter 2). Next, the sleep habits of individuals with overweight and obesity recruited from 
the location where the sleep behaviour intervention study takes place will be described (Chapter 
3). Since this research project makes use of an eight-week diet and exercise lifestyle intervention 
programme open to the public as the setting for the sleep behaviour intervention, any effects this 
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It was estimated that non-communicable diseases (NCDs) accounted for 38 million deaths globally 
in 2012 (World Health Organization, 2015) and are projected to further increase to 52 million by 
2030 (Mathers and Loncar, 2006). Currently, the main contributor to NCD mortality is 
cardiovascular disease (CVD), which accounts for 37% of all NCD deaths globally (World Health 
Organization, 2015). The prevalence of obesity, a major NCD risk factor, and type II diabetes 
mellitus (T2DM) are also increasing each year. Globally 10.8% of males and 14.9% of females 
were obese in 2014 and these numbers are estimated to rise to 18% and 21% in males and females 
respectively by 2025 (Ncd-RisC, 2016a). Similarly, the prevalence of T2DM was 9.0% and 7.9% in 
2014 in males and females respectively and it is estimated that 12.8% and 10.4% respectively of 
men and women globally will be diagnosed with T2DM by 2025 (Ncd-RisC, 2016b). To decrease 
the current and future burden of NCDs, especially obesity and cardiometabolic diseases (CMD), 
new interventions are being developed, assessed and validated. 
Mounting evidence is available to suggest that sleep is key to an individual’s health. Prospective 
studies and meta-analyses have shown that both short and long sleep durations (self-reported) 
increase risk for mortality and developing, or dying from, coronary heart disease and stroke 
(Cappuccio et al., 2011, Cappuccio et al., 2010, Gallicchio and Kalesan, 2009, Kripke et al., 2002). 
While both short and long sleep are associated with health risks, for the purpose of this review we 
will focus solely on short sleep, defined as <7 h per night, unless otherwise specified.  
Epidemiological studies report consistent relationships between short sleep duration and increased 
risk for mortality, T2DM, hypertension, CVD, stroke, coronary heart disease, overweight and 
obesity, weight gain, hyperglycaemia and impaired glucose tolerance (Anothaisintawee et al., 2016, 
Bliwise et al., 2017, Cappuccio et al., 2008, Chao et al., 2011, Gottlieb et al., 2005, Gottlieb et al., 
2006, Itani et al., 2017, Knutson et al., 2009, Patel and Hu, 2008, Roda et al., 2016, Sasaki et al., 
2016, Sperry et al., 2015, Walatara et al., 2016, Wu et al., 2014). Furthermore, poor lifestyle factors 
such as smoking (Wang et al., 2017), lack of physical exercise (Wang et al., 2017) and alcohol use 
(Galli et al., 2013) are more common in individuals with short sleep duration, presumably 
compounding their risk for developing NCDs. Both short and long sleep have also been associated 
with depression (Zhai et al., 2015), and depression severity has been associated with metabolic 
syndrome components (Hiles et al., 2016). 
Recognising that epidemiological evidence does not infer causality, examination of studies using 
acute sleep restriction protocols may shed light on the direction of the association between sleep 
duration and cardiometabolic risk factors. It seems likely that sleep restriction may alter energy 
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balance. For example, participants subjected to five nights of sleep restriction (4 h per night) 
displayed greater neuronal activation of brain regions sensitive to food stimuli and food intake in 
response to unhealthy food compared to when allowed a week of habitual of sleep (7-9 h) (St-
Onge et al., 2013). Indeed, increased caloric intake and subsequent weight gain has been observed 
in participants following eight nights of sleep restriction (two-thirds of habitual sleep duration) 
(Calvin et al., 2013), five consecutive nights of sleep restriction (4 h per night) (Spaeth et al., 2013) 
and just four or five nights of sleep restriction (Bosy-Westphal et al., 2008, Markwald et al., 2013). 
Additionally, restricting sleep to 4.3 h for two nights (Bromley et al., 2012) or 5.5 h for two weeks 
(Schmid et al., 2009) reduced the intensity and amount of physical activity participants choose to 
do. 
Sleep restriction has also been shown to negatively affect other aspects of cardiometabolic health. 
Two randomized crossover-controlled trials demonstrated that four or five nights of sleep 
restriction (4.5 h or 4 h per night respectively) reduced insulin sensitivity compared to longer sleep 
(8.5 h or 8 h sleep respectively) (Broussard et al., 2012, Rao et al., 2015). Likewise, just two days 
of sleep restriction (4 h per night) resulted in higher insulin and glucose peak responses to breakfast 
intake, suggesting an impairment of glucose tolerance, possibly caused by a decreased insulin 
sensitivity (Schmid et al., 2011). Similar results have been found in other studies with various study 
designs and cohorts (Buxton et al., 2010, Donga et al., 2010, Reynolds et al., 2012, Sweeney et al., 
2017, Wang et al., 2016). Finally, five nights of sleep restriction (4 h per night) increased 
lymphocyte activation and the production of proinflammatory cytokines, which have been 
associated with an increased risk for developing CVDs (van Leeuwen et al., 2009). 
In light of the association between short sleep duration and risk for NCDs and the effect of acute 
sleep restriction on cardiometabolic function, interventions aimed at increasing sleep duration are 
being trialled as a new approach to reducing risk for obesity and NCDs. One study reviewed the 
feasibility and effectiveness of sleep extension for weight management and CMD prevention, and 
concluded that prolonging sleep may improve cardiometabolic risk in short sleepers (Pizinger et 
al., 2018). However, the authors did not adopt a systematic approach, which increases the risk for 
bias, and only studies on short-sleeping participants were included, which ignores the potential 
benefit or risk of sleep-extension in normal-sleepers. Therefore, the aim of this study was to 
systematically review the effects of sleep extension interventions on cardiometabolic risk factors 





2.2.1 Literature search 
Peer-reviewed original studies in which sleep extension interventions were used, and 
cardiometabolic risk factors were measured as outcomes, were assessed using the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses guidelines (Moher et al., 2009). 
Articles were included if all of the following criteria were met: participants were adults (18 years 
or older); the study used a sleep extension intervention (i.e. any intervention aimed at increasing 
participants’ habitual sleep duration); outcomes were measured before and after the sleep 
extension intervention; reported outcomes included at least one cardiometabolic risk factor (i.e. 
blood pressure, BP; blood markers of cholesterol; triglycerides, TG, or glucose; body mass index, 
BMI; or waist circumference, WC) or other outcomes related to these risk factors; and originally 
published in English (or an English translation of the article was available). Exclusion criteria were: 
reviews, commentaries, letters, editorials, conference proceedings, case reports, conference 
abstracts or non-peer reviewed articles. No exclusions were made for the design of the reviewed 
study. 
The databases PubMed and Scopus were searched for articles published up to August 2018. The 
initial electronic search strategy included the following terms: “sleep-extension” or “sleep 
extension” or “extended sleep” or “extend sleep” or “increase sleep” or “bed time extension” or 
“time-in-bed extension” or “time in bed extension” or “tib extension” and “blood pressure” or 
“hypertension” or “cholesterol” or “glucose” or “weight” or “waist circumference” or “body mass 
index” or “BMI” or “metabolic syndrome” or “cardiovascular disease” or “cvd” or “non-
communicable disease” or “ncd” or “cardiometabolic” in the title or abstract of the paper. This 
initial search strategy identified 38 items in PubMed and 36 items in Scopus. When the search was 
repeated with only the terms related to sleep extension, thus excluding the risk factors, 199 items 
were identified in PubMed and 217 in Scopus. To assure that no papers that measured 
cardiometabolic risk factors were excluded from this systematic review, only sleep extension 
related terms were included in the final search strategy. The final search terms for the PubMed and 







Table 2.1. Final search terms used to search the Pubmed and Scopus databases.  
Database Search term 
PubMed  (“Sleep-extension” [Title/Abstract] OR “Sleep extension”[Title/Abstract] OR “extended 
sleep”[Title/Abstract] OR “extend sleep”[Title/Abstract] OR “increase sleep”[Title/Abstract] 
OR “bed time extension”[Title/Abstract] OR “time-in-bed extension”[Title/Abstract] OR “time 
in bed extension”[Title/Abstract] OR “tib extension”[Title/Abstract]) 
Scopus TITLE-ABS ("Sleep-extension") OR TITLE-ABS ("Sleep extension") OR TITLE-
ABS ("extended sleep") OR TITLE-ABS ("extend sleep") OR TITLE-ABS ("increase sleep") OR 
TITLE-ABS ("bed time extension") OR TITLE-ABS ("time-in-bed extension") OR TITLE-
ABS ("time in bed extension") OR TITLE-ABS ( "tib extension") 
 
2.2.2 Study selection 
In the first round, articles were screened on title and abstract only. The second round involved 
assessing the eligibility criteria. RH and PP screened the results and tested eligibility separately. 
Cases of conflicts were discussed with DR and LR who served as arbitrators. The item in question 
was then included or excluded accordingly.  
2.3 Results 
2.3.1 Literature 
The article search process is depicted in Figure 2.1. The initial search identified 416 items using 
the search criteria described above. One hundred and fifty-seven duplicates were removed and the 
titles and abstracts of the remaining 259 items were screened. Of these, 236 items were excluded 
and 23 tested for eligibility. A further 16 items were excluded for reasons mentioned in Figure 
2.1. Seven studies met the inclusion criteria set to review the effect of a sleep extension intervention 
on cardiometabolic risk factors. The citations in these items were also subjected to screening and 





Figure 2.1. Outline of the literature search procedure and article selection. 
2.3.2 Study characteristics 
Three of the seven included studies are randomized controlled trials (Haack et al., 2013, Al Khatib 
et al., 2018, Reynolds et al., 2012), two are crossover trials (Killick et al., 2015, Kubo et al., 2011), 
and two are intervention studies without concurrent control groups (Leproult et al., 2015, Tasali 
et al., 2014). The sample sizes of the included studies range from 10 to 42 participants. The 
participants comprised healthy adults (Al Khatib et al., 2018, Reynold et al., 2014), healthy, short-
sleeping (<6.5 h or <7 h per night) adults (Killick et al., 2015, Leproult et al., 2015), short-sleeping 
(<6.5 h per night) adults who were overweight (Tasali et al., 2014), short-sleeping (<6 h per night) 
factory workers (Kubo et al., 2011) and pre- or hypertensive adults (Haack et al., 2013). The sleep 
extension intervention strategies were either time-in-bed (TiB) extensions, or personalised sleep 
consultation or behaviour counselling with sleep hygiene tips, or a combination of the two. The 
intervention durations ranged from three days to six weeks, and sleep duration was extended 
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variables, glucose, insulin and insulin sensitivity indices, appetite and hormones that influence 
appetite, and inflammatory markers.  
2.3.3 Results of individual studies 
2.3.3.1 Sleep extension strategy types and efficacy 
The sleep extension strategies and the efficacy of the interventions in each of the included studies 
are summarized in Table 2.2. In the study with the longest intervention duration (6 weeks), 
prehypertensive and stage-1 hypertensive participants were randomized into sleep extension 
(n=13) and sleep maintenance (n=9) groups (Haack et al., 2013). The sleep extension group 
received sleep hygiene information and instructions to prolong TiB by 60 min daily for six weeks. 
Specifically, participants were instructed to go to sleep 30 min earlier and rise 30 min later than 
their usual bed and get-up times. The sleep maintenance group also received sleep hygiene 
information, but was instructed to maintain their habitual bedtimes for six weeks. TST was 
extended by 35±9 min to ~6.9 h in the sleep extension group and by 4±9 min to ~6.3 h in the 
sleep maintenance group as assessed by actigraphy (p=0.03, group-by-time interaction effect). 
Participants with shorter TST at baseline increased sleep duration more during the sleep extension 
phase (r=-0.71, p<0.01).  
Leproult et al. (2015) made use of a five- to six-week individualised sleep schedule aimed at 
increasing sleep duration by 60 min (Leproult et al., 2015). The 16 healthy short-sleeping (<7 h) 
adult participants who were not obese met with the study staff every two weeks to discuss potential 
difficulties with their schedules, and solutions to overcome these difficulties. The participants were 
also able to contact the investigators via email or telephone for further support if necessary. The 
study staff advised each participant to avoid physical activity within 2 h of bedtime. This sleep 
extension strategy increased mean actigraphy-assessed sleep duration on weekdays by 44±34 min 
from 6.0±0.5 h (p<0.001). This effect was not observed on weekends, presumably because the 
participants’ pre-intervention weekend TST was already >7 h.  
Tasali et al. (2014) made use of a two-week sleep extension intervention in which ten adults who 
were overweight, but otherwise healthy and usually slept less than 6.5 h per night were given tips 
on sleep hygiene and received individualized behavioural counselling on the first day of sleep 
extension (Tasali et al., 2014). A follow-up visit was planned at the end of the first week. The aim 
of the intervention was to extend TiB to 8.5 h and TST to 7-8 h per night. On average, the 
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participants went to bed 75 min earlier and got up 30 min later. Mean sleep duration assessed by 
actigraphy increased from 5.6±0.1 h to 7.1±0.1 h (p<0.001).  
In another study, 14 apparently healthy participants with self-reported sleep durations of 6-9 h per 
night and no sleep complaints were randomized to a TiB extension group (n=8) and a control 
group (n=6) (Reynold et al., 2014). The TiB extension group was instructed to increase TiB by 180 
min per night for one week by adhering to a fixed sleep schedule. The control group was instructed 
to maintain their median habitual TiB through a fixed sleep schedule. To avoid unintended change 
based on the participants’ expectations, the participants were told that the intervention could have 
a positive effect, a negative effect or no effect. Sleep duration was assessed using actigraphy. 
Participants in the sleep extension group extended their sleep duration by 120 min from 6.8±0.6 
h to 8.8±0.9 h whereas those in the sleep maintenance group decreased their sleep duration by 16 
min from 6.9±0.4 h to 6.7±0.2 h (p<0.001) (Reynold et al., 2014). It must be noted that this was 
the only included study where the participants did not have short sleep at baseline. The authors 
hypothesised detrimental effects of sleep extension on the outcome measures. 
In a more recent study, 42 healthy, habitually short-sleeping (<7 h) participants who were not 
obese were randomized into a sleep extension group (n=21) and a control group (n=21) (Al Khatib 
et al., 2018). The control group was requested to keep their lifestyle, including their bedtime and 
get-up times, as usual, but they were offered the intervention upon completion of the study. The 
sleep extension group received a 45 min sleep consultation session with a health psychologist. 
During this session, the participant was introduced to the importance of sleep, current 
recommendations of sleep duration, and the concept of sleep hygiene. The psychologist would 
then provide and talk the participant through a list of common sleep hygiene tips. The participant 
would select at least four tips that they thought were applicable to them, and easily implementable. 
These tips, barriers thereof, implementation intentions, and agreed-upon bedtimes were then 
added into a contract. Participants received diaries in which they noted whether they were 
successful in implementing the changes on each day of the four-week intervention period (Al 
Khatib et al., 2018). Sleep duration, assessed by actigraphy, increased by 21 min (95% CI: 6-36 
min) for the intervention group, which was significantly more than for the control group (-11 min, 
95% CI: -26-4 min, p=0.004).  
Kubo et al. (2011) applied a non-conventional sleep extension strategy; instead of extending sleep 
on every day of the week, sleep extension was attempted only on weekend nights (Friday, Saturday 
and Sunday), while the habitually short sleep during weekdays (<6 h) was maintained throughout 
the sleep extension period of three weeks (Kubo et al., 2011). Twenty-six daytime employees in a 
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manufacturing industry were included in this crossover-controlled trial and were instructed to stay 
in bed for at least 8 h between 22:00 and 09:00 without taking naps during the day. Sleep duration 
(assessed by actigraphy) increased by 60-120 min (p<0.001) on weekend days. However, sleep 
duration during weekdays remained at baseline level, which was approximately 5 h per night. 
Because significant time-by-group interactions were observed for bedtime (p<0.001), but not for 
wake time, the increased TST was mainly attributed to the change in bedtime (Kubo et al., 2011).  
Lastly, the study by Killick et al. (2015) was performed in a controlled environment with 10 h of 
forced TiB (Killick et al., 2015). Although this study design was indeed that of sleep extension, this 
intervention was not regarded as an appropriate strategy to increase habitual sleep duration. This 
study shall therefore not be discussed further in this section.  
In summary, sleep extension strategies included single or multiple personalized sleep consultation 
sessions (4), sleep hygiene recommendations (3), and TiB extension with or without bedtime 
recommendations (6). Interventions with a duration of more than one week, consistently included 
personalized sleep counselling and the TiB extension approach (e.g. personalized bedtime 
recommendations) was generally less prescriptive. In comparison, short-term interventions (≤1 
week) included a more instructive approach to achieve TiB extension (e.g. forced TiB), and did 
not include personalized counselling. The shorter interventions produced greater extensions in 
TiB duration compared to the longer interventions.  
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Table 2.2. Overview of the sleep extension strategies and efficacy in each of the included studies, in order of intervention duration. 
       Sleep duration  
Citation 
Study 




intervention From (h) To (h) 
Difference 
(min) p-value 
Haack et al. 
(2013) 
RCT Prehypertensive 
or stage 1 
hypertensive 




Intervention 13 Go to bed 30 min earlier and 30 min later 
(+60 min) 
Sleep hygiene recommendations 
Weekly contact to discuss problems 
6 weeks 6.3±0.2 ~6.9 35±9 0.03 
(GxT) 
  Comparison 9 Maintain habitual bedtimes 
Sleep hygiene recommendations 
6.2±0.3 ~6.3 4±9 
Leproult et 
al. (2015) 
IWOC Healthy adults 
who were not 




Intervention 16 Personalized sleep schedule to increase sleep 
by 60 min per day 
Biweekly meeting to discuss difficulties, 
apply improvements to schedule 
Ability to contact investigators via phone or 
email 
5-6 weeks 6.0±0.5 ~6.7 44±34 <0.000
1 (G) 
Al Khatib et 
al. (2018) 
RCT Healthy adults 
who were not 
obese (5-7 h 
habitual sleep 
duration)  
Intervention 21 Personalized sleep consultation session 
Sleep hygiene recommendations 
Personalized bedtime recommendations 
4 weeks 5.5 (95% 
CI: 5.8-
6.3) 

















       Sleep duration  
Citation 
Study 




intervention From (h) To (h) 
Difference 
(min) p-value 
Tasali et al. 
(2014) 
IWOC Young adults 
who were 
overweight (<6 
h sleep duration) 
Intervention 10 Individualized behavioural counselling on 
sleep hygiene on first day of intervention 
period:  
all social and environmental factors 
discussed; 
Counselling on modifiable factors and other 
barriers; 
TiB extension to 8.5 h; 
Further counselling provided if needed after 
1 week. 




RCT Healthy adults 





Intervention 8 Fixed personalized sleep schedule to spend 
an additional 180 min in bed each night 
TiB must be spent trying to sleep (no 
distractions) 
1 week 6.8±0.6 8.8±0.9 +120 
ES: 2.66 
NA  
  Comparison 6 Fixed habitual bedtime schedule 6.9±0.4 6.7±0.2 -16 
ES: 0.91 
Kubo et al. 
(2011) 
COT Adult daytime 
industrial 
workers (6 h 
sleep duration) 
Intervention 26 Stay in bed for at least 8 h between 22:00-
09:00 on Friday, Saturday and Sunday 




  Comparison 
(crossover) 







       Sleep duration  
Citation 
Study 




intervention From (h) To (h) 
Difference 
(min) p-value 
Killick et al. 
(2015) 
COT Healthy male 





Intervention 8 TiB extension to 10 h in sleep lab 3 days 6.2±0.1 ~9.2 ~177 NA 
  Comparison 
(crossover) 
8 TiB restriction to 6 h in sleep lab 3 days 6.2±0.1 ~5.8 ~-23 NA 
CI: Confidence interval; COT: crossover trial; ES: effect size; G: group-effect; GxT: group and time interaction; IWOC: intervention study without control group; NA: not 
applicable; RCT: randomized controlled trial; T: time-effect; TiB: time-in-bed. Values following ‘~’ are converted from text when no actual values were available. For example, 
“~<6 h” means that the approximate TST is less than 6 h, because the inclusion criteria was sleeping less than 6 h each night, and for “~6.9 h”, the post-intervention TST was not 
reported, so the difference was added to or subtracted from the pre-intervention TST. 
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2.3.4 Effect of sleep extension interventions on cardiometabolic risk factors 
The effects of the various sleep extension interventions utilised in the seven included studies on 
outcome variables are summarised in Table 2.3.  
2.3.4.1 Anthropometric measures 
Weight, BMI, WC and total body fat were outcome variables in the studies reviewed. Of these, 
two assessed changes in body weight (Al Khatib et al., 2018, Leproult et al., 2015), two assessed 
BMI (Haack et al., 2013, Al Khatib et al., 2018), two assessed total body fat (Haack et al., 2013, Al 
Khatib et al., 2018) and one assessed WC (Al Khatib et al., 2018) before and after the intervention. 
No change in mean body weight was observed following a six-week sleep extension intervention 
in 16 healthy adults who were not obese (Leproult et al., 2015). Likewise, four weeks of sleep 
extension did not change body weight in 21 short-sleeping (<7 h) adults (p-value not reported)(Al 
Khatib et al., 2018). No changes were found for BMI in 12 individuals with pre- or hypertension 
who received sleep extension for six weeks (Haack et al., 2013). In neither of the two studies that 
reported on total body fat as an outcome variable did total body fat change as a result of the sleep 
extension intervention (Haack et al., 2013, Al Khatib et al., 2018). Lastly, no change in WC was 
observed in adults who were healthy and short-sleeping (<7 h), following a four-week sleep 
extension intervention (Al Khatib et al., 2018).  
2.3.4.2 Resting blood pressure and heart rate 
Resting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were assessed in three 
of the included studies (Haack et al., 2013, Kubo et al., 2011, Reynold et al., 2014) and resting 
heart rate (RHR) in two of the studies (Haack et al., 2013, Reynold et al., 2014). While individuals 
with prehypertension and stage 1 hypertension both experienced reductions in resting SBP (14±3 
mmHg, p<0.001) and DBP (8±3 mmHg, p<0.02) following sleep extension (Haack et al., 2013), 
the extent of this reduction was not different to that experienced by an active control group (SBP 
and DBP decreased by 7±5 and 3±4 mmHg respectively, p=0.03 for time effect, p=0.15 for group-
by-time interaction effect) that was given sleep hygiene information. Reynold et al. (2014) found 
no changes in SBP or DBP (no p-value reported) in 14 healthy sleepers following a one-week sleep 
extension intervention (Reynold et al., 2014). Kubo et al. (2011) measured BP in daytime factory 
workers on a Monday and Thursday prior to a weekend sleep extension strategy, and on the same 
days after the intervention (Kubo et al., 2011). No changes in either SBP or DBP were found as a 
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result of the intervention. Neither Haack et al. (2013) nor Reynold et al. (2014) found changes in 
RHR following sleep extension (p=0.87, p-value not reported respectively) (Haack et al., 2013, 
Reynold et al., 2014). 
2.3.4.3 Fasting blood glucose, insulin and C-peptide levels 
Fasting blood glucose, insulin and measures of insulin resistance were outcome variables in two 
of the reviewed studies (Killick et al., 2015, Leproult et al., 2015). A three-day sleep extension 
intervention did not affect fasting blood glucose in 19 healthy, short-sleeping (<6.5 h) male adults 
(p>0.05) (Killick et al., 2015). Likewise, Leproult et al. (2015) found no effect on fasting blood 
glucose in 16 healthy, adults who were not obese following a 5-6 week sleep extension intervention 
(p-value not reported) (Leproult et al., 2015). However, changes in fasting blood glucose correlated 
with changes in sleep duration assessed by actigraphy (r=0.65, p=0.017), and with changes in TST 
assessed by polysomnography (PSG; r=0.53, p=0.041) (Leproult et al., 2015), suggesting that 
fasting blood glucose increases as sleep duration and TST increases. Fasting plasma insulin levels 
in habitually short-sleeping (<6.5 h) males were significantly lower following three nights of 
extended sleep (10 h) compared to three nights of sleep restriction (6 h, p<0.05) (Killick et al., 
2015). Levels of serum C-peptide, a polypeptide that is required in the insulin synthesis pathway 
and used as a measure of insulin secretion in individuals with diabetes (Jones and Hattersley, 2013), 
also decreased significantly (p<0.05) (Killick et al., 2015). Another study found that sleep extension 
did not significantly change fasting insulin levels in 16 healthy, adults who were not obese, 
however, the author reported that changes in both PSG-assessed TST (r=-0.60, p=0.025), and 
actigraphy-assessed sleep duration (r=-0.57, p=0.053) correlated with changes in fasting insulin 
levels with moderate effect size (ES), despite the correlation of the latter not being significant 
(Leproult et al., 2015). Changes in TST as assessed by PSG following sleep extension, correlated 
with changes in the insulin-to-glucose ratio (p=0.009) and the Quantitative Insulin Sensitivity 
Check Index (QUICKI) (p=0.002) (Leproult et al., 2015). QUICKI was also significantly improved 
following 10 h of sleep, as opposed to the habitual 6 h of sleep in the study by Killick et al. (2017), 
as well as other measures of insulin sensitivity, such as the homeostatic model assessment for 
insulin resistance (p<0.05) and β-cell function (p<0.05) (Killick et al., 2015). Lastly, sleep extension 
significantly increased insulin sensitivity as determined by the oral glucose tolerance test in healthy, 
short-sleeping (<6.5 h) male adults (p<0.05) (Killick et al., 2015).  
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2.3.4.4 Physical activity 
Of the seven identified studies, two reported on physical activity outcomes, namely step counts 
(Reynold et al., 2014) and physical activity intensity as percentage of awake time (Al Khatib et al., 
2018). The sleep extension group in the first study increased average daily step counts from 
6442±1772 to 7413±2281 steps, whereas the step count in the sleep maintenance group increased 
from 5662±1625 to 6246±1583 steps, which was reported as not significant (no p-value reported) 
(Reynold et al., 2014). The second study reported that the intervention had no effect on the 
percentages of awake time spent in sedentary behaviour, or vigorous, moderate or low physical 
activity intensities (p>0.05).  
To summarize, the sleep extension interventions used in the included studies resulted in no 
measurable changes in any of the anthropometric, cardiovascular or physical activity outcomes 
assessed. The two studies which did measure glucose and insulin-related outcomes provided 
preliminary evidence that increasing sleep duration may improve glucose control or insulin 
sensitivity. The results were inconsistent, however, indicating that more research is needed in this 
area.  
2.3.4.5 Other observations 
This section describes outcomes of sleep extension interventions that do not fall directly under 
the World Health Organisation’s cardiometabolic risk factors for NCDs, but may influence 
cardiometabolic health indirectly.  
2.3.4.5.1 Dietary intake 
Dietary intake is indirectly associated with an increased cardiometabolic risk, since it may 
contribute to overweight and obesity. Two studies assessed the effect of sleep extension on dietary 
intake (Haack et al., 2013, Al Khatib et al., 2018). Haack et al. (2013) assessed changes in daily 
caloric and sodium intake in individuals with prehypertension and stage 1 hypertension and found 
that at the end of a six-week sleep extension intervention neither outcome changed (Haack et al., 
2013). In another study, free sugar intake was reduced in the sleep extension group (by 9.6 g/day) 
but did not change in the control group (0.7 g/day) indicating a significant time-by-group effect 
of the intervention on sugar intake (p=0.042) (Al Khatib et al., 2018). Additionally, the percentage 
of daily energy intake from protein increased in the sleep extension group (by 1.6%) and decreased 
in the control group (-1.9%, p=0.018 for time-by-group effect). However, no changes were 
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observed in daily intake of carbohydrate, total sugar, total fat, saturated fat or fibre (Al Khatib et 
al., 2018).  
2.3.4.5.2 Satiety and appetite 
Satiety and appetite are partially regulated by neuronal and hormonal signals originating from the 
gastro-intestinal tract and adipose tissue, thereby contributing to a healthy energy balance. These 
regulators may therefore influence energy intake and may contribute to weight gain and obesity. 
However, only Killick et al. (2015) reported satiety and appetite regulatory hormones as outcome 
variables in response to sleep extension. Namely, significant decreases were found for plasma 
leptin (a hormone that increases satiety, p<0.05) and PYY (a peptide that reduces appetite, p<0.05) 
following sleep extension, but not for ghrelin (a hormone that induces hunger, p-value not 
reported) (Killick et al., 2015). 
Finally, in ten short-sleeping (<6.5 h) young participants who were overweight, appetite decreased 
by 14% (p=0.03) in response to the intervention. Moreover, while their desire for fruit, vegetables 
and protein-rich nutrients remained unchanged, their desire for sweet and salty foods decreased 
by 62% (p=0.017) (Tasali et al., 2014). 
2.3.4.5.3 Depression and anxiety 
One study included measures of depression and anxiety as outcome variables (Reynold et al., 
2014). Extending sleep duration for one week increased the Beck Depression Inventory (BDI) 
score from 2.4±1.8 to 5.3±4.4, suggesting an increase in depression symptoms severity, in 14 
physically and mentally healthy adults, whereas the BDI score in the sleep maintenance group 
increased from 4.8±6.3 to 6.0±9.2. While no p-value was reported, the authors report this 
difference (i.e. greater increase in BDI score in the sleep maintenance group) to be non-significant 
(Reynold et al., 2014). In the same study, anxiety as assessed by the State-Trait Anxiety Inventory 
increased from 31.3±7.4 to 33.5±9.7 in the intervention group, and decreased from 35.2±14.0 to 
33.0±12.9 in the sleep maintenance group; but the difference in these changes were reported to 




2.3.4.5.4 Inflammatory, sympatho-adrenal, and metabolic markers 
Several inflammatory, sympatho-adrenal and metabolic markers have been associated with an 
increased risk for cardiovascular and metabolic diseases. For example, high levels of the 
inflammatory marker CRP and white blood cells may be associated with a higher risk for coronary 
heart disease (Danesh et al., 1998); interleukin (IL)-6, a protein involved in both inflammatory and 
cardiometabolic pathways, has been linked to T2DM (Spranger et al., 2003); norepinephrine (NE) 
has been associated with an increased risk for mortality, especially from progressive heart failure 
(Cohn et al., 1984); adiponectin has been identified as an independent risk factor for MetS (Renaldi 
et al., 2009); and the inflammatory marker tumour necrosis factor alpha (TNF-α) has been shown 
to play a role in obesity-linked insulin resistance (Hotamisligil et al., 1993). Three of the seven 
studies explored the effects of sleep extension on these markers (Haack et al., 2013, Killick et al., 
2015, Reynold et al., 2014). Killick et al. (2015) reported no significant changes in cortisol (a 
hormone which is released in response to stress and hypoglycaemia, p-value not reported) (Killick 
et al., 2015). Likewise, sleep extension did not significantly improve white blood cell count, IL-6, 
CRP or NE in twelve pre- or hypertensive participants (Haack et al., 2013), and a one-week TiB 
extension intervention in healthy sleepers did not change CRP, IL-6, adiponectin or TNF-α levels 
(Reynold et al., 2014). 
2.3.4.5.5 Resting metabolic rate 
Resting metabolic rate (RMR) may be regarded as an indirect cardiometabolic risk factor due to its 
association with long-term weight gain (Ravussin et al., 1988). One study reported on the effect of 
sleep extension on RMR as assessed by indirect calorimetry and found that RMR did not increase 
more in the sleep extension group than in the sleep maintenance group (p>0.05) (Al Khatib et al., 
2018).  
Collectively, these studies have shown that sleep extension may decrease daily free sugar intake, 
increase daily energy intake from proteins, decrease leptin and PYY levels, and reduce appetite and 
desire for sweet and salty foods, all of which combined may contribute to a reduced energy intake 
and promote a healthy weight. Neither depression, anxiety, inflammatory, sympatho-adrenal, 
metabolic markers nor RMR changed in response to the sleep extension interventions 








design Population Sample size a 
Sleep 
extension Effect p-value 
Adiponectin Reynold et 
al. (2014) 
RCT Healthy adults (6-9 h sleep 
duration) 
8/14 ↑ 120±19 min 
in 1 week 
↔ NS, (ES=-0.08) 
Alcohol Al Khatib 
et al. (2018) 
RCT Healthy adults who were not 
obese (< 7 h sleep duration) 
21/42 ↑ 2 min in 4 
weeks 
↔ 0.226 (GxT) 
Appetite Tasali et al. 
(2014) 
IWOC Short-sleeping (<6.5 h) 
young adults who were 
overweight 
10/10 ↑ 96 min in 2 
weeks 
Overall appetite: ↓ 14% 0.03 (T) 
Desire for sweet and salty 
foods: ↓ 62% 
0.017 (T) 
Desire for fruits: ↔ 0.632 (T) 
Desire for vegetables: ↔ 0.478 (T) 
Desire for protein-rich 
nutrients: ↔ 
0.764 (T) 
BP Haack et al. 
(2013) 
RCT Pre- or hypertensive adults 
(<7 h sleep duration) 
13/22 ↑ 35±9 min 
for 6 weeks 
SBP: ↔ <0.001 (T)  
0.15 (GxT) 
DBP: ↔ <0.02 (T) 
0.21 (GxT) 
Kubo et al. 
(2011) 
COT Short-sleeping (≤6 h) 
daytime industrial workers 
26/26 ↑ 60-120 min 
for 3 days 
SBP: ↔ 0.171 (GxT) 
DBP: ↔ 0.869 (GxT) 
Reynold et 
al. (2014) 
RCT Healthy adults (6-9 h sleep 
duration) 
8/14 ↑ 120±19 min 
in 1 week 
SBP: ↔ NS, (ES=-0.07) 
DBP: ↔ NS, (ES=0.02) 
Total body fat Haack et al. 
(2013) 
RCT Pre- or hypertensive adults 
(<7 h sleep duration) 
13/22 ↑ 35±9 min 
for 6 weeks 
↔ 0.74 (GxT) 
Al Khatib 
et al. (2018) 
RCT Healthy adults who were not 
obese (5-7 h sleep duration) 
21/42 ↑ 21 min in 4 
weeks 
↔ NS (GxT) 
BMI Haack et al. 
(2013) 
RCT Pre- or hypertensive adults 
(<7 h sleep duration) 
13/22 ↑ 35±9 min 
for 6 weeks 
↔ 0.14 (GxT) 
Al Khatib 
et al. (2018) 
RCT Healthy adults who were not 
obese (5-7 h sleep duration) 
21/42 ↑ 21 min in 4 
weeks 






design Population Sample size a 
Sleep 
extension Effect p-value 
Body weight Leproult et 
al. (2015) 
IWOC Healthy adults who were not 
obese (<7 h sleep duration) 
-/16 ↑ 44±34 min 
in 5-6 weeks 
↔ 0.81 (G) 
Al Khatib 
et al. (2018) 
RCT Healthy adults who were not 
obese (5-7 h sleep duration) 
21/42 ↑ 21 min in 4 
weeks 
↔ NS (GxT) 
Cortisol Killick et al. 
(2015) 
COT Healthy male adults (<6.5 h 
sleep duration) 
8/8 ↑ 177 min in 3 
days 
↔ >0.05 (G) 
C-peptide Killick et al. 
(2015) 
COT Healthy male adults (<6.5 h 
sleep duration) 
8/8 ↑ 177 min in 3 
days 
↓ <0.05 (G) 
CRP Haack et al. 
(2013) 
RCT Pre- or hypertensive adults 
(<7 h sleep duration) 
13/22 ↑ 35±9 min 
for 6 weeks 
↔ 0.12 (GxT) 
Reynold et 
al. (2014) 
RCT Healthy adults (6-9 h sleep 
duration) 
8/14 ↑ 120±19 min 
in 1 week 





RCT Healthy adults (6-9 h sleep 
duration) 
8/14 ↑ 120±19 min 
in 1 week 
BDI: ↔  NS, (ES=-0.86) 
 STAI: ↔ NS, (ES=-0.26) 
Dietary intake Haack et al. 
(2013) 
RCT Pre- or hypertensive adults 
(<7 h sleep duration) 
13/22 ↑ 35±9 min in 
6 weeks 
Daily Caloric intake: ↔ 0.56 (GxT) 
Daily Sodium intake: ↔ 0.39 (GxT) 
Daily carbohydrate intake: ↔ >0.10 (GxT)  
Daily fat intake: ↔ >0.10 (GxT) 
Daily protein intake: ↔ >0.10 (GxT) 
Al Khatib 
et al. (2018) 
RCT Healthy adults who were not 
obese (5-7 h sleep duration) 
21/42 ↑ 21 min in 4 
weeks 
Free sugars intake g/day: ↓; 
%cal: ↔ 
0.042; 0.181 (GxT) 
Caloric intake g/day: ↔ 0.259 (GxT) 
Protein intake g/day: ↔; 
%cal: ↑ 
 
0.570; 0.018 (GxT) 
Carbohydrate intake g/day: 
↔; %cal: ↔ 
0.083; 0.898 (GxT) 
Total sugar intake g/day: ↔; 
%cal: ↔ 






design Population Sample size a 
Sleep 
extension Effect p-value 
Fiber intake g/day: ↔ 0.329 (GxT) 
Fat intake g/day: ↔; %cal: ↔ 0.162; 0.074 (GxT) 
Saturated fat intake g/day: ↔; 
%cal: ↔ 
0.390; 0.421 (GxT) 
Ghrelin Killick et al. 
(2015) 
COT Healthy male adults (<6.5 h 
sleep duration) 
8/8 ↑ 177 min in 3 
days 
↔ >0.05 (G) 
Glucose (fasting) Leproult et 
al. (2015) 
IWOC Healthy adults who were not 
obese (<7 h sleep duration) 
16/16 ↑ 44±34 min 
in 5-6 weeks 
↔ >0.05 (G) 
Killick et al. 
(2015) 
COT Healthy male adults (<6.5 h 
sleep duration) 
8/8 ↑ 177 min in 3 
days 
↔ >0.05 (G) 
Heart rate Haack et al. 
(2013) 
RCT Pre- or hypertensive adults 
(<7 h sleep duration) 
13/22 ↑ 35±9 min in 
6 weeks 
↔ 0.87 (GxT) 
Reynold et 
al. (2014) 
RCT Healthy adults (6-9 h sleep 
duration) 
8/14 ↑ 120±19 min 
in 1 week 
↔ NS, (ES=0.19) 
Insulin (fasting) Leproult et 
al. (2015) 
IWOC Healthy adults who were not 
obese (<7 h sleep duration) 
16/16 ↑ 44±34 min 
in 5-6 weeks 
↔ >0.05 (G) 
Killick et al. 
(2015) 
COT Healthy male adults (<6.5 h 
sleep duration) 
8/8 ↑ 177 min in 3 
days 
↓ <0.05 (G) 
Insulin sensitivity Leproult et 
al. (2015) 
IWOC Healthy adults who were not 
obese (<7 h sleep duration) 
16/16 ↑ 44±34 min 
in 5-6 weeks 
Insulin-to-glucose ratio: ↔ >0.05 (G) 
QUICKI: ↔ >0.05 (G) 
HOMA-IR: ↔ >0.05 (G) 
Killick et al. 
(2015) 
COT Healthy male adults (<6.5 h 
sleep duration) 
8/8 ↑ 177 min in 3 
days 
Insulin sensitivity (OGTT, 
minimal model analysis): ↑ 
<0.05 (G) 
HOMA-IR: ↓ <0.05 (G) 
HOMA-β: ↓ <0.05 (G) 
QUICKI: ↑ <0.05 (G) 
IL-6 Haack et al. 
(2013) 
RCT Pre- or hypertensive adults 
(<7 h sleep duration) 
13/22 ↑ 35±9 min 
for 6 weeks 






design Population Sample size a 
Sleep 
extension Effect p-value 
Reynold et 
al. (2014) 
RCT Healthy adults (6-9 h sleep 
duration) 
8/14 ↑ 120±19 min 
in 1 week 
↔ NS, (ES=-0.65) 
Leptin Killick et al. 
(2015) 
COT Healthy male adults (<6.5 h 
sleep duration) 
8/8 ↑ 177 min in 3 
days. 
↓ <0.05 (G) 
NE Haack et al. 
(2013) 
RCT Pre- or hypertensive adults 
(<7 h sleep duration) 
13/22 ↑ 35±9 min 
for 6 weeks 
↔ 0.92 (GxT) 
PYY Killick et al. 
(2015) 
COT Healthy male adults (<6.5 h 
sleep duration) 
8/8 ↑ 177 min in 3 
days 
↓ <0.05 (G) 
Physical activity Reynold et 
al. (2014) 
RCT Healthy adults (6-9 h sleep 
duration) 
8/14 ↑ 120±19 min 
in 1 week 
Average daily steps: ↔ NS, (ES: -0.48) 
Al Khatib 
et al. (2018) 
RCT Healthy adults who were not 
obese (5-7 h sleep duration) 
21/42 ↑ 21 min in 4 
weeks 
Physical activity intensity: ↔ NS (GxT) 
RMR Al Khatib 
et al. (2018) 
RCT Healthy adults who were not 
obese (5-7 h sleep duration) 
21/42 ↑ 21 min in 4 
weeks 
↔ NS (GxT) 
TNF-⍺	 Reynold et 
al. (2014) 
RCT Healthy adults (6-9 h sleep 
duration) 
8/14 ↑ 120±19 min 
in 1 week 
↔ NS, (ES: -0.09) 
WC Al Khatib 
et al. (2018) 
RCT Healthy adults who were not 
obese (5-7 h sleep duration) 
21/42 ↑ 21 min in 4 
weeks 
↔ NS (GxT) 
White blood cell 
count 
Haack et al. 
(2013) 
RCT Pre- or hypertensive adults 
(<7 h sleep duration) 
13/22 ↑ 35±9 min in 
6 weeks 
↔ 0.88 (GxT) 
Data are presented as mean ± SD. BDI: Beck Depression Inventory II; BMI: body mass index; BP: blood pressure; COT: crossover trial; CRP: C-reactive protein; DBP: diastolic 
blood pressure; ES: effect size; G: group-effect; GxT: group and time interaction; HOMA-IR: homeostatic model assessment for insulin resistance; HOMA-β: homeostatic model 
assessment for β-cell function; IL: interleukin; IWOC: intervention study without control group; NE: norepinephrine; NS: not significant; OGTT: oral glucose tolerance test; PYY: 
peptide tyrosine-tyrosine; QUICKI: Quantitative Insulin Sensitivity Check Index; RCT: randomized controlled trial; RMR: resting metabolic rate; SBP: systolic blood pressure; 
STAI: State-Trait Anxiety Inventory; T: time-effect; TNF: tumour necrosis factor; WC: waist circumference; %cal: as percentage of daily caloric intake. ↔: no significant change; ↓: 





The aim of this systematic review was to examine the effects of sleep extension interventions on 
cardiometabolic risk factors in adults. Based on the seven studies reviewed, three categories of 
outcome variables changed in response to sleep extension: those related to insulin sensitivity 
(Killick et al., 2015), to dietary intake (Al Khatib et al., 2018, Killick et al., 2015) and to appetite 
(Tasali et al., 2014).  
Since previous studies have shown that short sleep is associated with higher fasting glucose levels 
and insulin levels (Ford et al., 2013) and reduced insulin sensitivity (Matthews et al., 2012), it seems 
plausible that increasing sleep duration may improve these metabolic indices. It is intriguing that 
Killick et al. (2015) reported significant improvements in insulin sensitivity-related outcomes 
(HOMA-IR, HOMA-β, QUICKI) and fasting insulin in short-sleeping (<6.5 h) participants whose 
indices were within the healthy range at baseline (Killick et al., 2015). Furthermore, these changes 
were measured in response to the shortest sleep extension strategy (three days) reviewed. While 
these results may be attributed to the impressive sleep extension recorded, these data must be 
interpreted with care as sleep extension was achieved by forced TiB in a controlled environment 
which may not be translatable to a real-world situation. Given the short intervention period, these 
findings do not shed light on long-term improvements in insulin sensitivity-related outcomes, and 
future research is needed to confirm whether similar effects are observed in individuals with short 
sleep duration and insulin resistance or T2DM.  
At first glance the Leproult et al. (2015) study does not appear to provide support for sleep 
extension being a successful intervention for improving insulin sensitivity. However, the 
correlations between change in sleep duration and change in insulin sensitivity-related outcomes 
indicate some role for increasing sleep duration. While this study certainly had limitations (no 
control group, no direct assessment of insulin sensitivity in response to a glucose challenge 
(Leproult et al., 2015), the extent to which fasting glucose levels were reduced was similar to that 
observed in individuals who were overweight or obese and undertook 12 weeks of high intensity 
interval training (Batacan et al., 2016). Although comparisons between the two interventions are 
difficult because of the differences in populations studied and reporting of the data, one might 
speculate that a sleep extension intervention may be as effective in improving fasting glucose and 
insulin levels as exercise, specifically high intensity interval training.  
Conflicting findings exist between the two reviewed studies that reported on energy intake, with 
one finding a reduction in energy intake from free sugars, and an increase in energy intake from 
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protein in response to the sleep extension intervention (Al Khatib et al., 2018) and the other 
reporting no such changes (Haack et al., 2013). One might speculate that the reason for Haack et 
al. (2013) not observing any similar finding relates to the pre- or hypertensive nature of the 
participants studied. Without any normotensive control group, one cannot ascertain whether 
hypertension had any confounding effect on dietary intake. 
There is resonance between the observations that sleep extension reduces overall appetite and 
desire for sweet and salty food (Tasali et al., 2014) and reduces daily free sugar intake (Al Khatib 
et al., 2018). These studies suggest that short-sleeping adults may benefit from sleep extension in 
cases where appetite-control and food choice are desired behaviour changes relating to weight 
loss. However, there is no evidence to support that this may translate to a reduction in daily caloric 
intake, especially in light of the two studies included in this review which showed no change in 
caloric intake in response to sleep extension (Haack et al., 2013, Al Khatib et al., 2018). 
Furthermore, since Tasali et al. (2014) included no control group, one cannot conclude that sleep 
extension alone was responsible for the outcome observed. Additionally, since overall appetite and 
desire for sweet and salty food were only assessed in the morning, and since food desirability has 
been shown to be affected by time-of-day (Spaeth et al., 2013), one may speculate that appetite 
and desire for certain foods may be different in the evening. This is especially important since 
caloric intake and consumption of calories during late-night hours in individuals with chronic 
sleep-restriction may result in susceptibility to weight gain (Spaeth et al., 2013).  
Since leptin and PYY are understood to inhibit hunger (Batterham et al., 2002, Joannic et al., 1998), 
the observation of reduced leptin and PYY (but not ghrelin) following sleep extension (Killick et 
al., 2015) appears to be at odds with that of reduced appetite (Tasali et al., 2014). On one hand, 
since neither study measured both variables, one cannot conclude that lower levels of leptin and 
PYY translates to increased appetite. Differences in study design and participants may also account 
for these seemingly contradictory findings. Previous studies have found that sleep restriction 
increases plasma leptin, resulting in an increase in energy intake (Spiegel et al., 2004c), while others 
have found that sleep restriction increases energy intake despite a decrease in plasma leptin and 
PYY (Markwald et al., 2013). Thus the mechanisms behind any association between sleep, appetite, 
leptin and PYY appear to be more complicated and require further investigation.  
Given the large body of evidence that suggests that short sleep duration is associated with weight 
gain (Patel and Hu, 2008), overweight (Roda et al., 2016) and obesity (Wu et al., 2014), it is 
surprising that so few studies have explored the effect of sleep extension on body composition. 
Of the three that did so in this review, not one found significant improvements in any 
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anthropometric outcomes following sleep extension (Haack et al., 2013, Al Khatib et al., 2018, 
Leproult et al., 2015). A possible explanation for two of these studies may be that the participants 
were of healthy weight or not obese when recruited (Al Khatib et al., 2018, Leproult et al., 2015), 
thus improvements in anthropometric outcomes may have been unlikely. Additionally, one might 
speculate that the intervention durations of these three studies (4-6 weeks) may have been too 
short for reductions in weight or total body fat to occur, or co-interventions such as exercise and 
diet may be required. While the findings of the reviewed studies do not support the hypothesis 
that sleep extension interventions improve body weight, BMI or total body fat, studies in 
participants with obesity are needed before the hypothesis can be rejected.  
The participants in two of the three studies that assessed BP and RHR in response to sleep 
extension were normotensive on average, and baseline RHR was within the normal (60-100 bpm) 
range (Kubo et al., 2011, Reynold et al., 2014). It was therefore unlikely for improvements in these 
variables to occur. Since the participants in the Reynold et al. (2014) study did not have short sleep 
at baseline, the authors did not hypothesise that either BP or RHR would improve. Furthermore, 
the intervention durations of these two studies (three days to a week) may not have been 
sufficiently long to invoke any change in BP. To the best of my knowledge, no study has reported 
a decrease in SBP or DBP with any non-pharmacological intervention after just one week. On the 
other hand, Haack et al. (2013) had a longer sleep extension period of six weeks, and only included 
prehypertensive and stage 1 hypertensive participants, and still, no significant improvement in BP 
was observed. However, the reductions in SBP and DBP observed between the start and end of 
the sleep extension intervention (14 mmHg and 8 mmHg respectively) in the intervention group, 
although not significant, were similar to those observed in other lifestyle interventions, albeit in a 
shorter time frame (Blumenthal et al., 2010, Somers et al., 1991). For example, a six-month 
endurance training programme was shown to reduce resting SBP and DBP by 10 mmHg and 7 
mmHg respectively (Somers et al., 1991). Likewise, in a study in which both dietary and exercise 
interventions were implemented, SBP and DBP decreased by 10 mmHg and 5 mmHg respectively 
(Blumenthal et al., 2010). Therefore, one explanation for the absence of any significant change 
may be the study’s lack of statistical power due to a small sample size, rather than a lack of clinical 
change in BP. Collectively these data suggest that sleep extension is unlikely to benefit individuals 
who are normotensive by reducing resting BP. More research with medium- or long-term sleep 
extension interventions are required to establish the effect on lowering resting BP in individuals 
with short sleep duration and hypertension. 
None of the included studies found significant improvements in any physical activity-related 
outcomes following sleep extension. Limitations in the study by Reynold et al. (2014) were that the 
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ES between the two groups was calculated independently of the other group, and the results of 
hypothesis testing were not reported. Nevertheless, these findings are in line with studies 
conducted on individuals with sleep disorders (Kline et al., 2014, West et al., 2009). For example, 
Kline et al. (2014) used brief behavioural therapy to improve sleep quality in older adults with 
insomnia reported no change in daytime physical activity levels (Kline et al., 2014), and West et al. 
(2009) observed that continuous positive airway pressure treatment did not increase physical 
activity in patients with obstructive sleep apnoea, despite improvements in daytime sleepiness 
(West et al., 2009). More research is required to definitively conclude whether or not a sleep 
extension intervention plays any role in increasing voluntary moderate to vigorous physical activity 
levels, or reducing sedentary time in short-sleeping adults. In addition, the effect of extending sleep 
duration on compliance to supervised physical activity programs should also be investigated. 
The worsening of markers of depression and anxiety in the study by Reynold et al. (2014) may be 
regarded as an unexpected finding. One would expect depression to improve in response to such 
an intervention since depression has been associated with both short and long sleep (Zhai et al., 
2015). The authors hypothesised, however, that by extending TiB to ±10 h, and sleep to almost 9 
h, a scenario of forced sleep was created, which may worsen depression, as was indeed the case. It 
must be noted that the increase in BDI score following the TiB extension is minimal, since the 
BDI score ranges from 0 to 63, and scores below 9 (as observed in this study) are thought to reflect 
“minimal” depression. The difference between the baseline and follow-up BDI scores may not be 
clinically relevant as both indicate an absence of depression, even if the effect was significant. 
Furthermore, the sleep extension and sleep maintenance groups were not matched for depression 
and the analyses for one group was performed independently of the other (Reynold et al., 2014). 
The interactions between depression, cardiometabolic risk factors and sleep are complex and it is 
not fully understood whether sleep and depression are independent or overlapping risk factors for 
CMD (Mezick et al., 2011). Future studies on sleep extension in individuals with short sleep 
duration and symptoms of depression and anxiety may shed more light on the relationships 
between depression, cardiometabolic risk factors and sleep. 
The hypothesis that sleep extension might improve inflammatory, sympatho-adrenal and 
metabolic markers (i.e. cortisol, IL-6, CRP, adiponectin, NE, TNF-α levels or white blood cell 
count) are not supported by the reviewed studies. Study design may explain the lack of findings in 
these studies. First, two of the studies may have been underpowered due to the small sample size, 
and therefore not able to detect changes in these markers (Haack et al., 2013, Reynold et al., 2014). 
Second, the extent to which sleep duration was increased (Haack et al., 2013) or the short duration 
of the intervention (Reynold et al., 2014) may have been insufficient for changes in these markers 
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to occur. Third, the blood markers were all within a normal range at baseline; thus the effect of 
any non-pharmacological intervention that attempts to ‘normalise’ behaviour may not affect these 
markers. Future studies with larger sample sizes, longer intervention durations, and with 
individuals with short sleep duration and inflammatory, sympatho-adrenal and metabolic markers 
outside of the normal range at baseline, may help elucidate the effect of sleep extension on these 
markers. 
Lastly, to the best of my knowledge, only one study has investigated the relationship between sleep 
duration and RMR and found that RMR did not differ between short (5-6 h), average (7-8 h) and 
long (9-10 h) sleepers (Chaput et al., 2008). The finding by Al Khatib et al. (2018) that RMR was 
not affected by sleep extension is thus in line with this observation (Al Khatib et al., 2018).  
Of the seven different sleep extension strategies employed, those that reported the largest increases 
in TST were achieved by extending TiB by 2-4 h. It remains to be seen, however, whether these 
strategies are sustainable over an extended period of time. Indeed, of the reviewed studies, those 
that extended TST by the most also had the shortest study periods (Killick et al., 2015, Kubo et 
al., 2011, Reynold et al., 2014). Kubo et al. (2011) reported that after the TiB extension, the 
participants immediately returned to their habitual sleep duration suggesting that long-term, and 
drastic sleep extension may be difficult to achieve. Tasali et al. (2014) included sleep hygiene tips 
and behaviour change counselling in their TiB extension strategy and successful increased sleep 
duration over a longer period (two weeks). Thus, TiB extension alone, without any personalized 
counselling or improvement of sleep hygiene, may not result in sustainable changes in sleep 
duration in the long term. Furthermore, since none of the included studies performed long-term 
follow-ups, the sustainability of these interventions is unknown. Long-term sleep extension may 
not have been the aim of these studies and it is likely that different sleep extension interventions 
may be better suited for different populations of desired outcomes. Instructive TiB extension may 
increase TST dramatically from the first night, which is ideal for studies in which the effect of 
acute short-term sleep extension is investigated, while interventions that include sleep hygiene and 
bedtime routine may increase TST less dramatically initially, but may increase compliance over an 
extended period of time. Therefore, for the purpose of improving cardiometabolic health, 
suggestive, rather than instructive, personalized sleep extension strategies that include sleep 
hygiene education may be most appropriate and sustainable.  
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2.4.1 Study limitations 
In addition to the limitations present in the reviewed studies, this systematic literature review has 
its own limitations. First, only papers in the English language were included. Any relevant papers 
written in other languages that were not translated to English are therefore not included in this 
review. Second, the search terms used to describe the sleep extension intervention may not cover 
all terminology used for this type of intervention. It is therefore possible that papers by authors 
who describe the intervention differently are not included. However, the terminology used in the 
included articles and the papers in the reference lists of the included articles were also assessed 
without any other terminology of the sleep extension intervention mentioned. Finally, this review 
focuses only on the extension of sleep duration, not on the improvements of other aspects of 
sleep, such as sleep fragmentation, sleep timing, or sleep architecture. Thus, the results are not 
applicable to sleep behaviour interventions such as Cognitive Behavioural Therapy for Insomnia 
that aim to improve sleep in general (i.e. improve quality and quantity of sleep). 
2.5 Conclusion 
Evidence from this systematic review indicates that increasing sleep duration over a three-day to 
six-week period is a viable, implementable intervention which may improve direct and indirect 
measures of insulin sensitivity, as well as appetite and dietary intake. However, no changes were 
observed in other cardiometabolic risk factors such as anthropometric outcomes, BP, 
inflammatory, sympatho-adrenal or metabolic markers, depression and anxiety, physical activity 
and RMR. These findings may be relevant to researchers, medical practitioners, dieticians, exercise 
physiologists and other professionals who are involved in weight loss and preventive medicine. 
The current evidence to support the role of sleep extension interventions to reduce risk for CMD 
risk is sparse, however, and the diversity of study designs and participants used make the data 
difficult to synthesise. Future studies assessing sleep extension strategies in larger cohorts, 
encompassing children, teenagers, older adults and diseased populations are still required, 












3 A Comparison of Sleep Characteristics between 
adults who are Lean, Overweight and Class I 





Obesity and cardiometabolic impairment have been associated with sleep and circadian 
disturbances in populations around the world (Rangaraj and Knutson, 2016, Parsons et al., 2015) 
(see Section 1.5 for a summary). In light of the overarching purpose of this thesis, it is first 
necessary to describe the sleep characteristics and associated cardiometabolic risk in the population 
that will be studied in the intervention component of this thesis. Especially since the nature of the 
sleep-cardiometabolic risk relationship may well vary between population groups.  
A study on the self-reported sleep characteristics of individuals from Austria, Belgium, Brazil, 
China, Germany, Japan, Portugal, Slovakia, Spain, and South Africa, showed that the individuals 
from South Africa reported longer times to fall asleep, had the second highest prevalence of 
individuals who reported ‘they do not sleep well’ and the second highest prevalence of individuals 
who rated at least 6 on the Athens Insomnia Scale (Soldatos et al., 2005). Additionally, the 
individuals from South Africa reported to be ‘Very sleepy’ and ‘Dangerously sleepy’ most 
frequently, while bedtime, get-up time, sleep duration, and nap prevalence and duration in these 
individuals were similar to those from the other countries (Soldatos et al., 2005). In addition, a 
study on self-reported sleep duration among older adults in South Africa found that 11.6% 
reported sleeping less than 6 h, and 23.5% reported sleeping more than 10 h per night (Peltzer, 
2012). In contrast, a study with older adults from the United States of America found that more 
than 30% had self-reported sleep durations of less than 6 h, and less than 5% reported sleep 
durations of more than 9 h (Xiao et al., 2019). Furthermore, in the study by Peltzer (2012), white, 
mixed ancestral, and Indian-Asian ethnicities were associated with short sleep duration (<6 h), 
while lower wealth and hypertension were associated with long sleep duration (>10 h) (Peltzer, 
2012). Given the ethnic and socioeconomic diversity in South Africa, sleep duration and other 
sleep characteristics may vary depending on the demographic characteristics of the cohort. Lastly, 
our research group recently described lower body mass index (BMI), waist circumference (WC) 
and better insulin resistance in young African-origin South African women sleeping <7 h compared 
to those sleeping 7-9 h (self-reported) (Rae et al., 2018). This finding was in contrast with findings 
of similar studies in the United States of America and Europe, where shorter sleep duration was 
associated with increased adiposity and worse insulin resistance (Buxton and Marcelli, 2010, Donat 
et al., 2013, López-García et al., 2008, Bjorvatn et al., 2007). Thus, while these studies report that 
South Africa has a high prevalence of individuals who report poor sleep and long sleep duration, 
most of the above-mentioned studies on South Africans reported on the sleep duration and quality 
of individuals from low income settings and of African-origin.  
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The intervention component of this thesis will be performed on individuals who sign up for a 
commercial diet and exercise lifestyle intervention programme. It is prudent to first describe the 
sleep characteristics in a similar group of individuals, and to assess whether sleep disturbances in 
these individuals, if they exist at all, are related to obesity severity.  
Therefore, the aim of this study is to describe and compare the sleep characteristics between 
individuals who are lean (LEAN), individuals who are overweight and class I obese (OW-OBI), 
and those who are class II obese (OBII) and to determine the extent to which sleep characteristics 
are associated with cardiometabolic health in this sample, specifically in adults representative of the 
population that would be studied in the intervention component of this thesis. The first objective 
is to describe and compare actigraphy and polysomnography (PSG)-derived sleep characteristics 
(bedtime, get-up time, midpoint of sleep, time-in-bed (TiB), total sleep time (TST), sleep onset 
latency (SOL), awakening index, wake after sleep onset (WASO), sleep efficiency (SE), awakenings 
>5 min, simplified sleep regularity index (sSRI) and social jet lag), and subjective sleep 
characteristics (sleep quality, daytime sleepiness, and chronotype) between the three groups. The 
second objective is to describe and compare anthropometric (BMI, WC, waist-to-height ratio; 
WHtr), cardiometabolic (blood pressure (BP), fasting glucose and total cholesterol (TC) levels), 
and perceived stress characteristics between the three groups. The third objective is to explore 
associations between the anthropometric, cardiometabolic and sleep characteristics within the three 
groups. It is hypothesised that the OW-OBI and OBII groups will have later bedtimes, get-up 
times and midpoints of sleep, shorter sleep durations, longer SOL, more sleep fragmentation, more 
daytime sleepiness, worse subjective sleep quality and later chronotypes than the LEAN group. 
Lastly, it is hypothesised that unfavourable anthropometric and cardiometabolic outcomes will be 
associated with unfavourable sleep outcomes in all groups.  
3.2 Methods 
3.2.1 Participants 
Adults with overweight or obesity and a WC>88 cm (females) or >102 cm (males), 20 years of age 
or older and of all ethnicities were recruited near the sites in the Cape Town metropole where the 
sample for the intervention component of this thesis was recruited. Participants with a BMI >25 
kg·m-2 and ≤35 kg·m-2 comprised the overweight and class I obesity group (OW-OBI). Those with 
a BMI >35 kg·m-2 comprised the class II obesity group (OBII). The decision to combine the 
overweight and class I obesity group was made post-hoc due to the unbalanced nature of the groups. 
 
 60 
The participants were recruited through the local gym (e.g. newsletter, active recruitment), 
advertisement in local newspapers and by word-of-mouth in the Cape Town suburbs of Newlands 
and surroundings. Exclusion criteria were being diagnosed with a sleep disorder (excluding 
insomnia or mild obstructive sleep apnoea, OSA); exposure to any extrinsic factors that preclude 
normal nocturnal sleep (e.g. currently breastfeeding, parents of young children who routinely wake 
up in the night, shift work); transmeridian travel exceeding three time zones in the previous two 
months; participation in any sport or physical activity for which regular training is required (more 
than four times per week). Additionally, individuals who were lean and apparently healthy were 
recruited for the LEAN group from the same sites where the OW-OBI and OBII groups were 
recruited. Participants had a BMI ≤25 kg·m-2 and a WC ≤88 cm (females) or ≤102 cm (males), 
were 20 years of age or older, and of all ethnicities. The exclusion criteria were the same as for the 
OW-OBI and OBII groups.  
3.2.2 Study design 
In this descriptive cross-sectional study, the LEAN, OW-OBI, and OBII groups were compared 
with respect to the variables of interest. All volunteers completed a questionnaire detailing their 
demographics, medical history, sleep characteristics and perceived stress. The participants also had 
their weight, height, WC, resting BP, fasting glucose and TC levels measured. Over the following 
seven days, the participants wore a wrist actigraph, which, together with a diary, was used to assess 
their sleep habits. The testing took place between 06:00 and 10:00 to account for possible time-of-
day variation in some of the variables. The participants were instructed not to exercise in the 
morning of the assessment prior to testing and to refrain from eating and drinking anything but 
water from 22:00 the previous night until after the assessment. The participants were asked the 
time of their last meal and if they had not fasted since 22:00 the previous night, the appointment 
was rescheduled.     
3.2.3 Detailed procedures 
3.2.3.1 Demographic and lifestyle assessments 
The demographic, occupational, travel, and medical history questions in the questionnaire served 
to characterize the participants, as well as to ensure their eligibility for the study. Due to the fact 
that the city in which the study took place (Cape Town) is home to multiple ethnic groups, the 
demographic section of the questionnaire included one question asking participants to self-identify 
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their ethnicity (Black/African, White, Mixed Ancestry (coloured), Indian, Asian, or Other). 
Smoking status was categorized as ‘never’, ‘past’, or ‘current’. The participants were asked how 
many standard drinks containing alcohol they drink on a typical weekend/day-off day, and on a 
typical week/working day, from which the alcohol consumption in units per week was estimated. 
Alcohol consumption was categorized as ‘none’ if the participant did not consume alcohol at all, 
‘low’ if one to seven units per week for females or one to 14 units per week for males were 
consumed, ‘moderate’ if seven to 14 units per week for females or 14 to 21 units per week for 
males were consumed, and ‘high’ if more than 14 units for females or more than 21 units for males 
were consumed. For physical activity, participants were asked what their average total exercise time 
for the week was. Individuals were placed into one of three physical activity level categories based 
on the hours of exercise they regularly performed per week prior to the study: low levels of physical 
activity (<1 h of exercise per week), moderate (1-3 h of exercise per week), or high (>3 h of exercise 
per week). 
3.2.3.2 Anthropometric measures 
Each participant’s height (cm) was measured using a portable stadiometer (Seca 213, Seca 
Deutschland, 22089 Hamburg, Germany). Body weight (kg) was measured using a digital platform 
scale (Peninsula Scales, Killarney Gardens, Cape Town, South Africa) which was calibrated twice 
a year. The participants were instructed to empty their pockets, remove their shoes, and take off 
any loose clothing such as scarves, jackets and sweaters. Each participant’s BMI (kg⋅m-2) was 
calculated by dividing their weight in kilograms by the square of their height in metres. For WC, 
participants were asked to stand up straight with their feet as close together as physically possible. 
A metal anthropometric tape (Cescorf Equipment Ltd., Porto Elegre, Brazil) was used to measure 
the narrowest circumference between the tenth rib and iliac crest at the end of a normal exhalation. 
Measurements were taken in duplicates and averaged. WHtr was calculated by dividing WC in cm 
by height in cm. Outcome variables were height (cm), weight (kg), BMI (kg⋅m-2), WC (cm), and 
WHtr.  
3.2.3.3 Blood pressure 
After 10 minutes of seated rest, diastolic blood pressure (DBP) and systolic blood pressure (SBP) 
readings were taken three times at 1-minute intervals from the upper arm of each participant using 
an appropriately-sized cuff and an automated blood pressure monitor (Omron HEM-907, Omron 
Health Care, Kyoto, Japan). The three measurements were alternated between the left and right 
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arms. The two DBP readings that were closest together were averaged and the same was done for 
the SBP measurements. If the median DBP or SBP measurement was as close to the lowest as it 
was to the highest measurement, the median measurement was used (i.e. the average of the three 
measurements). Outcome variables were resting DBP and SBP (mmHg).  
3.2.3.4 Fasting glucose and total cholesterol levels 
The index or middle finger was punctured with a spring-loaded safety blade lancet. The first droplet 
of blood was removed with a swab and discarded, and the second drop was placed on a Accutrend 
Plus device testing strip (Roche Products, Randburg, South Africa). The linear measuring range for 
fasting glucose was between 1.1 and 33.3 mmol⋅L-1, and for TC between 3.88 and 7.76 mmol⋅L-1. 
If the result was below or above these ranges as indicated by the device with “Lo” or “Hi” 
respectively, the upper or lower limit was used for the analysis. Outcome variables were fasting 
glucose (mmol⋅L-1) and TC (mmol⋅L-1) levels.  
3.2.3.5 Perceived stress 
Perceived stress was assessed with the 14-item Cohen’s Perceived Stress Scale (CPSS), which 
provides a score between 0 and 56, where higher scores indicate higher levels of perceived stress 
(Cohen et al., 1983). 
3.2.3.6 Cardiometabolic risk factors 
Cardiometabolic risk factors were defined as follows: elevated WC (WC >88 cm for females, or 
WC >102 cm for males; elevated BP (DBP ≥130 mmHg, SBP ≥90 mmHg, or on antihypertensive 
medication); elevated fasting glucose levels (fasting glucose level ≥5.6 mmol·L-1) (Grundy et al., 
2005), and elevated TC levels (TC level ≥5.2 mmol·L-1) (Lloyd-Jones et al., 2010). 
3.2.3.7 Actigraphy 
Participants wore an actigraphy device (Actiwatch AW2, Philips Respironics, Bend, OR, USA) for 
seven consecutive nights and days on the wrist of their non-dominant hand. The participants were 
instructed to press and hold the marker button on the side of the Actiwatch for 3 s when they: 1) 
decided to close their eyes and try to sleep at the beginning of each nocturnal resting period, and 
2) woke to rise for the day or decided not to try to sleep any further. Participants were also 
instructed to keep a sleep diary, in which they would record bedtime and get-up time and any 
factors that may have disturbed their sleep (e.g. barking dog, use the toilet at night, stressful day). 
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For a dataset to be valid, a minimum of three weekday nights (Sunday – Thursday) and one 
weekend night (Friday or Saturday) was required. Philips Actiware software (version 6.0.9, 
Respironics Inc., Murrysville, PA, USA) was used to analyse the recordings. The researcher would 
manually set the start and end of each nocturnal resting period based on the activity and light levels 
and event markers, as previously described (Chow et al., 2016), and confirmed by the diary if 
needed. The wake threshold was set at 40 activity counts and the sleep interval detection algorithm 
was set at 10 min for sleep onset and 10 min for sleep end, as per default settings. The software 
predicted when the participant was awake or asleep for each 15 s epoch of the resting period. A 
simplified version of the sleep regularity index (SRI), a measure of sleep/wake pattern regularity 
(Phillips et al., 2017), was calculated as per equation 1, where n is day, and bedtime and get-up time 
are expressed in 24 h clock time, with minutes as a fraction of hours (e.g. 23.75 for 23:45). Where 
bedtime was later than 24:00, 24 h was added to the bedtime (e.g. 25.50 for 01:30). 
"#$%!	(%) = 100	 ×
(|∆!"#$%&"'(!"#$%&"'()|%&∆*"$(+,	$%&"'(*"$(+,	$%&"'()&)
())* 	× 100   (1) 
Social jet lag was calculated as the absolute difference between mean midpoint of sleep on weekdays 
and mean midpoint of sleep on weekend days (Wittmann et al., 2006). If sleep duration was longer 
on weekend days than weekdays, half the difference between TST on weekend days and weekdays 
was subtracted from social jet lag to correct for catch-up sleep (Jankowski, 2017). The outcome 
variables were actigraphy-derived bedtime (hh:mm), get-up time (hh:mm), TiB (h), TST (h), SOL 
(min), SE (%, TST divided by TiB multiplied by 100), WASO (min), number of awakenings >5 
min (count), awakening index (number of awakenings of any duration divided by TST), sSRI (%), 
midpoint of sleep (hh:mm), and corrected social jet lag (min). All variables were averaged over all 
days of actigraphy monitoring, with the exception of corrected social jet lag.  
3.2.3.8 Polysomnography 
A subset of participants who participated in the intervention component of this thesis underwent 
two consecutive nights of home-based PSG (Easy Ambulatory 2, Cadwell Industries, Inc., 
Kennewick, WA, USA). The first night served as a familiarisation night and was used only if the 
second night of PSG could not be used (e.g. when device malfunctioned). PSG was performed 
according to the American Academy of Sleep Medicine’s recommended electrode montages: 
electroencephalography (EEG): frontal (F3-M2, F4-M1), central (C3-M2, C4-M1) and occipital 
(O1-M2, O2-M1); electrooculography (EOG) (E1-M2, E2-M1); submental electromyography 
(EMG); electrocardiography (ECG); and body position (Berry et al., 2018). Data were sampled at 
200 Hz, the high and low-cut frequency filters were set at 35 Hz and 0.53 Hz respectively, and the 
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notch filter was set at 50 Hz. Sleep stages and arousals were scored according to the standard 
criteria of the American Academy of Sleep Medicine (Berry et al., 2018). Chest and abdominal 
respiratory inductance plethysmography; airflow pressure transducer; pulse oximetry; and body 
position were also recorded to assess sleep-disordered breathing, however, owing to technical and 
human errors, these data could not be used. Lights-on and lights-off were captured by the 
participant using an annotation button on the PSG device. If the participant did not annotate lights-
on or lights-off, the EEG, EOG and body position channels were used to estimate these times. 
Outcome variables were SOL (min), rapid eye movement onset latency (REMOL, min), WASO 
(min, wake time after at least three epochs of sleep have occurred), SE (%), sleep stages (time 
relative to TST (%) spent in non-REM (NREM)1, NREM2, NREM3 and REM sleep), and arousal 
index (number of cortical arousals per hour of sleep).  
3.2.3.9 Subjective sleep assessments 
Subjective sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) 
questionnaire, which provides scores from 0 to 3 on seven components (subjective sleep quality, 
SOL, sleep duration, habitual SE, sleep disturbances, use of sleeping medication, and daytime 
dysfunction) and a global sleep quality score (sum of the component scores) (Buysse et al., 2002). 
Daytime sleepiness was assessed with the Epworth Sleepiness Scale (ESS) which assigns a score 
between 0 and 24 to indicate levels of daytime sleepiness (Johns, 1991). Diurnal preference, or 
chronotype, was assessed with the Horne-Östberg morningness-eveningness personality 
questionnaire (HÖ-MEQ) where lower scores (16-41) indicate eveningness and higher scores (59-
86) morningness (Horne and Ostberg, 1976). 
3.2.3.10 Sleep health 
Five binary values for sleep duration, fragmentation, regularity, social jet lag and daytime sleepiness, 
and a sleep health score were created. For sleep duration, the American National Sleep 
Foundation’s recommendations for sleep duration for adults (7-9 h) was used (Hirshkowitz et al., 
2015). This recommendation is mainly based on self-reported sleep duration, however, which has 
been shown to be approximately 48 min higher than objective sleep duration measured in a group 
of young adults in the USA (Lauderdale et al., 2008). Therefore, 48 min was subtracted from this 
recommendation. Thus, participants were assigned a 1 if TST <6.2h, or a 0 if TST ≥6.2h. High 
sleep fragmentation was defined based on the American National Sleep Foundation’s sleep quality 
recommendations (Ohayon et al., 2017) for SE (<85%), WASO (>20 min), and awakenings >5 
min (>1 awakening). If any two of these conditions were met, participants were assigned a 1 for 
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sleep fragmentation, or a 0 if not. High sSRI was defined based on the study by Lunsford-Avery et 
al. (Lunsford-Avery et al., 2018), where irregular sleepers were defined as those with a SRI below 
the 20th percentile of their cohort, namely 61%. However, since the sSRI is by definition higher 
than SRI, as it ignores nocturnal awakenings and daytime naps, the 20th percentile of the present 
cohort was used as a cut-off point, namely 90%. Participants were assigned a 1 if sSRI was less 
than this cut-off value, or a 0 if not. The participants were assigned a 1 for social jet lag if the 
corrected social jet lag was more than 60 min, or a 0 if not (Mota et al., 2017). The four objective 
indicators of sleep health were based on actigraphy. Participants with excessive daytime sleepiness 
(EDS), which was defined as having an ESS score >10, were assigned a 1, and those without EDS 
a 0. Lastly, the poor sleep health indicators that were present in each individual were summed and 
reported as the sleep health score. 
3.2.4 Data and statistical analyses 
All data were reported as mean ± standard deviation or median with interquartile range (IQR). To 
test for differences of the continuous outcome variables between groups, the one-way analysis of 
covariance (ANCOVA) with age as a covariate was used if the group × age interaction effect was 
not statistically significant, and the model residuals were normally distributed. Otherwise, if the 
group × age interaction effect in the ANCOVA model was statistically significant, the one-way 
analysis of variance (ANOVA) with Bonferroni post-hoc test was used if the model’s residuals were 
normally distributed. If the residuals of the ANCOVA or ANOVA were not normally distributed, 
the data was transformed, or the Kruskal-Wallis one-way ANOVA with the Bonferroni-adjusted 
Dunn’s post-hoc test was used (Dunn, 1964).  
Categorical distributions were analysed using Pearson’s chi-squared. The p-values for the chi-
squared post-hoc test were calculated from the adjusted residuals, and were Bonferroni-adjusted (p-
value times number of cells of the contingency table).  
For the association analyses, linear regressions between variables of interest were used while 
correcting for age if the predictor variable × age interaction effect was not statistically significant, 
and the model’s residuals were normally distributed. If the residuals for the linear regression were 
not normally distributed, ordered logistic regression between the quintiles of the outcome variables 
and the continuous predictor variables (including age) were used. If the assumption for 
proportionality of odds for the ordered logistic regressions were not met, generalized ordered 
logistic regressions were used. The p-values for the linear and (generalized) ordered logistic 
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regressions were Bonferroni-adjusted. Statistical significance was accepted when p<0.05. Data were 
analysed using Stata (v15.1, StataCorp, Texas USA). 
3.3 Results 
3.3.1 Participants 
One-hundred and seventy-one individuals consented to participate in the study. Of these, 13 did 
not meet the eligibility criteria, and another six were excluded because of actigraphy data acquisition 
errors. The remaining participants comprised the LEAN group (n=39), OW-OBI group (n=50) 
and OBII group (n=63). Of the included participants, none reported a previous diagnosis of 
insomnia. 
3.3.2 Demographic and lifestyle characteristics 
The demographic and lifestyle characteristics of the three groups are presented in Table 3.1. The 
OW-OBI group was significantly older than the LEAN (p=0.044) and OBII (p<0.001) groups. The 
OBII group had fewer White (p<0.001) and more mixed ancestral (p<0.001) individuals than the 
expected frequencies. Fewer participants in the LEAN group reported ‘low’ levels of physical 
activity (p=0.036), and more participants reported ‘high’ levels of physical activity (p=0.001) than 
the expected frequency, while more participants reported ‘low’ levels of physical activity than the 
expected frequency in the OBII group (p=0.049).  
 
 
Table 3.1. Demographic and lifestyle characteristics of the LEAN, OW-OBI, and OBII groups.   










Age (y)  41.4 (28.0)  53.8 (15.6) a  42.5 (14.1)  0.002 
Gender        0.910 
    Female  31 (80%)  38 (76%)  48 (76%)   
    Male  8 (20%)  12 (24%)  15 (24%)   
 Ethnicity        <0.001 
    White  31 (80%)  41 (82%)  32 (51%) *   
    Mixed ancestry  4 (10%)  5 (10%)  28 (44%) *   
    Black  2 (5%) b  3 (6%) b  1 (2%) b   
    Indian  2 (5%) b  -  2 (3%) b   
    Other  -  1 (2%) b  -   
 Smoking status        0.067 
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    Never  32 (82%)  33 (66%)  39 (62%)   
    Past  4 (10%)  15 (30%)  17 (27%)   
    Current  3 (8%) b  2 (4%) b  7 (11%) b   
Alcohol consumption        0.249 
    None  12 (31%)  15 (30%)  31 (49%)   
    Low  22 (56%)  27 (54%)  26 (41%)   
    Moderate  4 (10%)  7 (14%)  6 (10%)   
    Heavy  1 (3%) b  1 (2%) b  -   
Physical activity level        0.001 
    Low  10 (25%) *  22 (44%)  37 (59%) *   
    Moderate  12 (31%)  19 (38%)  19 (30%)   
    High  17 (44%) *  9 (18%)  7 (11%)   
Data are presented as median (interquartile range) or count (percentage). LEAN: lean control group; OBII: class II 
obese group; OW-OBI: overweight-class I obese group. The p-values for the between-group comparisons were 
determined using the Kruskal-Wallis ANOVA with Dunn’s post-hoc test, or Chi-squared tests. The cells indicated with 
* are significantly different to the expected frequency. a The OW-OBI group was significantly older than the LEAN 
and OBII groups. The cells indicated with b were excluded from the analyses as expected cell frequency <5.  
 
3.3.3 Anthropometric, cardiometabolic and perceived stress outcomes 
The anthropometric, cardiometabolic and perceived stress characteristics of the three groups are 
presented in Table 3.2. One observation for each of the OW-OBI and OBII groups was missing 
for the fasting glucose and TC tests due to the inability to obtain blood because of poor blood 
perfusion to the fingers. TC levels were higher than the linear measuring range for two participants 
in the LEAN group, one participant in the OW-OBI group, and two participants in the OBII 
group, and thus 7.76 mmol⋅L-1 was used. In addition, TC levels were lower than the linear 
measuring range for one participant in the LEAN group, three participants in the OW-OBI group 
and two participants in the OBII group, and thus 3.88 mmol⋅L-1 was used. By design, the OW-OBI 
group was heavier and had higher BMI, larger WC, and larger WHtr than the LEAN group, and 
the OBII group had a higher BMI, larger WC, and larger WHtr than both the LEAN and OW-
OBI groups. The OBII group had higher DBP than the OW-OBI and LEAN groups. Both OW-
OBI and OBII groups had higher fasting glucose levels than the LEAN group.  
Finally, the OBII had a higher prevalence of elevated WC (p<0.001) and BP (p=0.009), while the 
LEAN group had a lower prevalence of elevated WC (p<0.001) and BP (p=0.021) than the 
expected frequencies (Table 3.3). Although the prevalence of elevated fasting glucose level was 
different between the groups, the difference could not be detected with post-hoc tests. 
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Table 3.2. Anthropometric, cardiometabolic and perceived stress characteristics of the LEAN, OW-OBI, and OBII groups.   













Anthropometric measures               
    Height (cm)  168.9±7.3 39  168.6±8.7 50  166.6±8.2 63  0.233 NA NA NA 
    Weight (kg)  61.8 (11.2) 39  90.3 (17.6) 50  111.7 (29.1) 63  <0.001 t <0.001 t <0.001 t <0.001 t 
    BMI (kg⋅m-2)  22.2 (3.0) 39  31.8 (3.9) 50  39.2 (6.9) 63  <0.001 ♰ <0.001 ♰ <0.001 ♰ <0.001 ♰ 
    WC (cm)  72.1±6.3 39  95.1±9.6 50  111.5±12.4 63  <0.001 <0.001 <0.001 <0.001 
    WHtr  0.43±0.03 39  0.56±0.04 50  0.67±0.07 63  <0.001 <0.001 <0.001 <0.001 
Blood pressure               
    DBP (mmHg)  71.0 (15.0) 39  77.0 (11.5) 50  82.5 (16.0) 63  <0.001 0.117 0.016 <0.001 
    SBP (mmHg)  114.0 (13.5) 39  115.5 (22.0) 50  118.5 (23.5) 63  0.751 
♰ NA NA NA 
Fingerprick tests               
    Fasting glucose (mmol⋅L-1)  4.5 (0.8) 39  5.0 (1.1) 49  5.3 (1.2) 62  <0.001 ♰ 0.012 ♰ 0.075 ♰ <0.001 ♰ 
    TC (mmol⋅L-1)  5.4 (1.5) 39  5.9 (1.7) 49  5.4 (1.7) 62  0.315 ♰ NA NA NA 
CPSS  16.3±6.2 39  19.0±6.4 50  17.9±5.9 63  0.062 NA NA NA 
Data are presented as mean ± standard deviation or median (interquartile range). BMI: body mass index; CPSS: Cohen’s perceived stress scale; DBP: diastolic blood pressure; 
LEAN: lean control group; NA: not applicable; OBII: class II obese group; OW-OBI: overweight-class I obese group; SBP: systolic blood pressure; TC: total cholesterol; WC: waist 
circumference; WHtr: waist-to-height ratio. The p-values for the between-group comparisons were determined using the ANCOVA with age as a covariate, with (t) or without (no 






Table 3.3 Prevalence of cardiometabolic risk factors in the LEAN, OW-OBI and OBII groups.  




Elevated WC  0 (0%) * 39  40 (80%) 50  62 (98%) * 63  <0.001 
Elevated BP  7 (18%) * 39  17 (34%) 50  33 (52%) * 63  0.002 
Elevated fasting glucose  5 (13%) 39  12 (24%) 49  24 (39%) 62  0.015 a 
Elevated TC  24 (62%) 39  34 (69%) 49  38 (61%) 62  0.632 
Data are presented as count (percentage). BP: blood pressure; LEAN: lean control group; OBII: class II obese 
group; OW-OBI: overweight-class I obese group; TC: total cholesterol; WC: waist circumference. The p-values for 
the between-group comparisons were determined using Chi-squared tests. The cells indicated with * are significantly 
different to the expected frequency. a Post-hoc analyses were not sensitive enough to detect differences between 
groups.  
3.3.4 Actigraphy, polysomnography and subjective sleep outcomes 
The actigraphy, PSG and sleep questionnaire outcomes are presented in Table 3.4. Two 
observations are missing for the actigraphy measures that depend on accelerometer data, due to an 
accelerometer calibration error. Bedtime, get-up time and derivatives were not affected by this 
error.  
From actigraphy, the OBII group had shorter TiB and TST and lower SE than the OW-OBI and 
LEAN groups. The OBII group had more awakenings >5 min than the LEAN group. Of the sleep 
timing-related measures, bedtime was delayed in the OBII group compared to the LEAN group, 
and the OBII group had a lower sSRI than the LEAN group. With all three groups combined, 
sSRI correlated with age (⍴=0.307, p<0.001). However, due to the non-normal distribution of the 
ANCOVA residuals for sSRI, even after data transformation, age could not be adjusted for.  
PSG sleep characteristics were only different for NREM3 sleep, such that the OBII had less 
NREM3 sleep than the LEAN group. Although PSG TST was longer in the OW-OBI group than 
in the OBII group, these variables were only reported for descriptive purposes, and will not be 
discussed further. Rather actigraphy-derived TST is used since it is more representative of habitual 
sleep duration.  
The OW-OBI and OBII groups reported higher PSQI scores than the LEAN group. Specifically, 
the distribution of habitual SE (component 4 of the PSQI) and sleep disturbances (component 5 
of the PSQI) were different between the groups (Table 3.5). However, Bonferroni-adjusted post-
hoc analyses could not detect significance between groups. Lastly, the OW-OBI and OBII groups 
had higher ESS scores than the LEAN group. 
Of the five indicators of poor sleep health, only the prevalence of short sleep duration and high 
sleep fragmentation were different between the groups (Table 3.6). More individuals in the OBII 
group (p<0.001), and fewer individuals in the LEAN group (p=0.039) had short sleep duration 
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than the expected frequencies. Post-hoc analyses lacked sensitivity to detect between-group 
differences in the prevalence of high sleep fragmentation. The sleep health score was higher (i.e. 
worse sleep health) in the OBII group than in the LEAN and OW-OBI groups.  
Because the groups were not similar in physical activity level and because physical activity is known 
to affect sleep, the associations of these characteristics with the sleep variables were assessed. With 
all three groups combined, sSRI was lower in those reporting to be ‘low’ physically active 
(median=91.7, interquartile range (IQR)=4.2, n=69), than in those who report being “moderate” 
physically active (median=93.2, IQR=4.0, n=50, p=0.017) or “high” physically active 
(median=93.9, IQR=2.9, n=33, p=0.005). None of the other sleep measures were different 




Table 3.4. Actigraphy, PSG, and subjective sleep characteristics of the LEAN, OW-OBI, and OBII groups.  













Actigraphy               
    TiB (h)  7.6 (1.0) 39  7.6 (1.2) 50  7.3 (1.2) 63  0.008 0.377 0.033 0.003 
    TST (h)  7.0±0.6 39  6.7±0.8 50  6.3±0.8 61  <0.001 0.295 0.002 <0.001 
    SOL (min)  7.0 (7.5) 39  5.5 (7.5) 50  7.9 (9.5) 61  0.177 t NA NA NA 
    SE (%)  90.1 (5.2) 39  90.2 (4.2) 50  87.5 (6.1) 61  0.001 ♰ 1.000 ♰ 0.002 ♰ 0.003 ♰ 
    WASO (min)  23.3 (13.6) 39  25.6 (14.3) 50  28.4 (18.2) 61  0.106 t NA NA NA 
    Awakenings > 5 min   0.43 (0.55) 39  0.46 (0.80) 50  0.67 (1.14) 61  0.050 ♰ a 0.660 ♰ 0.146 ♰ 0.028 ♰ 
    Awakening index  5.6 (2.5) 39  5.5 (2.3) 50  5.7 (2.1) 61  0.148 t NA NA NA 
    Bedtime (hh:mm)  22:49 (0:50) 39  22:49 (1:05) 50  23:16 (1:08) 63  0.027 ♰ 0.765 ♰ 0.078 ♰ 0.019 ♰ 
    Get-up time (hh:mm)  06:32 (0:51) 39  06:28 (1:04) 50  06:29 (0:43) 63  0.802 ♰ NA NA NA 
    sSRI (%)  94.2 (5.6) 39  93.2 (4.1) 50  92.2 (3.7) 63  0.010 ♰ 0.335 ♰ 0.101 ♰ 0.004 ♰ 
    Midpoint of sleep (hh:mm)  02:44 (0:44) 39  02:41 (1:05) 50  02:54 (0:49) 63  0.505 t NA NA NA 
    Corrected social jet lag (min)  31.1 (54.8) 39  29.2 (29.6) 50  47.1 (42.5) 61  0.587 t NA NA NA 
Polysomnography               
    TiB (h)  7.6 (0.6) 12  7.3 (1.2) 14  6.6 (1.3) 16  0.053 t NA NA NA 
    TST (h)  6.6±1.0 12  6.8±0.9 14  5.9±1.1 16  0.045 0.705 0.020 0.062 
    SOL (min)  4.5 (5.3) 12  4.3 (6.5) 14  3.8 (3.8) 16  0.448 ♰ NA NA NA 
    REMOL (min)  102.3 (85.8) 12  67.0 (20.0) 14  73.3 (84.8) 16  0.379 t NA NA NA 
    WASO (min)  28.8 (34.3) 12  17.5 (19.0) 14  27.3 (49.3) 16  0.066 NA NA NA 
    SE (%)  93.5 (10.0) 12  93.5 (3.0) 14  93.0 (11.0) 16  0.690 ♰ NA NA NA 
    NREM1 (%TST)  11.0 (9.7) 12  10.1 (7.9) 14  13.4 (9.1) 16  0.474 t NA NA NA 
    NREM2 (%TST)  47.8±6.8 12  48.5±7.4 14  52.0±9.5 16  0.224 NA NA NA 
    NREM3 (%TST)  22.0±8.4 12  17.7±10.2 14  12.8±8.0 16  0.020 0.191 0.111 0.006 
    REM (%TST)  17.6±6.8 12  21.1±5.2 14  20.2±4.8 16  0.300 NA NA NA 


















Questionnaires               
    PSQI  4.0 (4.0) 39  7.0 (4.0) 50  7.0 (4.0) 63  <0.001 t 0.002 t 0.546 t <0.001 t 
    ESS  7.0 (6.0) 39  8.0 (6.0) 50  8.0 (5.0) 63  0.006 t 0.003 t 0.602 t 0.008 t 
    HÖ-MEQ  62.0 (13.0) 39  58.5 (16) 50  56.0 (11.0) 63  0.174 t NA NA NA 
Data are presented as mean ± standard deviation or median (interquartile range). ESS: Epworth Sleepiness Scale; HÖ-MEQ: Horne-Östberg morningness-eveningness personality 
questionnaire; LEAN: lean control group; NA: not applicable; NREM: non rapid eye movement sleep; OBII: class II obese group; OW-OBI: overweight-class I obese group; PSQI: 
Pittsburgh Sleep Quality Index; REM: rapid eye movement sleep; REMOL: REM onset latency; SE: sleep efficiency; SOL: sleep onset latency; sSRI: simplified sleep regularity index; 
TiB: time-in-bed; TST: total sleep time; WASO: wake after sleep onset. The p-values for the between-group comparisons were determined using the ANCOVA with age as a 
covariate, with (t) or without (no superscript symbol) transformation to achieve normal distribution of ANCOVA residuals, or the Kruskal-Wallis ANOVA (♰) with Dunn’s post-hoc 



















Component 4: Habitual SE        0.024 b 
    0  28 (72%)  20 (40%)  34 (54%)   
    1  5 (13%)  16 (32%)  12 (19%)   
    2  5 (13%)  9 (18%)  6 (10%)   
    3  1 (3%)  5 (10%)  11 (17%)   
Component 5: Sleep disturbances        0.016 b 
    0  2 (5%) a  0 (0%) a  1 (2%) a   
    1  27 (69%)  24 (48%)  28 (44%)   
    2  10 (26%)  26 (52%)  30 (48%)   
    3  0 (0%) a  0 (0%) a  4 (6%) a   
Data are presented as count (percentage). LEAN: lean control group; OBII: class II obese group; OW-OBI: 
overweight-class I obese group; PSQI: Pittsburgh sleep quality index; SE: sleep efficiency. Higher component scores 
indicate worse sleep. The p-values for the between-group comparisons were determined using Chi-squared tests. The 
cells indicated with a were excluded from the post-hoc test as expected cell frequency <5. b Post-hoc analyses were not 
sensitive enough to detect differences between groups.  
 
 
Table 3.6. Prevalence of poor sleep health indicators and sleep health score in the LEAN, OW-OBI and OBII 
groups.  




Short sleep duration  5 (13%) * 39  10 (20%) 50  30 (49%) * 61  <0.001 
High sleep fragmentation  5 (13%) b 39  13 (26%) b 50  24 (39%) b 61  0.015 
High sSRI  9 (23%) 39  11 (22%) 50  16 (25%) 63  0.910 
High corrected social jet lag  11 (28%) 39  7 (14%) 50  17 (28%) 61  0.161 
EDS  4 (10%) 39  14 (28%) 50  14 (22%) 63  0.120 
Sleep health score  0.0 (2.0) 39  1.0 (2.0) 50  2.0 (1.0) c 61  0.003 ♰ 
Data are presented as count (percentage) or median (interquartile range). EDS: excessive daytime sleepiness; LEAN: 
lean control group; OBII: class II obese group; OW-OBI: overweight-class I obese group; sSRI: simplified sleep 
regularity index. The p-values for the between-group comparisons were determined using Chi-squared tests (no 
superscript symbol) or the Kruskal-Wallis ANOVA (♰) with Dunn’s post-hoc. The cells indicated with * are 
significantly different to the expected frequency. b Post-hoc analyses were not sensitive enough to detect differences 
between groups. c Significantly different to LEAN (p<0.001) and OW-OBI (p=0.029) groups.  
3.3.5 Association analyses 
Association analyses were performed combining data from all three groups and adjusting for age. 
Higher BMI, WC, and WHtr were associated with lower TST, and higher PSQI and ESS scores 
were associated with a higher CPSS score (Fig 3.1). Additionally, higher quintiles of WHtr were 
associated with lower actigraphy SE, more awakenings >5 min, and higher PSQI score, and higher 
quintiles of WC were also associated with lower actigraphy SE, more awakenings >5 min (Fig 3.2). 
Lastly, individuals in the lowest WC quintile were more likely to have lower PSQI scores than those 




Figure 3.1. Linear regression plots for BMI and TST (A), WC and TST (B), WHtr and TST (C), CPSS and PSQI 
(D), and CPSS and ESS (E). ●: lean control group (LEAN); ○: overweight-class I obese group (OW-OBI); ●: class II 
obese group (OBII). BMI: body mass index; CPSS: Cohen’s perceived stress scale; ESS: Epworth sleepiness scale; 
PSQI: Pittsburgh sleep quality index; TST: total sleep time; WC: waist circumference; WHtr: waist-to-height ratio. All 
TST is actigraphy-based. Data are presented as beta coefficients (95% confidence interval) and p-values shown were 






Figure 3.2. Dot plots for the residuals of SE for each WHtr (A) and WC (B) quintile, residuals of awakenings >5 
min for each WHtr (C) and WC (D) quintile, and residuals of PSQI for each WHtr quintile (E). ●: lean control group 
(LEAN); ○: overweight-class I obese group (OW-OBI); ●: class II obese group (OBII). OR: odds ratio; PSQI: 
Pittsburgh sleep quality index; SE: sleep efficiency; WC: waist circumference; WHtr: waist-to-height ratio. SE and 
awakenings >5 min are actigraphy-based. The OR (95% confidence interval) and p-values were determined using 





Figure 3.3. Dot plots for the residuals of PSQI for each WC quintile. ●: lean control group (LEAN); ○: overweight-
class I obese group (OW-OBI); ●: class II obese group (OBII). OR: odds ratio; PSQI: Pittsburgh sleep quality index; 
WC: waist circumference. The OR (95% confidence interval) and p-values were determined using generalized 
ordered logistic regression analyses correcting for age, and represent the odds for having lower PSQI scores in the 
quintile below the solid bracket compared to those in the dotted bracket.  
 
3.4 Discussion 
Anthropometric and cardiometabolic health, and actigraphy, polysomnographic, and subjective 
sleep characteristics of individuals who are lean, individuals with overweight or class I obesity, and 
individuals with class II obesity were investigated and compared. The main finding was that the 
OBII group had less TiB and TST, and lower SE than the OW-OBI and LEAN groups. The OBII 
group also had more awakenings >5 min, later bedtimes, lower sSRI, and less NREM3 sleep than 
the LEAN group, but not the OW-OBI group. Furthermore, the OW-OBI and OBII groups had 
worse subjective sleep quality and levels of daytime sleepiness than the LEAN group. Additionally, 
the prevalence of short sleep duration in the OBII group was higher, and that of the LEAN group 
was lower, than the expected frequencies. Over and above the between-group differences in 
anthropometric measures by study design, the OBII group had higher DBP than the OW-OBI and 
LEAN groups, and the OBII and OW-OBI groups had higher levels of fasting glucose than the 
LEAN group. Likewise, the prevalence of elevated BP in the OBII group was higher, and that of 
the LEAN group was lower than the expected frequencies. Higher WC and WHtr were associated 
with shorter TST, lower SE, more awakenings >5 min, and higher PSQI scores (worse sleep 
quality), and higher BMI was associated with lower TST. Finally, higher CPSS scores were 
associated with higher PSQI and ESS scores. 
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Interestingly, differences in objective measures of sleep were observed between the LEAN and 
OBII groups, but not between the LEAN and OW-OBI groups. This finding suggests that mere 
overweight and class I obesity may not affect objective sleep measurably, and that true differences 
in sleep start to be detectable only in class II obesity. However, since the OW-OBI group had 
worse subjective sleep quality and daytime sleepiness than the LEAN group, other measures of 
impaired sleep, not assessed by actigraphy or PSG may exist in the OW-OBI.  
The finding of increased sleep fragmentation and prevalence of high sleep fragmentation in the 
OBII group, and the correlation of WC and WHtr with SE, and awakenings >5 min in the pooled 
cohort, are in line with studies that show associations between sleep fragmentation and BMI or 
obesity (van den Berg et al., 2008, Lauderdale et al., 2009, Stamatakis and Punjabi, 2010, Mezick et 
al., 2014). Moreover, sleep fragmentation may lead to reductions in NREM3 sleep (Hursel et al., 
2011), which was indeed observed in the OBII group. Both reduced NREM3 sleep and sleep 
fragmentation (possibly through a reduction in NREM3 sleep) have been associated with impaired 
glucose homeostasis and insulin resistance (Tasali et al., 2008, Herzog et al., 2013, Koren et al., 
2011, Stamatakis and Punjabi, 2010, Gonnissen et al., 2013). This may, at least in the OBII group, 
contribute to the higher fasting glucose levels observed. Moreover, sleep fragmentation has been 
associated with increased blood pressure (Corbalan-Tutau et al., 2012), which is consistent with the 
finding of higher SBP in the OBII group.  
In addition to the increased sleep fragmentation, the OBII group also had later bedtimes and 
consequently shorter TiB. The decision to retire later and spend less time sleeping may either be 
conscious, driven by deprioritising sleep over other activities such as entertainment (e.g. watching 
TV, reading) and socializing, or subconscious, driven by a decreased sleep propensity (i.e. feeling 
less sleepy) or sleep need (i.e. requiring less sleep). Given the higher levels of daytime sleepiness in 
the OBII group, it is more likely that, if subconscious, the difference in TiB is not driven by a 
decreased sleep need, but rather by a decreased sleep propensity at night.  
Based on the two-process model of sleep regulation (Borbely et al., 2016), the suggested decrease 
in sleep propensity may be explained by two different mechanisms: one that involves the 
homeostatic process and one that involves the circadian process. 
First, although sleep outside of the nocturnal sleep period (i.e. daytime naps) was not captured in 
this study, it is possible that the OBII group napped during the day, thereby affecting the 
homeostatic process, subsequently decreasing night-time sleep propensity, resulting in later 
bedtimes and shorter TiB. In addition, day-to-day variation in napping occurrence and duration, 
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influenced by work and social commitments, may have caused variation in night-time sleep 
propensity, and could thus also explain the decreased sSRI.  
Second, if one assumes that daytime napping did not occur, and given that the OBII group spent 
less time asleep and had more fragmented sleep, they presumably had longer episodes of 
wakefulness in a 24 h period than the LEAN group. One may therefore speculate that the 
homeostatic process drives an increase in sleep propensity, and that the OBII would retire earlier, 
not later as is observed in the present study. It is thus plausible that rather the circadian process, 
and not the homeostatic process, plays a larger role in this observation. Furthermore, since neither 
midpoint of sleep nor chronotype were different between the groups, the lower sleep propensity 
is unlikely to be explained by changes in the phase (i.e. timing) of the circadian process, but rather 
by the amplitude of the circadian process. That is, the circadian amplitude of alerting in the OBII 
group is suppressed, not only resulting in decreased alertness during the day, but also decreased 
sleepiness at night. However, to the best of my knowledge, no studies have compared the circadian 
rhythm amplitude of melatonin, core body temperature or measures of sleepiness or alertness of 
individuals who are obese and individuals who are lean using constant routine or forced 
desynchrony protocols to support this observation. On the other hand, studies assessing diurnal 
variation under entrained conditions have shown that the amplitude of the leptin rhythm is 
attenuated in individuals with obesity (Saad et al., 1998), and inversely associated with weight gain 
(Matkovic et al., 1997), while the diurnal rhythms of melatonin (Brambilla et al., 1988) and core 
body temperature (Heikens et al., 2011) were not different in obese compared to individuals who 
were lean. Additionally, the shorter sleep duration may also explain a change in the circadian 
process; sleep restriction has been shown to decrease the diurnal amplitude of leptin (Spiegel et al., 
2004a), the Stanford sleepiness scale rating, oral temperature (Taub, 1981) and the circadian 
amplitude of gene expression (Moller-Levet et al., 2013). Others have suggested that the phase-
advancing effect of light is attenuated when sleep need is high following sleep restriction (Burgess, 
2010). These mutual influences of the homeostatic and circadian processes, and their mechanisms 
are well known and have been described in detail elsewhere (Borbely et al., 2016).   
Regardless of the potential mechanisms described above, the lower sSRI observed in the OBII 
group may be indicative of a decreased circadian amplitude on its own. Namely, as sleep propensity 
becomes less driven by time-of-day (i.e. the circadian process) it becomes more dependent on time 
awake and the accumulation of sleep debt (i.e. homeostatic process), which varies more between 
days. Others found that SRI was associated with delayed sleep timing, increased daytime sleep and 
sleepiness, reduced light exposure and cardiometabolic risk in a cohort of older adults (Lunsford-
Avery et al., 2018). Future intervention studies focusing on improving sleep regularity in individuals 
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with overweight and obesity may shed more light on the direction of the association between 
circadian amplitude and cardiometabolic risk.  
The between-group difference in sSRI may also be explained by the difference in levels of physical 
activity between the groups. Those who reported lower levels of physical activity had lower sSRI, 
irrespective of their groups. Indeed, regular exercise has been shown to be associated with rest-
activity rhythm consolidation and regularity in healthy elderly males (Van Someren et al., 1997). 
Moreover, children with higher weekday-weekend sleep regularity had more consistent and more 
intensive activity than children with lower sleep regularity (Stone et al., 2013). A possible 
mechanism for this observation in humans may have been found in mice, namely, spontaneous 
exercise during the active period was shown to increase suprachiasmatic nuclei (SCN) activity 
amplitude (van Oosterhout et al., 2012). Thus, a higher SRI may be caused by an increased circadian 
amplitude that results from more regular activity and resting behaviour. The differences in sSRI 
between the LEAN and OBII groups may thus not be exclusively dependent on adiposity.  
The decreased TiB and increased sleep fragmentation in the OBII group compared to the LEAN 
group, ultimately resulted in the shorter TST in the OBII group. This finding, and the correlation 
between anthropometric measures and TST, are in line with studies that have shown associations 
between short sleep duration and BMI (Taheri et al., 2004, Lauderdale et al., 2009), and obesity 
(Cappuccio et al., 2008, Rasmussen et al., 2008). Furthermore, others have shown that individuals 
with short sleep durations (≤5 h) may be at a greater risk of weight gain over the following 6 to 16 
years (Patel et al., 2006, Chaput et al., 2008), and thus individuals in the present study who are 
obese and with short sleep durations may also be at risk of further weight gain. However, the sleep 
durations of the participants in OBII group in the present study were not as short as that of those 
in the aforementioned studies. As such, it is possible that the participants of the present study may 
be protected against further weight gain, provided that sleep duration does not decrease further. 
Short sleep duration has also been associated with type 2 diabetes mellitus (T2DM) (Xu et al., 2010, 
Cappuccio et al., 2009), and 14 days of sleep restriction (5.5 h) in individuals who are healthy and 
non-obese has been shown to lead to reduced glucose tolerance and insulin sensitivity (Nedeltcheva 
et al., 2009). Again, although the sleep duration of the individuals with obesity in the present study 
is not as short as that of the cited studies, the participants may be protected against developing 
(further) insulin resistance. 
Despite no differences in objective sleep between the OW-OBI and LEAN groups, the OW-OBI 
group reported higher levels of daytime sleepiness. The objective measures of sleep assessed in the 
present study may thus not explain these differences. Although the participants were excluded if 
they were diagnosed with OSA or received treatment for OSA, participants were not systematically 
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subjected to a sleep study to confirm the absence of sleep-disordered breathing. Given that obesity 
is a risk factor for OSA and the high estimated number of undiagnosed OSA cases (Kapur et al., 
2002), it cannot be assumed that all participants did not have OSA. Therefore, undiagnosed OSA 
may explain the increased levels of daytime sleepiness in some of the individuals in the OW-OBI 
group. However, sleepiness in individuals with obesity and OSA might only be partially explained 
by sleep apnoea. For example, the apnoea-hypopnoea index and ESS score are only moderately 
correlated (Serafini et al., 2001, Kingshott et al., 1995), and a proportion of individuals with OSA 
and daytime sleepiness continue to experience sleepiness after receiving continuous positive airway 
pressure therapy (Antic et al., 2011, Pepin et al., 2009). Moreover, bariatric surgery in individuals 
with obesity and OSA seems to decrease daytime sleepiness dramatically, without addressing OSA 
(Holty et al., 2011, Fritscher et al., 2007). Together, these findings suggest that adiposity itself, 
regardless of the presence of OSA, is associated with daytime sleepiness. Others have suggested 
that these mechanisms may be associated with metabolic or circadian disturbances, and more 
research is needed to confirm these findings (Vgontzas et al., 1998). It must also be noted that 
although the OW-OBI and OBII groups had ESS scores that were statistically higher than those 
of the LEAN group, the difference is small and may not be clinically relevant or noticeable in 
everyday life. Moreover, the groups did not differ in the prevalence of EDS, regarded as the severity 
at which sleepiness becomes debilitating.  
Although the OW-OBI and OBII groups had higher PSQI scores, which indicates worse sleep 
quality, it cannot be assumed that these participants are less satisfied with their sleep than the 
individuals in the LEAN group, since, the groups did not differ in the first component of the PSQI, 
i.e. rating of subjective sleep quality. Instead, the PSQI components that were different between 
the groups were sleep disturbance and habitual SE, which only confirms the between-group 
difference in actigraphy-assessed sleep fragmentation.  
Finally, despite the differences in sleep characteristics between the groups of the present study, it 
must be noted that the prevalence of poor sleep health indicators and the sleep health score was 
generally low, even in the highest adiposity group (OBII). Therefore, not all individuals with 
cardiometabolic impairment or class II obesity may have impaired sleep, and thus not all individuals 
in this category may benefit from sleep improvement categories. 
3.4.1 Study limitations 
This study had several limitations. First, by not including daytime naps and dozing, it cannot be 
assumed that participants with less total nocturnal sleep time did not nap during the day and 
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ultimately extend 24 h TST, which could subsequently decrease sleep propensity in the evening. 
While instructed to annotate naps, the participants were inconsistent with annotating naps in their 
diaries and automatic or visual detection of naps without these annotations are guesses at best. It 
was therefore decided to only include the nocturnal sleep period in the analysis. Second, only a 
subset of participants in each group underwent PSG, leading to decreased power in the analyses of 
these variables. Third, the common disconnection of the finger pulse oximeter and nasal cannula 
of the PSG device made the data unsuitable for the detection of sleep-disorder breathing. It could 
therefore not be determined whether or not the participants had undiagnosed sleep-disordered 
breathing, or whether the sleep impairment observed in the OBII group was due to their adiposity 
alone and not compounded by sleep-disordered breathing. Fourth, while both cardiometabolic 
health and sleep have been associated with socioeconomic status (Ogunsina et al., 2018, Grandner 
et al., 2010), measures of the latter were not included in the data collection or analysis of the present 
study. To minimize differences in socioeconomic status between individuals, all participants were 
recruited from the same site in the Cape Town metropole. Therefore, this convenience sample is 
not generalizable to the larger Cape Town Metropole. Fifth, due to scheduling and time constraints, 
some of the actigraphy nights overlapped with the PSG nights. Because PSG is considered invasive 
and may alter normal sleep, it is possible that allowing the actigraphy and PSG nights to overlap 
may have affected the actigraphy data. However, since the actigraphy data shown is the average 
over four to seven nights, the impact of the PSG nights on these data is minimal. Indeed, when all 
overlap nights were removed from the analysis, the significance did not change (data not shown).  
3.5 Conclusion 
Combined, these findings suggest that the individuals with class II obesity experienced more sleep 
fragmentation, which may have led to a decrease in NREM3 sleep, more irregular sleep, and shorter 
sleep duration than individuals who are lean. This sleep impairment may put them at risk for 
worsening of their cardiometabolic health, including additional weight gain and insulin resistance, 
which in turn, may perpetuate sleep impairment. These findings are in line with those from other 
cohorts around the world. Future research should investigate whether sleep improvement strategies 
may prevent or mitigate cardiometabolic impairment in individuals with overweight and obesity 














4 The Effect of an eight-week Diet and Exercise 
Lifestyle Intervention Programme on the Sleep 





Short sleep duration (Lucassen et al., 2012, Cappuccio et al., 2011), sleep fragmentation (van den 
Berg et al., 2008, Lauderdale et al., 2009), delayed and irregular sleep timing (Merikanto et al., 2013, 
Taylor et al., 2016), social jet lag (Mota et al., 2017), and decreased non-rapid eye movement 
(NREM)3 sleep (Rao et al., 2009, Tasali et al., 2008) have been bidirectionally associated with 
obesity and worse cardiometabolic health in populations around the globe (see Chapter 1 for a 
full discussion). In Chapter 3, it was found that South African individuals with class II obesity had 
shorter sleep duration, less regular sleep timing, more sleep fragmentation, and less NREM3 sleep 
compared to individuals who are lean. Their sleep habits may put them at an increased risk of 
further weight gain and future insulin resistance and may thus perpetuate the vicious cycle of poor 
sleep and impaired cardiometabolic health.  
Traditionally, weight-loss interventions primarily consist of nutritional modulation or exercise, or 
a combination thereof, to increase energy expenditure and decrease energy intake. The aim is to 
induce a negative energy balance which increases reliance on fat metabolism, thereby reducing fat 
stores and body weight. The effects of these interventions on cardiometabolic health are well-
described. For example, a twelve-month weight-loss lifestyle intervention with nutritional 
modulation and exercise reduced fasting glucose, triglycerides (TG), insulin resistance, glycated 
haemoglobin (HbA1c) and leptin, and increased high-density lipoprotein (HDL) levels in adults 
with overweight and obesity with the metabolic syndrome (MetS) (Salas-Salvado et al., 2019). 
Likewise, another twelve-month lifestyle intervention resulted in reductions in HbA1c, systolic 
blood pressure (SBP), diastolic blood pressure (DBP), TG, and an increase in HDL in 5,145 
individuals with overweight and obesity and type 2 diabetes mellitus (T2DM) (Look Ahead 
Research Group, 2007).  
The effect of sleep modulation, most commonly sleep extension, on cardiometabolic health has 
also been described, albeit to a lesser extent (see Chapter 2 for a full discussion). For example, 
three weekend nights of catch-up sleep has been shown to improve insulin sensitivity in men with 
chronic sleep restriction (Killick et al., 2015). In contrast, six weeks of sleep extension was found 
to be ineffective for improving body mass index (BMI), total body fat, or blood pressure (BP) in 
pre- or hypertensive adults (Haack et al., 2013). Likewise, BMI and total body fat were not affected 
in short-sleeping healthy adults following four weeks of sleep extension (Al Khatib et al., 2018).  
Thus, both diet and exercise, and sleep modulation may improve cardiometabolic health. However, 
to the best of my knowledge, no studies have described the effect of a diet and exercise lifestyle 
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intervention programme on sleep, or the interplay between sleep and cardiometabolic health 
within lifestyle interventions. The effects of exercise on sleep in isolation, however, have been 
investigated, and these studies can be divided into three categories.  
In the first category are the studies with cohorts of individuals with diagnosed insomnia. Studies 
in this category were recently reviewed systematically (Banno et al., 2018). The authors concluded 
that exercise may indeed improve sleep quality (assessed with the Pittsburgh Sleep Quality Index, 
PSQI; and Insomnia Severity Index) without any notable adverse effects in patients with diagnosed 
insomnia (Banno et al., 2018). For example, a six-month moderate-intensity aerobic training 
protocol (three 50-min sessions per week) decreased sleep onset latency (SOL) and wake after 
sleep onset (WASO), and increased sleep efficiency (SE) and subjective sleep quality (PSQI) in 
sedentary adults with chronic primary insomnia (Passos et al., 2011). Similarly, insomnia symptom 
severity (Insomnia Severity Index) in inactive adults with diagnosed insomnia decreased following 
6 months of moderate- to vigorous intensity physical activity (≥150 min per week) (Hartescu et 
al., 2015). The authors of the review paper also mentioned that the effect of exercise on sleep may 
be greater in individuals with diagnosed insomnia than in those without diagnosed insomnia but 
with sleep complaints (Banno et al., 2018). 
The second category of studies comprises those on individuals without diagnosed insomnia but 
with insomnia symptoms or sleep complaints. These studies have also been systematically 
reviewed, albeit less recently, and only cohorts of middle-aged and older adults were included 
(Yang et al., 2012). Nevertheless, when the results of the six included papers were combined, it 
was found that exercise training improved subjective sleep quality (PSQI) in these cohorts (Yang 
et al., 2012). For example, one of the included papers reported that 16 weeks of aerobic exercise 
(four 10-40 min sessions per week), in combination with sleep hygiene education, improved self-
reported SOL, increased sleep duration, and subjective sleep quality (PSQI) in healthy sedentary 
adults with insomnia symptoms (Reid et al., 2010). A more recent study, not included in the review 
paper, reported that SOL (piezoelectric bed sensor) and self-reported difficulty initiating sleep 
improved in a group of participants with chronic insomnia symptoms, most of whom were 
overweight or obese, following a six-month aerobic exercise programme (one to five 30-60 min 
session(s) per week) (Tan et al., 2016). In this study, differences between baseline and follow-up 
measures were also observed for WASO, SE and subjective sleep quality in the exercise group, 
although not significantly different to those found in the control group (Tan et al., 2016). Thus, 
although evidence is available to suggest that exercise may change, and more specifically improve, 
sleep, it is important to note that the participants of these studies had diagnosed insomnia or 
insomnia symptoms.  
 
 85 
For the last category, which includes studies with individuals who were not specifically recruited 
for having diagnosed insomnia or symptoms thereof, no review papers are available. However, 
one original study found that 12 weeks of aerobic exercise and resistance training (180 min weekly) 
increased sleep duration and SE in obese adolescents with no diagnosed insomnia or sleep 
complaints (Mendelson et al., 2016). On the other hand, in a randomized controlled trial with 
middle-aged women with low levels of physical activity, four months of walking or yoga did not 
affect subjective sleep quality (PSQI) (Elavsky and McAuley, 2007).  
Lastly, another systematic review, which only included randomized controlled trials, found that 
resistance training, especially when combined with aerobic exercise improved sleep quality 
(assessed with various tools, including PSQI and the Insomnia Severity Index) (Kovacevic et al., 
2018). However, this review included both clinical and nonclinical populations with and without 
insomnia, and effect-differences between cohorts with and without insomnia were not unpacked. 
Thus, while sufficient evidence is available to suggest that exercise may improve insomnia 
symptoms or sleep complaints in individuals with insomnia, evidence to support a role of exercise 
in improving sleep in individuals without sleep complaints is less abundant.  
Little is known about the effect of nutritional modulation on sleep. Studies have found that some 
foods such as cherries and kiwi fruit improve aspects of sleep, possibly due to their rich contents 
of circadian phase-advancing substances, e.g. melatonin, serotonin, tryptophan (Garrido et al., 
2010, Lin et al., 2011). Moreover, the glycaemic index, carbohydrate and fat contents of diets have 
also been shown to affect sleep. For example, SOL was reduced in healthy participants who had 
eaten a meal with a high glycaemic index 4 h before bedtime compared to those who had eaten a 
meal with a low glycaemic index (Afaghi et al., 2007). Additionally, an older study found that a 
high-carbohydrate/low-fat diet resulted in less NREM3 sleep than a low-carbohydrate/high-fat 
diet or a balanced diet, and that both high-carbohydrate/low-fat diets and low-carbohydrate/high-
fat diets resulted in more rapid eye movement (REM) sleep than a balanced diet (Phillips et al., 
1975). Another older study found that three days of high-carbohydrate bedtime food 
supplementation resulted in more REM sleep (three-day average) than carbohydrate-free or low-
carbohydrate bedtime food supplementation (Porter and Horne, 1981). Similarly, and more 
recently, a short-term very low-carbohydrate diet resulted in an acute decrease in REM sleep and 
an acute increase in NREM3 sleep (Afaghi et al., 2008). Thus, evidence seems to suggest that both 
exercise and diet modulation in isolation may affect sleep. However, little is known about the 
combined effect of exercise and diet modulation, such as seen in lifestyle intervention programmes 
may affect sleep.  
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Therefore, the aim of this study was to determine whether the sleep characteristics of individuals 
with overweight and obesity were altered as a result of participation in an eight-week diet and 
exercise lifestyle intervention programme. The first objective was to compare actigraphy-derived 
sleep characteristics (bedtime; get-up time; midpoint of sleep; time-in-bed, TiB; total sleep time, 
TST; SOL; awakening index; WASO; awakenings >5 min; SE; and simplified sleep regularity index, 
sSRI), and subjective sleep characteristics (PSQI; Epworth sleepiness scale, ESS; and the Horne-
Östberg morningness-eveneningness personality questionnaire, HÖ-MEQ) score in individuals 
with overweight and obesity measured before and after participation in an eight-week diet and 
exercise lifestyle intervention programme to those measured in BMI-matched individuals not 
participating in the programme (i.e. control group). The second objective was to determine 
whether any changes in sleep characteristics were associated with changes in anthropometric or 
cardiometabolic measures over the eight-week period. The hypothesis was that individuals with 
overweight and obesity participating in the eight-week diet and exercise lifestyle intervention 
programme would advance their bedtimes, increase their sleep durations, decrease sleep 
fragmentation, become earlier chronotypes, and improve subjective sleep quality and daytime 
sleepiness to a greater extent than a control group at the end of the eight-week period. It was also 
hypothesised that capacity for improvements in anthropometric and cardiometabolic measures 
depends on the baseline sleep measures, and that the extent to which sleep changes from baseline 
will determine the extent to which anthropometric and cardiometabolic measures change in 
response to the intervention.  
4.2 Methods 
4.2.1 Participants 
Participants were recruited from the pool of individuals with overweight and obesity who 
voluntarily enrolled in a commercial eight-week diet and exercise lifestyle intervention programme, 
called ‘the Healthy Weight Programme’ (HWP group). Participants who enrolled in the 
programme were informed about the study via an email after enrolment, via their individual goal-
setting session, and via the workshop in the first week of the programme. Additionally, participants 
with overweight and obesity who did not enrol in the eight-week lifestyle intervention programme, 
were recruited from the same area in the Cape Town metropole for the control (CON) group. 
Participants in both groups had a BMI >27.5 kg·m-2 and abdominal obesity (waist circumference 
(WC) >88 cm for females, or >102 cm for males); were 20 years of age or older; and of all 
ethnicities. Participants with a narrower WC, but a BMI >28.5 kg·m-2 were also included. 
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Participants were not eligible if they had been diagnosed with a sleep disorder (excluding insomnia 
or mild obstructive sleep apnoea, OSA); were exposed to any extrinsic factor that precludes normal 
nocturnal sleep (e.g. currently breastfeeding, parents of young children who routinely wake up in 
the night, shift work); had undergone transmeridian travel exceeding three time zones in the 
previous two months; or participated in any sport or physical activity for which regular (more than 
four times per week) training was required.  
4.2.2 Study design 
In this natural experiment, participants of the HWP group were compared to the age and gender-
matched CON group with respect to change in the variables of interest over an eight-week period. 
During this period, the HWP group participated in the lifestyle intervention programme, while the 
CON group did not. Both groups underwent baseline and follow-up assessments. During the 
baseline assessment, the participants completed a questionnaire detailing their demographics, 
medical history, and various sleep questionnaires and a perceived stress questionnaire. The 
participants also had their weight, height, WC, resting BP, and fasting glucose and TC levels 
measured. Over the following seven days, the participants wore a wrist actigraph, which, together 
with a diary, was used to assess their habitual sleep habits. This assessment was repeated after eight 
weeks. Both baseline and follow-up assessments took place between 06:00 and 10:00 to account 
for possible time-of-day variation in some of the variables. Within this timeframe, however, the 
baseline and follow-up assessment may not have been at exactly the same time per se. The 
participants were instructed not to exercise in the morning of the assessment and to refrain from 
eating and drinking anything but water from 22:00 the previous night until after the assessment. 
The participants were asked the time of their last meal the night before, and if they had not fasted 
since 22:00 the previous night, the appointment was rescheduled.     
4.2.3 Lifestyle intervention programme 
The aim of the commercial lifestyle intervention programme, called the Healthy Weight Programme, 
was to make sustainable lifestyle modifications (exercise and diet) for the individuals to reduce 
their weight and improve their health. In the first week, the HWP group received a goal setting 
session with a psychologist and a dietary consultation session (including an individualised eating 
plan) with a dietician. The participants also attended a workshop to improve knowledge about diet 
and exercise and to learn skills to reduce and manage their weight. Over the following eight weeks, 
the participants attended periodized group exercise sessions specifically for individuals with 
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overweight and obesity three to four times per week. Each participant’s diet and exercise were 
closely monitored, and adjusted if necessary, by the programme dieticians and biokineticists 
(clinical exercise physiologists). Although recruited from the same suburbs of the Cape Town 
metropole, the participants of the lifestyle intervention programme had to pay a considerable fee 
and may thus have been of higher socioeconomic status than the control participants.  
4.2.4 Detailed procedures 
The detailed procedures were identical to those described in Section 3.2.3, with the exception of 
the PSG assessment which was not included in this study.  
4.2.5 Data and statistical analyses 
All data were reported as mean ± standard deviation or median with interquartile range. A 
Student’s t-test or Kruskal-Wallis analysis of variance (ANOVA) was used to compare the 
characteristics of the two groups at baseline. To test if the changes in outcome variables from 
baseline to follow-up assessments were different between the groups, an analysis of covariance 
(ANCOVA) was used with baseline as a covariate if the group × baseline interaction was not 
significant. If the group × baseline interaction was significant, this assumption for ANCOVA was 
violated, and a one-way ANOVA was used instead. If the residuals of the ANCOVA or ANOVA 
were not normally distributed, the Kruskal-Wallis ANOVA was used. Cohen’s effect size (ES) was 
reported if change in the outcome variable was significantly different between groups. ES was 
considered small if less than 0.5, moderate if 0.5 or higher and less than 0.8, and large if 0.8 or 
higher. Categorical distributions at baseline and follow-up were analysed using Pearson’s chi-
squared or Fisher’s exact tests. For the analyses of change in the binary cardiometabolic and sleep 
conditions between baseline and follow-up, participants were first categorized as ‘0’ if they did not 
have the condition at baseline and follow-up, ‘1’ if they did not have the condition at baseline, but 
did have the condition at follow-up, ‘2’ if they had the condition at baseline, but did not have the 
condition at follow-up, and ‘3’ if they had the condition at baseline and follow-up. The 
distributions of these new categorical variables were then analysed with the Pearson’s chi-squared 
or Fisher’s exact tests. The p-value for the chi-squared post-hoc test was calculated from the adjusted 
residuals and were Bonferroni adjusted (p-value times number of cells of the contingency table). 
Correlations between baseline and change in anthropometric and cardiovascular health outcomes 
and sleep variables were analysed using Pearson’s (for parametric data) and Spearman’s (for non-
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parametric data) correlations as appropriate. The p-value for the significance was accepted when 
p<0.05. Data were analysed using Stata (v15.1, StataCorp, Texas USA). 
4.3 Results 
4.3.1 Participants 
Forty-four participants who enrolled for the eight-week lifestyle intervention programme were 
recruited and tested at baseline. Of these, eleven participants were lost to follow-up and two were 
lost due to technical errors with the Actiwatch. One female participant with a WC of 84.6 cm but 
a BMI of 28.7 kg·m-2 was also included in the HWP group. The final sample size for the HWP 
group was 31. In addition, 30 CON individuals who did not, and never had, participated in the 
lifestyle intervention programme were recruited and tested at baseline. Of these, three participants 
were lost to follow-up, three due to technical errors with the Actiwatch, and one for not collecting 
sufficient actigraphy data. One female participant with a WC of 86.0 cm and BMI of 33.1 kg·m-2 
was included in the CON group. The final CON group comprised 23 individuals. None of the 
included participants reported a previous diagnosis of insomnia. 
The participants of the HWP group were also included in the OW-OBI (n=10) or OBII (n=21) 
groups of Chapter 3, and participants of the CON group were also included in the OW-OBI 
(n=14) or OBII (n=9) groups of Chapter 3. 
4.3.2 Demographic and lifestyle characteristics 
The demographic and lifestyle characteristics of the CON and HWP groups at baseline and at 
follow-up are presented in Table 4.1. There were no differences between the two groups in any 
of these characteristics at baseline. At follow-up, however, as a consequence of the exercise 
component of the lifestyle intervention, more participants in the HWP group reported ‘high’ levels 
of physical activity, and fewer participants reported ‘low’ levels of physical activity compared to 
the CON group. The groups were not different in smoking status or alcohol consumption at 
follow-up.  
4.3.3 Anthropometric, cardiometabolic and perceived stress outcomes 
The baseline and change in anthropometric, cardiometabolic and perceived stress characteristics 
of the HWP and CON groups are presented in Table 4.2. One HWP and two CON BP 
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observations were lost as the pulse was too weak to be detected with the automatic BP monitor. 
One HWP observation and two CON observations were lost for fasting glucose, while two HWP 
and one CON TC observations were lost due to poor blood perfusion to the fingers. TC levels 
were higher than the linear measuring range for one participant in the HWP group at baseline, and 
for one participant in the CON group at baseline and follow-up, and thus 7.76 mmol⋅L-1 was used. 
In addition, TC levels were lower than the linear measuring range for three participants in the 
CON group at baseline and thus 3.88 mmol⋅L-1 was used. The groups did not differ in any of the 
anthropometric or cardiometabolic variables at baseline. The HWP group had a significantly larger 
change in BMI, WC, WHtr and CPSS than the CON group over the eight-week period. The ES 
for BMI, WC, and WHtr were large, and that of CPSS was moderate. Neither change in DPB and 
SBP, nor change in fasting glucose and TC levels were different between the groups.  
The prevalence of cardiometabolic risk factors are presented in Table 4.3. Neither elevated WC, 
BP, fasting glucose levels or TC were different between the groups at baseline or follow-up. 
Change in prevalence of cardiometabolic risk factors from baseline to follow-up was also not 





Table 4.1. Demographic and lifestyle characteristics of the CON and HWP groups at baseline and follow-up.  
 
 







  Baseline Follow-up  Baseline Follow-up  p-value p-value 
Age (y)  47.9±11.1 -  44.5±11.4 -  0.284 - 
Gender        0.220 - 
    Female  19 (83%) -  20 (65%) -    
    Male  4 (17%) -  11 (35%) -    
Ethnicity        0.074 - 
    White  16 (70%) -  16 (52%) -    
    Mixed ancestry  4 (17%) -  14 (45%) -    
    Black  2 (9%) b -  1 (3%) b -    
    Other  1 (4%) b -  0 (0%) b -    
Smoking status        1.000 0.574 
    Never  15 (65%) 13 (57%)  18 (58%) 18 (58%)    
    Past  8 (35%) 10 (43%)  11 (36%) 11 (36%)    
    Current  0 (0%) a 0 (0%) a  2 (6%) a 2 (6%) a    
Alcohol consumption        0.573 0.776 
    None  9 (39%) 9 (39%)  14 (45%) 13 (42%)    
    Low  12 (52%) 12 (52%)  13 (42%) 14 (46%)    
    Moderate  2 (9%) a 2 (9%) a  4 (13%) a 2 (6%) a    
    Heavy  0 (0%) a 0 (0%) a  0 (0%) a 2 (6%) a    
Physical activity level        0.374 <0.001 
    Low  9 (39%) 9 (39%) *  18 (58%) 1 (3%) *    
    Moderate  9 (39%) 9 (39%)  9 (29%) 4 (13%)    
    High  5 (22%) 5 (22%) *  4 (13%) 26 (84%) *    
Data are presented as mean ± standard deviation or count (percentage). CON: control group; HWP: Healthy Weight Programme group. The p-values for the between-group 
comparisons were determined using the Student’s t-test, or Fisher’s exact test. The cells indicated with * are significantly different to the expected frequency. The cells indicated with 




Table 4.2. Anthropometric, cardiometabolic and perceived stress characteristics of the CON and HWP groups at baseline, and change from baseline to follow-up.  
  CON  
  
HWP    
Between-group  
comparison at  
baseline 
 Between-group  
comparison of  
change  
    Baseline Change n  Baseline Change n  p-value  ES p-value 
Anthropometric measures               
    Height (cm)  164.5 (9.0) - 23  168.7 (12.4) - 31  0.088♰  - - 
    Weight (kg)   97.1 (22.3) -0.2 (2.6) 23  105.2 (29.4) -2.3 (3.3) 31  0.089  0.928 0.002 bl 
    BMI (kg⋅m-2)   34.5 (6.0) -0.1 (1.1) 23  37.1 (7.4) -0.8 (1.1) 31  0.431  1.015 <0.001 bl 
    WC (cm)   98.3 (15.2) 0.1 (4.2) 23  109.3 (22.6) -3.1 (2.4) 31  0.073♰  1.075 <0.001♰ 
    WHtr  0.61 (0.08) 0.00 (0.02) 23  0.64 (0.12) -0.02 (0.01) 31  0.187♰  1.073 <0.001♰ 
Blood pressure               
    DBP (mmHg)   81.6±9.3 -4.7±6.2 21  80.7±10.5 -3.4±6.9 30  0.741  -0.189 0.566 bl 
    SBP (mmHg)   121.0±14.3 -6.6±10.2 21  121.6±18.2 -3.5±11.6 30  0.902  -0.281 0.171 bl 
Fingerprick tests               
    Fasting glucose (mmol⋅L-1)   4.8 (1.0) 0.2 (1.1) 21  5.4 (1.1) 0.1 (1.0) 30  0.356  0.174 0.867 bl 
    TC (mmol⋅L-1)   5.7 (2.2) -0.1 (0.7) 22  5.4 (1.1) 0.0 (0.8) 29  0.865  -0.194 0.478 bl 
CPSS   18.0 (11.0) 1.0 (6.0) 23  18.0 (10.0) -3.0 (5.0) 31  0.930♰  0.530 0.009♰ 
Data are presented as mean ± standard deviation or median (interquartile range). BMI: body mass index; CON: control group; CPSS: Cohen’s perceived stress scale; DBP: diastolic 
blood pressure; ES: effect size; HWP: Healthy Weight Programme group; SBP: systolic blood pressure; TC: total cholesterol; WC: waist circumference; WHtr: waist-to-height ratio. 
The p-values for the between-group comparisons at baseline were determined using the Student’s t-test (no superscript symbol) or Kruskal-Wallis (♰), and those for the between 
group comparisons of change were determined using the ANCOVA adjusted for baseline values (bl), Student’s t-test (no superscript symbol) or Kruskal-Wallis(♰). The ES 
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  Baseline  Follow-up n  Baseline  Follow-up n  p-value p-value 
Elevated WC  22 (96%) ↔ 22 (96%) 23  29 (94%) ↓ 25 (81%) 31  1.000 0.218 
Elevated BP  11 (52%) ↓ 5 (24%) 21  16 (53%) ↓ 11 (37%) 30  1.000 0.375 
Elevated fasting glucose  5 (24%) ↔ 5 (24%) 21  13 (43%) ↓ 11 (37%) 30  0.234 0.375 
Elevated TC  13 (59%) ↓ 12 (55%) 22  17 (59%) ↓ 16 (55%) 29  1.000 1.000 
Data are presented as count (percentage). BP: blood pressure; CON: control group; HWP: Healthy Weight Programme group; TC: total cholesterol; WC: waist circumference. ↑ 
indicates prevalence increased, ↓ indicates prevalence decreased, and ↔ indicates prevalence did not change between baseline and follow-up. The p-values for the between-group 






4.3.4 Actigraphy and subjective sleep outcomes 
The baseline and change in actigraphy and subjective sleep characteristics of the HWP and CON 
groups are presented in Table 4.4. Two HWP observations for some of the actigraphy variables 
were lost due to data acquisition errors, which resulted in only bedtime, get-up time and their 
derivatives being retrievable. None of the sleep characteristics were different at baseline between 
the groups and none of the sleep variables changed differently between the two groups over the 
eight-week period. 
The prevalence of poor sleep health indicators and the sleep health score are presented in Table 
4.5. In both groups, most (>50%) of the individuals did not have poor sleep health at baseline or 
follow-up. Prevalence of poor sleep health indicators was not different between the groups at 
baseline or follow-up. Likewise, change in the prevalence of poor sleep health indicators or in the 





Table 4.4. Actigraphy and subjective sleep characteristics of the CON and HWP groups at baseline, and change from baseline to follow-up. 







   Baseline Change n   Baseline Change n  p-value  ES p-value 
Actigraphy               
    TiB (h)  7.6±1.0 -0.3±1.0 23   7.2±0.6 0.1±0.8 31  0.150  -0.518 0.438 bl 
    TST (h)  6.6±0.8 -0.3±0.9 23   6.3±0.7 0.1±0.7 29  0.247  -0.402 0.148 bl 
    SOL (min)  8.0 (9.2) -0.6 (10.2) 23   6.5 (10.7) 1.0 (8.0) 29  0.971♰  -0.088 0.537 
♰ 
    SE (%)  88.3 (6.0) 0.1 (4.6) 23   88.4 (4.1) -0.6 (4.1) 29  0.992  -0.310 0.273 
    WASO (min)  29.6 (25.9) -1.0 (13.2) 23   27.3 (9.5) -0.4 (10.0) 29  0.314  -0.406 0.311 bl 
    Awakenings >5 min   0.6 (1.0) 0.0 (1.0) 23   0.4 (0.9) 0.0 (0.6) 29  0.157  -0.073 0.955 bl 
    Awakening index (awakenings/h of TST)  6.3 (3.5) 0.0 (0.7) 23   5.6 (2.9) 0.1 (1.6) 29  0.832♰  0.070 0.876 
♰ 
    Bedtime (hh:mm)  23:01±0:40 0:08±0:47 23   23:10±0:42 0:04±0:37 31  0.455  0.110 0.974 bl 
    Get-up time (hh:mm)  6:34 (1:23) -0:08 (1:05) 23   6:22 (0:36) 0:01 (0:43) 31  0.409  -0.450 0.108 
    sSRI (%)  92.5±2.9 0.0±3.8 23   92.5±2.7 -0.5±3.8 31  0.940  0.151 0.586 
    Midpoint of sleep (hh:mm)  2:47±0:37 0:00±0:29 23   2:46±0:37 0:06±0:29 31  0.912  -0.202 0.465 
    Corrected social jet lag (min)  33.0±25.3 6.1±41.9 23  45.2±33.3 -7.1±42.6 29  0.151  0.312 0.269 
Questionnaires               
    PSQI  7.4±3.1 -0.3±1.7 23   6.5±3.2 -1.6±3.2 31  0.279  0.490 0.081 
    ESS  8.7±3.7 -0.7±2.6 23   8.3±4.2 -0.7±3.0 31  0.706  -0.018 0.949 
    HÖ-MEQ  60.5±9.9 0.5±3.2 23   56.8±9.6 1.5±5.1 31  0.179  -0.234 0.817 bl 
Data are presented as mean ± standard deviation or median (interquartile range). CON: control group; ES: effect size ESS: Epworth sleepiness scale; HÖ-MEQ: Horne-Östberg 
morningness-eveningness personality questionnaire; HWP: Healthy Weight Programme group; PSQI: Pittsburgh sleep quality index; SE: sleep efficiency; SOL: sleep onset latency; 
sSRI: simplified sleep regularity index; TiB: time-in-bed; TST: total sleep time; WASO: wake after sleep onset. The p-values for the between-group comparisons at baseline were 
determined using the Student’s t-test (no superscript symbol) or Kruskal-Wallis (♰), and those for the between group comparisons of change were determined using the ANCOVA 







Table 4.5. Prevalence of poor sleep health indicators and sleep health score in the CON and HWP groups. 
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   HWP 
 







  Baseline  Follow-up n  Baseline  Follow-up n  p-value p-value 
Short sleep duration  7 (30%) ↑ 11 (48%) 23  11 (38%) ↑ 12 (41%) 29  0.770 0.780 
High sleep fragmentation  9 (39%) ↓ 7 (30%) 23  11 (38%) ↔ 11 (38%) 29  1.000 0.770 
High sSRI  4 (17%) ↓ 3 (13%) 23  6 (19%) ↑ 8 (26%) 31  1.000 0.319 
High corrected social jet lag  3 (13%) ↑ 5 (22%) 23  7 (24%) ↓ 6 (21%) 29  0.482 1.000 
EDS  6 (26%) ↔ 6 (26%) 23  9 (29%) ↓ 7 (23%) 31  1.000 1.000 
  CON 
 
   HWP 
 







  Baseline  Change n  Baseline  Change n  p-value p-value 
Sleep health score  1.0 (2.0)  0.0 (0.0) 23  1.0 (2.0)  0.0 (2.0) 29  0.510 0.859 bl 
Data are presented as count (percentage) or median (interquartile range). CON: control group; EDS: excessive daytime sleepiness; HWP: Healthy Weight Programme group; sSRI: 
simplified sleep regularity index. ↑ indicates prevalence increased, ↓ indicates prevalence decreased, and ↔ indicates prevalence did not change between baseline and follow-up. The 
p-values for the between-group comparisons of the binary variables were determined using the Fisher’s exact test, for the between-group comparison of sleep health score at 
baseline with the Student’s t-test, and for the between-group comparisons of change between baseline and follow-up with the ANCOVA adjusted for baseline values (bl). The ES 






4.3.5 Association analyses 
At baseline, TST correlated with WC (Fig 4.1A) and WHtr (Fig 4.1B). Change in anthropometric 
and cardiometabolic health characteristics did not correlate with sleep characteristics at baseline 
(data not shown). No correlations were found between change in anthropometric and 
cardiometabolic health characteristics in response to the lifestyle intervention programme and 
change in sleep characteristics (data not shown).  
 
 
Figure 4.1. Correlation plots for WC and TST (A), and WHtr and TST (B) at baseline. ○ control group (CON); ● 
Healthy Weight Programme group (HWP). TST: total sleep time; WC: waist circumference; WHtr: waist-to-height 
ratio. The coefficients and p-values were determined using Pearson’s correlation.   
 
4.4 Discussion 
In this study, the effects of an eight-week diet and exercise lifestyle intervention programme on 
the cardiometabolic health and sleep characteristics of individuals with overweight and obesity 
were described. The main finding was that participation in the lifestyle intervention programme 
aimed at weight-loss, improving fitness and improving cardiometabolic health, does not per se lead 
to concomitant changes in actigraphy-derived and subjective sleep characteristics, despite 
improving anthropometric measures and perceived stress.  
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Research suggests a role for both exercise and diet in isolation on sleep (see Section 4.1). To the 
best of my knowledge, however, the present study is the first to describe the effect of a combined 
diet and exercise lifestyle intervention programme, designed for weight-loss, on sleep.  
As discussed in Section 4.1, most evidence for a role of exercise in improving sleep comes from 
studies of which participants had either insomnia or symptoms thereof. Although insomnia 
symptoms were not measured in the participants of the present study, none reported being 
previously diagnosed with insomnia, and they did also not have poor sleep health in particular, 
which may explain the lack of effect observed in the present study. Despite the potential effect of 
some foods and diet on sleep, any change in the individual’s dietary intake in the present study, if 
they occurred at all, in combination with the effects of other exposures from the intervention, did 
not measurably affect sleep. It must be noted, however, that the dietary advice was different for 
each participant of the intervention programme, and that dietary intake was not assessed 
throughout the intervention. Therefore, any discussion in this regard is speculative at best, and is 
beyond the scope of this study.  
Evidence of a bidirectional association between anthropometric measures and aspects of sleep is 
abundant. Even in the current cohort of individuals with overweight and obesity, WC and WHtr 
were associated with TST. It was therefore surprising that sleep was not affected by an 
improvement in the anthropometric measures in the present study. There are several possible non-
mutually exclusive reasons for the absence of an improvement in sleep following the intervention. 
First, as the sleep health score was low in both the HWP and CON groups, participants may not 
have had a particularly poor sleep health to begin with, and improvements in sleep may have thus 
been an unlikely outcome for the majority of participants. In addition, these findings show that 
despite the association between adiposity and poor sleep, it cannot be assumed that all participants 
of a lifestyle intervention programme who are overweight or obese have poor sleep. The effect of 
the intervention on sleep may have been more profound if all participants had poor sleep at 
baseline. This was not, however, an objective of the present study.  
Second, the duration of the intervention (eight weeks) may have been too short for any 
spontaneous changes in sleep to occur, following changes in dietary modulation, exercise, and 
cardiometabolic health. Although changes in sleep have been observed following shorter-duration 
sleep-improvement interventions (Suzuki et al., 2008, Chen et al., 2010), sleep improvement 
through weight-loss interventions may require more time. That is, weight-loss intervention-
mediated changes in sleep may occur through both changes in lifestyle (i.e. diet and exercise) and 
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changes in cardiometabolic health (e.g. weight-loss). The effect of changes in cardiometabolic 
health on sleep, however, may require more time.  
Third, it is also possible that in order to halt the vicious cycle of adiposity and poor sleep, more 
weight-loss than what was achieved during the lifestyle intervention of the present study is 
required, or other aspects of cardiometabolic health must improve. It is also possible that although 
adiposity and poor cardiometabolic health may drive an individual to have disrupted sleep, weight-
loss in combination with sleep modulation are required to restore sleep. It may be difficult, if 
possible at all, to investigate the effect of weight-loss, without the effect of diet and exercise, on 
sleep. To the best of my knowledge, no such studies have been published.  
Evidence suggests that weight-loss is dependent on sufficient sleep. For example, one study found 
that adults with overweight and obesity who were experimentally sleep-restricted, lost less total fat 
mass following eight weeks of caloric restriction than adults with overweight or obesity who could 
sleep ad libitum (Wang et al., 2018). Another study reported that adolescents with obesity who lost 
more than 1 kg⋅m-2 of their BMI following a multidisciplinary weight management programme, 
had longer sleep duration at baseline than those who lost less than 1 kg⋅m-2 of their BMI (Sallinen 
et al., 2013). These studies are in line with a study of American Indian and Alaska Native 
participants of a lifestyle intervention focussing on diet, exercise and behaviour modification, 
where short sleep duration (≤6 h) predicted less weight-loss (Nuyujukian et al., 2016). A lifestyle 
intervention programme in combination with a sleep intervention programme may thus not only 
improve aspects of sleep, but also improve weight-loss and possibly other aspects of 
cardiometabolic health. In the present study, however, changes in anthropometric measures were 
independent of how the participants were sleeping at baseline. The predominantly good sleep 
health in the majority of the participants of the present study may have disassociated sleep at 
baseline from change in cardiometabolic health. More research is needed to explore whether good 
sleep health supports weight-loss and improvements in cardiometabolic health in lifestyle 
intervention programmes.  
Finally, the decrease in perceived stress following the lifestyle intervention programme may be the 
result of the programme’s exercise sessions. Other studies found that perceived stress reduced 
following four and twelve weeks of aerobic gymnastic exercise in postnatal women (Yang and 
Chen, 2018), and in older adults following a ten-week physical activity intervention (Starkweather, 
2007). Higher levels of perceived stress have been associated with shorter sleep duration and worse 
sleep quality (Doolin et al., 2018, Rawat et al., 2016), and higher CPSS scores were also associated 
with higher PSQI and ESS scores in Chapter 3. If a reason for sleep disturbance originates from 
 
 100 
high levels of perceived stress, it is likely that improving stress levels may improve sleep quality. 
In the present study, however, improvements in perceived stress were not associated with changes 
in sleep. These findings may suggest that the perceived stress did not affect the participant’s sleep, 
or, as mentioned above, sleep was of good duration and quality in the first place.  
4.4.1 Study limitations 
The participants in this natural experiment did not have particularly poor sleep to start with, and 
thus were unlikely to improve on this aspect. The findings of this study may thus not apply to 
participants of lifestyle intervention programmes who have poor sleep health. Another limitation 
is the modest sample size, which may increase the chance of type II error, following the 
Bonferroni-adjustment. Namely, the alpha-level for the post-hoc test and correlations were 
Bonferroni-adjusted to avoid the multi-comparison problem (chance of type I errors increases 
with the number of tests performed). However, this Bonferroni-adjustment has been suggested to 
be too conservative, and thus increasing the chance of type II error (Rothman, 1990, Perneger, 
1998), especially in combination with the small sample size in the present study. To illustrate, no 
associations were found between sleep indices at baseline and change in anthropometric or 
cardiometabolic measures with Bonferroni-adjustment, while without Bonferroni-adjustment, 
change in SBP correlated with corrected social jet lag and HÖ-MEQ score, such that those with 
less corrected social jet lag and earlier chronotypes at baseline experienced the highest reduction 
in SBP. Those with earlier chronotypes and worse sleep quality at baseline had the largest reduction 
in fasting glucose levels. Lastly, those with the lower corrected social jet lag at baseline experienced 
larger decreases in TC levels. Further research on larger cohorts is required to confirm that the 
absence of an association between baseline sleep and change in anthropometric and 
cardiometabolic measures are indeed true negatives. Furthermore, a larger sample size would allow 
for the adjustment of confounding factors such as age and participation or compliance. Other 
factors may include those that have not been assessed and may therefore be listed as additional 
study limitations. One of these factors may be knowledge of sleep hygiene, which may have been 
assessed with the Sleep Hygiene Index; a tool which tests the presence of 13 common poor sleep 
hygiene behaviours (Mastin et al., 2006). Another of those confounding factors may be dietary 
intake, which may have been assessed with a food diary. Lastly, the study was designed as a natural 
experiment and not as a randomized controlled trial. The sample was drawn from the same area, 
but separately from one another. For the HWP group, the sample was drawn from a population 
of individuals from the Cape Town metropole who had enrolled for the commercial diet and 
exercise lifestyle intervention programme. The CON group was drawn from a population from 
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the Cape Town metropole who had not enrolled for the commercial lifestyle intervention 
programme. To match the two groups for age and sex, the CON group was recruited after the 
HWP group. This setting did therefore not allow for randomisation. Due to this limitation, it is 
possible that the two groups differed by other factors, not accounted for in the current study, that 
may explain some of the outcomes. For example, it cannot be ruled out that the changes in 
anthropometric measures and CPSS score were not due to factors that also affected the decision 
to enrol for the lifestyle intervention programme, rather than the intervention itself.  
4.5 Conclusion 
This study showed that a commercial eight-week lifestyle intervention programme with nutritional 
modulation and exercise does not lead to concomitant changes in sleep in individuals with 
overweight and obesity. The relatively good sleep health and cardiometabolic health of the majority 
of participants upon entering the programme and the duration or efficacy of the lifestyle 
intervention programme may explain the findings of the present study. Further research should 
investigate whether the addition of a sleep behaviour intervention to lifestyle intervention 














5 A Sleep Behaviour Intervention to Improve 
Cardiometabolic Health in Adults with 





Cardiometabolic disease (CMD), and an important risk factor thereof, obesity, pose a major health 
burden on the world’s population (World Health Organization, 2015). Poor sleep has been 
associated with cardiometabolic impairment in populations around the world (see Chapter 1). As 
shown in Chapter 3, individuals with class II obesity recruited from the population studied in the 
intervention component of this thesis, had shorter sleep duration, more sleep fragmentation, 
delayed bedtime, less regular sleep and less non-rapid eye movement (NREM)3 sleep than those 
who were overweight or had class I obesity.  
Although evidence for the association between sleep and cardiometabolic health is abundant, 
surprisingly few studies have looked into the effect of improving sleep as a means to improve 
cardiometabolic health. For example, only seven studies have looked at the effect of sleep 
extension specifically on cardiometabolic health (see Chapter 2). Collectively, these studies 
described improvements in insulin sensitivity, a decrease in leptin and peptide tyrosine-tyrosine 
(PYY), and change in appetite and food intake following sleep extension interventions. However, 
due to the small number of studies, small study cohorts, and disparities between findings, evidence 
to support a role for sleep improvement interventions in reducing risk for CMD is promising but 
inconclusive. Another reason for the discrepancies between the findings of these studies may be 
that diet and exercise have been insufficiently controlled for.  
Therefore, the aim of this randomized controlled trial was to measure the effects of a sleep 
behaviour intervention within an eight-week diet and exercise lifestyle intervention programme on 
sleep and cardiometabolic health in individuals with overweight and obesity, and to determine 
whether changes in sleep were associated with changes in cardiometabolic health outcomes. The 
reason for applying the sleep behaviour intervention within the setting of this lifestyle intervention 
was to ensure that both diet and exercise were controlled for, at least to some extent, so that any 
confounding effects on cardiometabolic outcomes might be minimised. It was hypothesised that 
the sleep behaviour intervention would improve participants’ sleep (e.g. increase sleep duration, 
reduce sleep fragmentation, and decrease social jet lag) and that these improvements would be 






5.2.1 Participants  
Men and women with overweight or obesity who enrolled in a commercial eight-week lifestyle 
intervention programme were invited to participate in this study. Participants were eligible if their 
body mass index (BMI) was ≥25 kg·m-2, their waist circumference (WC) was >88 cm (females) or 
>102 cm (males) and their age was >20 years. Participants with narrower WC were also included 
provided their BMI was >28.5 kg·m-2. Participants were not eligible if they had been diagnosed 
with a sleep disorder (excluding insomnia or mild obstructive sleep apnoea, OSA); used hypnotic 
drugs on a regular basis; were exposed to any other factor that precludes normal nocturnal sleep 
(e.g. currently breastfeeding, parents of young children who routinely wake up in the night, shift 
work); had undergone transmeridian travel exceeding three time zones in the two months leading 
up to the baseline assessment or before the follow-up assessment; or participated in any sport or 
physical activity for which regular training is required (more than four times per week). Eligible 
participants were randomly assigned to either the CON or the SBI group. 
5.2.2 Study design 
This study was a randomized controlled trial. The participants voluntarily enrolled in a commercial 
eight-week lifestyle intervention programme where they underwent a goal-setting session with a 
psychologist and a dietary consultation session (including an individualised eating plan) with a 
dietician (see Section 4.2.3). The participants had baseline and follow-up measurements taken 
which included a questionnaire, one week of actigraphy and measures of cardiometabolic health 
and perceived stress. The assessments were performed within two weeks of the start and end of 
the lifestyle intervention programme. All questionnaire, anthropometric and clinical measurements 
took place in the morning between 06:00 and 10:00 to avoid diurnal variation bias of these 
variables. Within this timeframe, however, the baseline and follow-up assessments may not have 
been at exactly the same time per se. The participants were instructed not to exercise in the morning 
before the assessment and to refrain from eating and drinking anything but water from 22:00 the 
previous night until after the assessment to ensure an 8-h fast. The participants were asked the 
time of their last meal. If participants were not fasted since 22:00 the previous night, the 
appointment was rescheduled. Following the baseline assessment, but still within two weeks of the 
start of the programme, the participants were randomly assigned to either the CON or SBI group 
by means of drawing. Participants in the SBI group underwent a sleep behaviour intervention 
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aimed at improving nocturnal sleep over the duration of the lifestyle intervention programme. 
Participants in the CON group were asked not to change their sleep habits or patterns during the 
eight-week period and did not receive the sleep behaviour intervention.  
5.2.3 Sleep behaviour intervention 
The aim of the intervention was to improve nocturnal sleep, i.e. ensure optimal sleep-timing, fall 
asleep with ease, stay asleep throughout the night, wake up at desired wake-up time and acquire 
sufficient sleep. The intervention comprised of individualized, one-on-one, consultation sessions 
with techniques borrowed from motivational interviewing (e.g. open questions, affirmation, 
listening, reflection, and summaries). The intervention was based on four principles. First, 
awareness, which related to making the participant cognizant of the need for behaviour change. 
Second, education or transfer of information, which related to the education about sleep in general, 
the consequences of poor sleep, and an introduction to tools that may help one sleep better. The 
third principle related to the individual’s intrinsic motivation to change. The last principle on which 
the intervention was based is support with behaviour change itself, and may involve affirmation 
to progress made, and addressing challenges the individuals may experience with behaviour 
change. During the first session, the participant and researcher identified challenges that the 
participant had with their sleep, including social and environmental barriers to sleep. Baseline 
actigraphy data were used to evoke the participant’s realisation of suboptimal sleep (e.g. if sleep 
duration was less than 6.5 h, or sleep onset latency (SOL) was longer than 30 min). The participant 
also received verbal education about sleep in general and the importance of sleep. At the end of 
this session, which took approximately 60 min, a plan of action was agreed upon, which the 
participant tried to implement at home. Typical action points were related to sleep hygiene and 
included maintaining regular bedtime and get-up times; avoiding electronic screen time from 20:00 
in the evening; having their evening meal before 19:00; and using relaxation techniques. During 
each successive session, which took between 30 and 60 min, the progress and obstacles to the 
suggested behavioural changes were discussed and new suggestions were made accordingly. This 




5.2.4 Detailed procedures 
The detailed procedures for demographic and lifestyle assessments, anthropometric 
measurements, blood pressure (BP), perceived stress, actigraphy and subjective sleep assessments 
were as those described in Section 3.2.3.  
5.2.4.1 Dual X-ray absorptiometry  
A whole-body dual X-ray absorptiometry scan (Discovery-W, Hologic Inc., Bedford, MA, USA) 
was used to determine total body fat (as a percentage of total weight) and lean mass (kg) 
(Micklesfield et al., 2012).  
5.2.4.2 Insulin resistance and lipids 
Fasting blood samples were taken from all participants for the assessment of glucose, insulin, 
glycated haemoglobin (HbA1c), and blood lipid levels. All blood samples were analysed by a 
medical diagnostic laboratory (Lancet Laboratories, Century City, Cape Town, South Africa). The 
homeostatic model assessment 2 for insulin resistance (HOMA2-IR) calculator (v2.2.3, Diabetes 
Trials Unit, University of Oxford) was used to determine insulin resistance from fasting glucose 
and insulin levels (Levy JC, 1998). Outcome variables were fasting glucose (mmol⋅L-1) and insulin 
levels, HOMA2-IR, HbA1c (%), TC (mmol⋅L-1), low-density lipoprotein (LDL, mmol⋅L-1), high-
density lipoprotein (HDL, mmol⋅L-1), as well as triglyceride (TG, mmol⋅L-1) levels.  
5.2.4.3 Resting metabolic rate 
Resting metabolic rate (RMR) was determined by indirect calorimetry using the ventilated hood 
technique in a fasted state (Quark RMR, Cosmed, Rome, Italy). Participants were asked to lie still 
in a supine position and be quiet but remain awake for the duration of the RMR assessment. 
Oxygen uptake and carbon dioxide production were measured at 5 s intervals for 20 min, or until 
a steady state was achieved for at least 10 min (<5% change in respiratory exchange ratio). The 
last 10 min of data where steady state was achieved was used for the analysis. Before each 
assessment, the gas analyser was calibrated with a 3-L syringe and standard gas mixtures of oxygen 
(26% O2 with the balance nitrogen) and carbon dioxide (4% CO2, 16% O2 and the balance 
nitrogen) (BOC Special Gas, Afrox, Cape Town, South Africa). The gas analyser was validated by 
ethanol burns every two weeks. The outcome variable was RMR (kcal·kg·day-2).  
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5.2.4.4 Cardiometabolic risk 
The cardiometabolic risk factor criteria defined by the American Heart Association and the 
National Heart, Lung, and Blood Institute were used (Grundy et al., 2005). Elevated WC was 
defined as having a WC >88 cm for females, or WC >102 cm for males. Elevated TG was defined 
as having triglyceride levels ≥1.7 mmol⋅L-1. Reduced HDL was defined as having HDL levels 
<1.30 mmol⋅L-1 for females, or <1.03 mmol⋅L-1 for males, or taking medication for 
hyperlipidaemia. Elevated BP was defined as having systolic blood pressure (SBP) ≥130 mmHg, 
diastolic blood pressure (DBP) ≥85 mmHg, or being on antihypertensive medication. Elevated 
fasting glucose was defined as fasting glucose levels ≥5.6 mmol⋅L-1. Participants were classified as 
being at high cardiometabolic risk if at least three of these cardiometabolic risk factors were present 
(Grundy et al., 2005).  
5.2.5 Data and statistical analyses 
All data were reported and analysed as described in Section 4.2.5.  
5.3 Results 
5.3.1 Participants 
Forty-six participants consented to participate of whom 30 were included in the final analysis (SBI: 
n=15, CON: n=15). Eight participants had insufficient actigraphy data due to technical errors, 
seven were lost at follow-up, and one participant did not meet the eligibility criteria. The SBI group 
included one female participant with a WC of 86.7 cm but a BMI of 36.1 kg·m-2. The CON group 
included three female participants with WC of 75.5, 83.5, and 84.9 cm but a BMI of 29.1, 31.5, 
and 29.9 kg·m-2 respectively. None of the participants reported a previous diagnosis of insomnia. 
Participants in both groups attended a similar number of exercise classes during the eight-week 
lifestyle intervention programme (SBI: 19.7±5.6, CON: 19.1±6.0, p=0.780). Participants in the 
SBI group also attended 3.7±1.0 (range: 2-5 sessions) sleep behaviour intervention sessions during 
the trial.  
The participants in the SBI group were included in the OW-OBI (n=7) or OBII (n=8) groups of 
Chapter 3, and the participants of the CON group were also included in the OW-OBI (n=6) or 
OBII (n=9) groups of Chapter 3. 
 
 108 
5.3.2 Demographic and lifestyle characteristics 
Baseline and follow-up demographic and lifestyle characteristics of the two groups are presented 
in Table 5.1. The groups were not different in any of the demographic and lifestyle characteristics 
at baseline, nor at follow-up.  
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Table 5.1. Demographic and lifestyle characteristics of the CON and SBI groups at baseline and follow-up.  
 
 







  Baseline Follow-up  Baseline Follow-up  p-value p-value 
Age (y)  46.7±12.2 -  47.4±11.0 -  0.722 - 
Gender        1.000 - 
    Female  11 (73%) -  11 (73%) -    
    Male  4 (27%) -  4 (27%) -    
Ethnicity        0.700 - 
    White  10 (66%) -  9 (60%) -    
    Mixed ancestry  4 (27%) -  6 (40%) -    
    Indian  1 (7%) a -  0 (0%) a -    
Smoking status        0.678 0.683 
    Never  9 (60%) 9 (60%)  10 (67%) 9 (60%)    
    Past  5 (33%) 5 (33%)  3 (20%) 3 (20%)    
    Current  1 (7%) a 1 (7%) a  2 (13%) a 3 (20%) a    
Alcohol consumption        0.440 0.688 
    None  4 (26%) 4 (26%)  6 (40%) 5 (33%)    
    Low  10 (67%) 9 (60%)  7 (46%) 7 (47%)    
    Moderate  1 (7%) a 1 (7%) a  1 (7%) a 2 (13%) a    
    Heavy  0 (0%) a 1 (7%) a  1 (7%) a 1 (7%) a    
Physical activity level        1.000 1.000 
    Low  7 (47%) 1 (7%) a  7 (47%) 1 (7%) a    
    Moderate  7 (47%) 2 (13%)   6 (40%) 3 (20%)     
    High  1 (6%) a 12 (80%)  2 (13%) a 11 (73%)    
Data are presented as mean ± standard deviation or count (percentage). CON: control group; SBI: sleep behaviour intervention group. The p-values represent the between-group 




5.3.3 Actigraphy and subjective sleep outcomes 
Baseline and change from baseline to follow-up actigraphy and subjective sleep characteristics are 
presented in Table 5.2. The only variable that differed between the groups at baseline was 
awakening index, which was higher in the SBI group than in the CON group. From baseline to 
follow-up, get-up time advanced more in the SBI group than in the CON group. Additionally, 
while the midpoint of sleep advanced in the SBI group, it delayed in the CON group. The effect 
size (ES) for both get-up time and midpoint of sleep were large.  
The prevalence of poor sleep health indicators and the sleep health score are presented in Table 
5.3. The prevalence of indicators of poor sleep health was low (<50%) in both groups. The groups 
were not different in the prevalence of poor sleep health indicators at baseline or in change from 
baseline to follow-up (p>0.05). Likewise, the sleep health score at baseline or change from baseline 





Table 5.2. Actigraphy and subjective sleep characteristics of the CON and SBI groups at baseline and change from baseline to follow-up.  







    Baseline Change n  Baseline Change n   p-value  ES p-value 
Actigraphy                        
    TiB (h)   7.2±0.9 0.2±0.6 15  7.7±1.1 0.0±1.0 15  0.145  -0.198 0.573 bl 
    TST (h)   6.4±0.9 0.2±0.6 15  6.8±1.0 0.2±0.9 15   0.239  -0.085 0.543 bl 
    SOL (min)   8.9 (23.4) -0.6 (11.4) 15  7.7 (9.6) -0.4 (15.6) 15   0.445  0.307 0.408 
    SE (%)   88.6±4.6 1.3±4.8 15  88.1±2.7 2.0±4.9 15  0.736  0.142 0.807 bl 
    WASO (min)   20.9 (11.0) 2.5 (11.9) 15  30.1 (13.7) 1.7 (29.0) 15   0.070  -0.492 0.188 
    Awakenings >5 min    0.57 (0.71) -0.14 (0.90) 15  0.60 (1.00) 0.19 (0.98) 15   0.964  0.094 0.798 
    Awakening index (awakenings/h of TST)   5.2 (1.4) 0.3 (1.4) 15  6.1 (1.3) -0.2 (2.0) 15   0.046  -0.526 0.411 bl 
    Bedtime (hh:mm)   23:26±1:08 0:04±0:33 15  23:12±0:59 -0:20±0:56 15   0.542  -0.519 0.166 
    Get-up time (hh:mm)   6:37 (0:39) -0:03 (0:51) 15  6:49 (2:16) -0:18 (0:37) 15   0.404  -0.811 0.035 
    Midpoint of sleep (hh:mm)   3:02±0:50 0:08±0:31 15  3:04±0:55 -0:20±0:40 15  0.947  -0.815 0.034 
    sSRI (%)   93.0 (4.1) -1.8 (4.7) 15  92.2 (4.3) -0.5 (4.2) 15   0.263♰  0.533 0.147♰ 
    Corrected social jet lag (min)  38.2±20.7 -3.6±25.0 15  41.5±26.7 2.8±40.8 15  0.702  0.189 0.609 
Sleep questionnaires                    
    PSQI   7.3±3.1 -2.1±3.3 15  7.5±3.0 -2.5±2.5 15   0.905  -0.158 0.669 
    ESS   7.0 (7.0) 0.0 (2.0) 15  9.0 (3.0) -2.0 (3.0) 15   0.251  -0.333 0.750 bl 
    HÖ-MEQ   55.0 (13.0) 1.0 (4.0) 15  56.0 (15.0) 2.0 (6.0) 15  0.880  0.481 0.147 bl 
Data are presented as mean ± standard deviation or median (interquartile range). CON: control group; ES: effect size; ESS: Epworth sleepiness scale; HÖ-MEQ: Horne-Östberg 
morningness-eveningness personality questionnaire; PSQI: Pittsburgh sleep quality index; SBI: sleep behaviour intervention group; SE: sleep efficiency; SOL: sleep onset latency; 
sSRI: simplified sleep regularity index; TiB: time-in-bed; TST: total sleep time; WASO: wake after sleep onset. The p-values for the between-group comparisons at baseline were 
determined using the Student’s t-test (no superscript symbol) or Kruskal-Wallis (♰), and those for the between group comparisons of change were determined using the ANCOVA, 








Table 5.3. Prevalence of poor sleep health indicators and sleep health score in the SBI and CON groups. 











  Baseline  Follow-up n  Baseline  Follow-up n  p-value p-value 
Short sleep duration  7 (47%) ↓ 5 (33%) 15  4 (27%) ↓ 1 (7%) 15  0.450 0.169 
High sleep fragmentation  4 (27%) ↓ 3 (20%) 15  4 (27%) ↑ 5 (33%) 15  1.000 0.682 
High sSRI  3 (20%) ↑ 4 (27%) 15  4 (27%) ↓ 3 (20%) 15  1.000 1.000 
High corrected social jet lag  2 (13%) ↓ 1 (7%) 15  4 (27%) ↓ 3 (20%) 15  0.651 0.598 
EDS  2 (13%) ↔ 2 (13%) 15  3 (20%) ↓ 1 (7%) 15  1.000 1.000 
  CON 
 









  Baseline  Change n  Baseline  Change n  p-value p-value 
Sleep health score  1.2±1.0  -0.2±1.2 15  1.3±0.8  -0.4±1.2 15  0.843 0.650 
Data are presented as count (percentage) or mean ± standard deviation. CON: control group; EDS: excessive daytime sleepiness; SBI: sleep behaviour intervention group; sSRI: 
simplified sleep regularity index. ↑ prevalence increased, ↓ prevalence decreased, and ↔ prevalence did not change between baseline and follow-up. For poor sleep health at follow-
up, analysis was not performed as expected cell frequency was <1 in two cells. The p-values for the between-group comparisons of the binary variables were determined using the 
Fisher’s exact test, and for the between-group comparison of the sleep health score at baseline and change between baseline and follow-up with the Student’s t-test. The ES 







5.3.4 Anthropometric, cardiometabolic and perceived stress outcomes 
Baseline and change in anthropometric measures, BP, fasting glucose, insulin and lipid levels are 
presented in Table 5.4. The weight of one individual in the CON group exceeded the dual X-ray 
absorptiometry scanner’s weight limit, and thus one observation was missing for total body fat and 
lean mass. Blood could not be obtained from two participants in the CON group, which resulted 
in two observations missing for the fasting glucose, insulin, and blood lipids outcomes. One 
additional observation was missing in the CON group for blood lipids outcomes due to human 
error. Lastly, one observation was missing for RMR in the SBI group, and two observations were 
missing in the CON group, due to human and technical errors. The groups were not different in 
any of the anthropometric or cardiometabolic health outcomes at baseline.  
In response to the intervention, SBP increased in the SBI group, while it decreased in the CON 
group. The ES was moderate. Moreover, participants in the SBI group had a greater reduction in 
HbA1c than those in the CON group following the intervention. The ES was found to be 
moderate. Lastly, RMR increased in the SBI group, while it decreased in the CON group, and the 
ES was large.  
The prevalence of cardiometabolic risk factors and high cardiometabolic risk in the SBI and CON 
groups at baseline and follow-up are presented in Table 5.5. The groups did not differ in 
prevalence of cardiometabolic risk factors or high cardiometabolic risk at baseline or follow-up. 





Table 5.4. Anthropometric and cardiometabolic characteristics of the CON and SBI groups at baseline and the change from baseline to follow-up. 







    Baseline Change n   Baseline Change n   p-value  ES p-value 
Anthropometric measures                         
    Height (cm)  169.4 (14.6) - 15  167.7 (15.8) - 15  0.443 ♰  - - 
    Weight (kg)   105.7 (53.0) -1.3 (2.4) 15   99.1 (16.1) -1.9 (2.9) 15   0.494 ♰  -0.271 0.373 ♰ 
    BMI (kg⋅m-2)   38.8±9.8 -0.7±0.9 15   36.0±6.0 -0.9±0.5 15   0.348  -0.290 0.509 bl 
    WC (cm)   103.9 (36.3) -1.9 (2.6) 15   103.3 (14.6) -3.1 (2.9) 15   0.756 ♰  -0.477 0.152 ♰ 
    WHtr  0.62 (0.20) -0.01 (0.02) 15  0.62 (0.09) -0.02 (0.01) 15  0.950 ♰  -0.471 0.085 ♰ 
    Total body fat (%)   47.2±4.9 -0.3±1.5 14   46.7±5.4 -1.1±2.0 15   0.813  -0.460 0.232 bl 
    Lean mass (kg)  53.9±12.7 -2.4±2.7 14  52.5±8.8 -2.7±1.7 15  0.730  -0.160 0.642 bl 
Blood pressure                    
    DBP (mmHg)   78.2±12.9 -1.4±7.2 15   82.8±9.9 -2.1±9.6 15   0.289  -0.083 0.791 bl 
    SBP (mmHg)   116.0±22.1 -2.8±11.3 15   118.5±15.9 4.8±12.8 15   0.732  0.627 0.039 bl 
Glucose and Insulin                    
    Fasting glucose (mmol⋅L-1)   5.2 (0.8) 0.2 (0.9) 13   5.3 (0.9) 0.1 (0.5) 15   0.593  0.136 0.723 
    Fasting insulin (mU⋅L-1)   14.9 (14.1) 1.3 (8.0) 13   17.2 (11.2) 1.0 (5.0) 15   0.311 ♰  -0.327 0.713 ♰ 
    HOMA2-IR   1.9 (1.9) 0.2 (1.1) 13   2.3 (1.6) 0.1 (0.6) 15   0.869  -0.284 0.481 bl 
    HbA1c (%)   5.1 (0.6) 0.1 (0.1) 13   5.4 (0.6) -0.1 (0.3) 15   0.282  -0.784 0.049 
Blood lipids                    
    TC (mmol⋅L-1)   5.3 (1.2) -0.3 (1.1) 12   5.8 (1.5) -0.1 (0.6) 15   0.626 ♰  -0.226 0.922 ♰ 
    LDL (mmol⋅L-1)   3.4 (1.5) -0.2 (1.1) 12   3.6 (1.0) 0.0 (0.7) 15   0.555  -0.071 0.840 bl 
    HDL (mmol⋅L-1)   1.3 (0.4) 0.0 (0.1) 12   1.2 (0.5) 0.0 (0.2) 15   0.625  0.204 0.602 bl 
    TG (mmol⋅L-1)   1.4±0.5 0.2±0.5 12   1.7±0.7 -0.1±0.3 15  0.342  -0.740 0.077 bl 
RMR (kcal⋅kg⋅day-2)   16.3±1.0 -0.7±1.6 13   16.4±2.7 0.9±1.3 13   0.879  1.110 0.007 bl 
CPSS  15.7±5.9 -2.7±2.7 15  19.2±5.9 -4.6±4.2 15  0.111  -0.531 0.510 bl 
Data are presented as mean ± standard deviation or median (interquartile range). BMI: body mass index; CON: control group; CPSS: Cohen’s perceived stress scale; DBP: diastolic 
blood pressure; ES: effect size; HbA1c: glycated haemoglobin; HDL: high-density lipoprotein; HOMA2-IR: homeostatic model assessment 2 for insulin resistance; LDL: low-
density lipoprotein; RMR: resting metabolic rate; SBI: sleep behaviour intervention group; SBP: systolic blood pressure; TC: total cholesterol; TG: triglycerides; WC: waist 
circumference; WHtr: waist-to-height ratio. The p-values for the between-group comparisons at baseline were determined using the Student’s t-test (no superscript symbol) or 
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Kruskal-Wallis (♰), and those for the between group comparisons of change were determined using the ANCOVA adjusted for baseline values (bl), Student’s t-test (no superscript 
symbol) or Kruskal-Wallis(♰). The ES represents Cohen’s d.  
 
Table 5.5. Prevalence of cardiometabolic risk factors and high cardiometabolic risk in the CON and SBI groups at baseline and follow-up. 







  Baseline  Follow-up n  Baseline  Follow-up n  p-value p-value 
Elevated WC  12 (80%) ↔ 12 (80%) 15  14 (93%) ↓ 12 (80%) 15  0.598 1.000 
Elevated BP  5 (33%) ↓ 4 (27%) 15  9 (60%) ↓ 7 (47%) 15  0.272 0.450 
Elevated fasting glucose  3 (23%) ↔ 3 (23%) 13  4 (27%) ↔ 4 (27%) 15  1.000 1.000 
Reduced HDL  4 (33%) ↑ 5 (42%) 12  9 (60%) ↓ 8 (53%) 15  0.707 0.707 
Elevated TG  3 (25%) ↑ 4 (33%) 12  6 (40%) ↓ 5 (33%) 15  0.683 1.000 
High cardiometabolic risk  3 (25%) ↔ 3 (25%) 12  6 (40%) ↓ 5 (33%) 15  0.704 1.000 
Data are presented as count (percentage). BP: blood pressure; CON: control group; HDL: high-density lipoprotein; SBI: sleep behaviour intervention group; TG: triglycerides; WC: 
waist circumference. ↑ indicates prevalence increased, ↓ indicates prevalence decreased, and ↔ indicates prevalence did not change between baseline and follow-up. The p-values 




5.3.5 Association analyses 
When the groups were pooled, change in sSRI correlated with change in TC (Fig 5.1A) and with 
change in RMR (Fig 5.1B), such that an increase in sSRI was associated with a decrease in TC and 
an increase in RMR. However, these correlations were lost when the groups were split. Moreover, 
one individual in the SBI group experienced a much larger change in sSRI than the other 
individuals in the SBI and CON groups. After removing this observation, significance is lost for 
the correlation between change in sSRI and TC (⍴=-0.513, p=0.111, n=26), but not that of change 
in sSRI and RMR (⍴=0.590, p=0.029, n=26). No other changes in sleep measures correlated with 




Figure 5.1. Correlation plots for change in sSRI and change in TC (A) and between sSRI and change in RMR. ○: 
control group (CON); ●: sleep behaviour intervention (SBI) group. RMR: resting metabolic rate; sSRI: simplified 
sleep regularity index; TC: total cholesterol. Significance was determined using Spearman’s correlation.   
 
5.4 Discussion 
The effects of a sleep behaviour intervention within a diet and exercise lifestyle intervention 
programme designed to improve cardiometabolic health in individuals with overweight and obesity 
were described. The SBI group advanced get-up time and midpoint of sleep, demonstrated 
increased RMR and decreased HbA1c, and improvements in sSRI were associated with 
improvements in TC and RMR. 
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Besides the improvements in RMR and HbA1c, the advancement of midpoint of sleep and get-up 
time in the present study, may also be beneficial to the participants from a cardiometabolic 
perspective. For instance, delayed sleep timing has been associated with increased caloric intake 
after 20:00 and type 2 diabetes mellitus (T2DM) (Merikanto et al., 2013, Baron et al., 2011). It must 
be noted, however, that changes in bedtime, get-up time and midpoint of sleep were not associated 
with measures of cardiometabolic health in the present study.  
One explanation for change in sleep timing-related behaviour, but not in other aspects of sleep, in 
the present study, may be that sleep timing is reflected immediately, whereas changes related to 
other aspects of sleep are indirect. For example, to advance midpoint of sleep, one would only 
need to consciously retire and get-up earlier, whereas changes in TST require a shorter SOL and 
increased maintenance of sleep, which are unconscious processes, and may be more difficult to 
achieve. Moreover, twenty-two healthy men and women who were classified as late chronotypes 
based on the Munich Chronotype Questionnaire advanced their midpoint of sleep on free days by 
approximately 2 h by receiving sleep hygiene recommendations, which included instructions to 
advance bedtime and get-up times (Valshtein et al., 2019). These findings demonstrate that even 
in late chronotypes, sleep hygiene instructions, even without individualized counselling can induce 
significant changes in sleep timing. One study was successful in increasing commitment to bedtime 
procrastination using a self-regulatory intervention in undergraduate students who were concerned 
about their delayed bedtimes (Valshtein et al., 2019). Although no subjective or objective measures 
of sleep timing were taken, the difference between self-reported planned and actual bedtime was 
significantly less in the intervention group than in the control group. The findings also suggest that 
changes to sleep timing, or at least aligning planned and actual bedtime, are relatively easy to make.  
Although the changes that occurred in sleep timing in the present study must thus not be 
underappreciated, it was surprising that the other measures of poor sleep health that were observed 
in the OBII group of Chapter 3, such as short sleep duration and sleep fragmentation were not 
affected by the sleep behaviour intervention in the present study. The findings of the present study 
were aligned, however, to those of a four-session sleep behaviour intervention study with 
adolescents, where changes in objective sleep characteristics were not different to that of a control 
group (Cain et al., 2011). While the intervention by Cain et al. incorporated aspects to increase 
participant motivation, further support to behavioural change was lacking, which might have 
contributed to the lack of response in their objective sleep measures. The authors did report 
improvements in motivation of the adolescents to change, which may be an important first step 
to actual behaviour change. Unfortunately, no measures of motivation were taken in the present 
study, and thus the two studies cannot be compared in this regard.  
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While not observed in the present study, others have found that sleep duration and sleep 
fragmentation change in response to similar sleep behaviour interventions. For example, a four-
session sleep intervention in older adults with sleep difficulties in a non-residential day care facility 
improved actigraphy-assessed sleep efficiency (SE), awakenings and wake after sleep onset 
(WASO), but not TST and PSQI scores (Martin et al., 2017). Additionally, a sleep extension 
intervention in short-sleeping adults increased time-in-bed (TiB), TST, SE, awakening index and 
PSQI scores, but not SOL (Al Khatib et al., 2018).  
In contrast to the aforementioned studies, the participants in the present study were not subjected 
to sleep-related inclusion criteria, except for not being exposed to external factors which may affect 
sleep (e.g. shift work, parents of young children), and for not being diagnosed with moderate to 
severe obstructive sleep apnoea (OSA). Thus, one explanation for the absence of changes in sleep 
fragmentation and duration in the present study may be that the participants were sleeping well in 
the first place. Indeed, only 4 out of 15 participants of the SBI group had short sleep duration, 
high sleep fragmentation, high sSRI, and high corrected social jet lag at baseline, while EDS was 
only found in 3 out of 15 participants in the SBI group at baseline. As such, the participants of the 
SBI groups were not particularly poor sleepers, which may make it more challenging to improve 
sleep. In fact, attempting sleep modulation in individuals with good sleep health may be 
detrimental. For example, forced TiB extension in healthy sleepers resulted in an increase in 
depression, interleukin (IL)-6 levels, and ESS score (Reynold et al., 2014).  
Another explanation as to why improvements in sleep measures were modest may be that the 
participants in the present study were participating in a lifestyle intervention programme with 
nutritional and exercise modulation and were thus already implementing changes to their lifestyle. 
Making changes to sleep in addition may have been overwhelming to the participants and may 
have decreased compliance, which was not quantitatively measured throughout the intervention. 
Building on this, participants took part in the lifestyle intervention programme to lose weight, 
improve fitness and improve health and were told that the sleep behaviour intervention may either 
result in more weight loss, less weight loss, or have no effect at all. Therefore, the participants may 
have been less incentivised to make changes to sleep-related behaviour, than to make changes 
related to diet and exercise, which also may affect compliance to the sleep behaviour intervention.  
Additionally, the association of cardiometabolic health with short sleep duration and poor sleep 
quality is thought to be bidirectional (Lucassen et al., 2012). Lifestyle and stress factors, depression, 
sleep disordered breathing, decreased circadian amplitude, and – where diabetes mellitus is 
involved – thirst, nocturia and rapid declines in blood glucose levels have all been suggested to 
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explain how obesity may result in poor sleep (Lucassen et al., 2012). It may therefore be challenging 
to improve sleep in individuals with obesity without first addressing these psychological and 
physical factors. Although others were successful in improving sleep in individuals who were 
overweight (Tasali et al., 2014), to the best of my knowledge, the present study is the first to 
attempt sleep improvement in individuals who are predominantly obese. Since individuals with 
class II obesity experience more sleep disturbances than individuals with overweight and class I 
obesity (see Chapter 3), sleep in individuals with severe obesity may also be more difficult to 
improve than sleep in those with moderate or mild obesity. This may thus further explain why 
increasing sleep duration and decreasing sleep fragmentation, in this cohort of individuals who are 
predominantly obese, may be more difficult to achieve than initially hypothesised. Differences in 
response to the sleep behaviour intervention between the various obesity categories would ideally 
have been explored but could not be done due to the small sample size.  
Sleep duration and quality may not have improved in the participants due to reasons specific to 
the intervention. Previously, our research group recommended applying suggestive, rather than 
instructive, personalised strategies that include sleep hygiene education for the purpose of 
improving cardiometabolic health through sleep extension (Henst et al., 2019). Notwithstanding 
that the aim of the present intervention was general nocturnal sleep improvement, and not sleep 
extension specifically. Indeed, sleep hygiene education is an important aspect of cognitive 
behavioural therapy for insomnia (CBT-I), which is the preferred treatment for primary insomnia 
(Morgenthaler et al., 2006), however, as one may expect, sleep hygiene education in isolation has 
been found to be ineffective for the treatment of clinical insomnia (Schutte-Rodin et al., 2008). 
Furthermore, evidence to support the role of sleep hygiene recommendations in improving sleep 
in nonclinical populations is lacking (Irish et al., 2015). The present study suggests that 
personalized sleep hygiene recommendations in individuals with overweight and obesity who do 
not have a poor sleep health per se may not affect sleep noticeably outside of the clinical setting. 
Moreover, these sleep hygiene recommendations were communicated with techniques borrowed 
from motivational interviewing, which is an elaborative and evocative counselling style to resolve 
ambivalence, and was originally designed to help individuals with drinking addictions by finding 
intrinsic motivators to drive change (Rollnick and Miller, 1995). This technique may thus be 
suitable if the participants of the present study were ambivalent about changing their sleep 
behaviour and have intrinsic motivation. However, less so without intrinsic motivators, for 
example if the participants did not believe they had a problem with their sleep, or they did not see 
the benefit of making sleep-related behaviour changes. Therefore, an instructive approach may 
have resulted in more drastic changes in sleep, however, its long-term efficacy is undetermined.  
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Finally, the short intervention duration was unlikely to have played a role, as others have been 
successful in changing measures of sleep with interventions of shorter durations, namely of three 
days to six weeks (Haack et al., 2013, Al Khatib et al., 2018, Killick et al., 2015, Kubo et al., 2011, 
Leproult et al., 2015, Reynold et al., 2014, Tasali et al., 2014). Likewise, the number of intervention 
sessions in the present study was similar to, or higher than, those of other sleep intervention 
strategies which successfully increased sleep duration and does therefore not explain the lack of 
effect following the sleep behaviour intervention in the present study (Al Khatib et al., 2018, 
Leproult et al., 2015, Tasali et al., 2014). 
It was also hypothesised that the sleep behaviour intervention would improve anthropometric and 
cardiometabolic measures. Indeed, favourable effects of the sleep behaviour intervention were 
observed for HbA1c and RMR. The observed improvement in HbA1c is not surprising, given the 
association of increased HbA1c with both short and long sleep duration, and poor subjective sleep 
quality in patients with T2DM (Lee et al., 2017). Additionally, patients with T2DM who underwent 
a diabetes sleep education program and thereby improved their sleep hygiene, decreased their 
PSQI scores and Hba1c levels more than those who did not undergo the programme (Li et al., 
2018). Since all but one of the participants in the present study did not have T2DM, the finding 
of improved HbA1c is all the more convincing. Furthermore, HbA1c has been associated with 
sleep duration and sleep quality (Knutson et al., 2006), and others have suggested that HbA1c may 
be a target for interventions to improve sleep quality in individuals with T1DM (Martyn-Nemeth 
et al., 2018). Since poor and short sleep have been associated with a decrease in insulin sensitivity 
(Stamatakis and Punjabi, 2010), the reverse may have occurred following the sleep behaviour 
intervention in the present study, resulting in an increased insulin sensitivity and consequently 
decreased average blood glucose levels, and thus HbA1c. However, measures of these mechanisms 
were not taken and therefore this speculation cannot be confirmed in the present study.  
The present study is the first to report an increase in RMR following a sleep behaviour 
intervention. This finding is favourable since lower RMR has been associated with weight gain 
(Buscemi et al., 2005), and higher RMR has been associated with weight maintenance after weight-
loss (Vogels et al., 2005). While short sleep duration has been associated with reduced RMR in at 
least two studies (Benedict et al., 2011, Spaeth et al., 2015), the present study is the first to suggest 
a relationship between measures of sleep timing and RMR. First, RMR improved in the SBI group, 
where advances in get-up time and midpoint of sleep were also observed. Second, RMR was 
associated with sSRI when the SBI and CON groups were combined. Furthermore, despite the 
evidence for an association between RMR and sleep duration, RMR did not change following sleep 
extension in another study (Al Khatib et al., 2018).  
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As mentioned above, in the present study, those that experienced the largest increase in RMR also 
had the largest increase in sSRI (i.e. sleep timing became more regular). However, since sSRI was 
not affected by the sleep behaviour intervention, change in sSRI may be explained by the same 
mechanisms that caused the increase in RMR. For instance, regular sleep timing is an indicator of 
a robust circadian clock, i.e. the circadian amplitude of the biological processes that exhibit 
circadian variation are high, including those that influence an individual’s sleep onset and wake-up 
times. Since RMR exhibits circadian variation (Zitting et al., 2018), an increase in sleep regularity 
may be paralleled by a higher circadian amplitude of RMR. This, in combination with an 
advancement of the circadian clock, possibly indicated by the advanced midpoint of sleep in the 
present cohort, may result in a higher RMR at the time-of-day the indirect calorimetry was 
performed (i.e. between 06:00 and 10:00). Future research is needed to confirm the association 
between RMR and measures of sleep timing. 
Despite no changes in sSRI or TC in response to the intervention, those with the highest increase 
in sSRI experienced the highest reduction in TC when the groups were pooled. Although this 
correlation was no longer significant after removal of an outlier for change in sSRI, Spearman’s 
rho was minimally affected. This correlation is independent of group, and thus unrelated to the 
sleep behaviour intervention. Moreover, TC was unaffected by the lifestyle intervention 
programme in Chapter 4, and did also not correlate with sSRI, or any other sleep outcomes in 
that study. To the best of my knowledge, the current study is the first to find an association 
between sleep regularity and TC. More research is needed to confirm this finding, and to explore 
possible mechanisms. 
In addition to the favourable effects of HbA1c, RMR, and cardiometabolic risk, an unfavourable 
effect was observed for SBP, which increased in response to the sleep behaviour intervention. 
Although this finding was surprising, it must be noted that the ES was only moderate, the average 
SBP was still below normal clinical range after the intervention, and the prevalence of elevated BP 
in the SBI group dropped from nine to seven. The significance of this finding on cardiometabolic 
health is therefore debatable. To the best of my knowledge, this is the first study to demonstrate 
an increase in single-recording SBP following sleep modulation. One week of extending sleep 
duration by 1 h, however, decreased SBP by 7.0±3.0 mmHg in healthy undergraduate students 
(Stock et al., 2019). Other studies using sleep extension interventions (Kubo et al., 2011, Haack et 
al., 2013, Reynold et al., 2014) and a web-delivered sleep hygiene, stimulus control, and cognitive 
behavioural therapy intervention (McGrath et al., 2017) found no effects on DBP or SBP. 
Likewise, a diabetes sleep education programme reported a decrease in SBP, but not DBP, 
although this effect was lost after adjustment for covariates (Li et al., 2018).  
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Lastly, the effect of the sleep behaviour intervention on cardiometabolic measures may only 
become apparent after an extended period of time. For example, delayed midpoint of sleep has 
been associated with weight regain following an exercise intervention in postmenopausal women 
(McNeil et al., 2019), possibly due to an increased energy intake in the evening (Baron et al., 2011). 
Therefore, one may speculate that the advanced midpoint of sleep in the participants of the SBI 
may reduce the chance of weight regain, and the participants may thus only experience the benefits 
of the sleep behaviour intervention sometime after the programme. However, the long-term 
benefit of the sleep behaviour intervention was outside the scope of this study.  
Contrary to the hypothesis, anthropometric variables, measures of insulin resistance and blood 
lipids were not affected by the sleep behaviour intervention. One explanation may be the limited 
effect of the intervention on sleep itself. That is, if these measures of cardiometabolic health were 
expected to improve in response to changes in sleep following the sleep behaviour intervention, 
then changes in sleep must occur for changes in cardiometabolic health to happen. Changes in 
sleep timing alone may not be sufficient to drive change in these measures of cardiometabolic 
health. Indeed, the associations with cardiometabolic health are most frequently found for sleep 
duration (see Section 1.5.2) and sleep fragmentation (see Section 1.5.3), and less so for sleep 
timing (Baron et al., 2011). Second, although the participants were overweight or obese, not all 
participants were in poor cardiometabolic health per se. Specifically, 9 out of 15 participants of the 
SBI group had elevated BP or reduced HDL, but only 4 and 6 out of 15 participants had elevated 
fasting glucose and elevated TG levels respectively. Furthermore, only 6 out of 15 participants of 
the SBI group at baseline met the criteria for being at high cardiometabolic risk. Therefore, changes 
in these outcomes may have been unlikely for the majority of participants.  
5.4.1 Study limitations 
These results must be interpreted in context of the limitations of this study, which are a small 
sample size; not having a measure of compliance to the sleep behaviour intervention; and the 
exclusion of analyses of naps, food intake and exercise. The small sample size may increase the 
chance of type II errors and decrease the representability of the sample to the general population. 
In addition, a larger sample size would allow for the adjustment for factors such as exercise and 
intervention session attendance, which may have decreased the unexplained variance of the 
models. Such information may also explain whether the absence of an effect on the sleep variables 
were due to the poor compliance, or because of the minimal impact of these changes on sleep. 
Another analysis that may be performed with a larger sample size is the comparison of responders 
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versus non-responders. Moreover, the intervention may have affected other aspects of sleep which 
were not measured, for example napping frequency and duration. Although the participants wore 
an actigraphy device throughout the day, the participants were not instructed to annotate naps in 
the present study. The same can be said about food intake, since factors affecting food intake such 
as appetite and circulating levels of leptin and ghrelin are associated with sleep (Taheri et al., 2004, 
Spiegel et al., 2004a, Spiegel et al., 2004b). Another limitation is that, while one of the reasons for 
using the diet and exercise lifestyle intervention programme as the setting for the sleep behaviour 
intervention was to attempt to control for exercise, exercise exposure was not measured. It is thus 
possible that inter-individual differences in exercise frequency, intensity and duration might have 
impacted the findings of this study. Lastly, as mentioned in Section 3.2.3.8, the participants in the 
present study who were included in Chapter 3 of this thesis underwent PSG. Due to insufficient 
PSG data available, it was decided to exclude the PSG analysis from the present study. However, 
due to scheduling and time constraints, some of the actigraphy nights from the present study 
overlapped with the PSG nights. Because PSG is considered invasive and may alter normal sleep, 
it is possible that allowing the actigraphy and PSG nights to overlap may have affected the 
actigraphy data. However, since the actigraphy data shown are the average over four to seven 
nights, the impact of the PSG nights on these data is minimal. Indeed, when all overlapping nights 
were removed from the analysis, the significance did not change (data not shown).   
5.5 Conclusion 
These findings add to the limited available literature that describe sleep modulation as a candidate 
for interventions to improve cardiometabolic health. Evidence to support this statement is scarce 
and more studies are needed before sleep modulation is readily applied to existing or new lifestyle 
interventions. I suggest that future research should be focused on participants with 
cardiometabolic impairment and poor sleep, as changes in cardiometabolic health, sleep duration 
and sleep fragmentation are more likely to occur and more necessary. Moreover, studies are needed 
to explore the long-term benefits of sleep behaviour interventions on cardiometabolic health, 
specifically on weight regain. I also suggest that measures of appetite, satiety, hunger and timing 
of food and food intake are included, as these are likely candidates for change. Finally, studies with 

















The findings of the studies described in this thesis suggest that sleep behaviour interventions are 
a promising strategy to mitigate the global burden of cardiometabolic disease (CMD). More 
research is needed, however, to better understand who may benefit from such interventions, and 
how these individuals may be identified. In this chapter, practical implementations and 
recommendations for the implementation of sleep behaviour interventions for the betterment of 
cardiometabolic health are discussed and directives for future research are provided. 
6.1 Practical implications and recommendations 
The findings of this thesis suggest that developers of lifestyle intervention programmes and their 
participants may benefit from a sleep behaviour intervention, especially when decreased glycated 
haemoglobin (HbA1c) and increased resting metabolic rate (RMR) are desirable. Moreover, good 
sleep health may be necessary to support weight-loss and cardiometabolic health improvements. 
For example, following participation in a weight-loss intervention, women with overweight and 
obesity and higher sleep fragmentation lost less weight than those with less sleep fragmentation 
(Sawamoto et al., 2014). As such, the addition of sleep behaviour interventions may make lifestyle 
intervention programmes more effective.  
6.1.1 Other stakeholders 
Sleep behaviour interventions may not only be implementable or valuable to lifestyle intervention 
programmes. Other stakeholders that may benefit from sleep behaviour intervention programmes 
are patient or hospital wellness programmes, employee wellness programmes, schools, and health 
and life insurance providers.  
6.1.1.1 Patient or hospital wellness programmes 
Patients with cardiometabolic impairment and impaired sleep, who are under supervision of their 
general practitioner or specialist doctor may benefit from participation in a sleep behaviour 
intervention. Regardless of cardiometabolic health, general practitioners in the United Kingdom 
prefer alternative strategies to prescribing hypnotic drugs to patients with sleep problems, such as 
personal counselling, raising awareness around sleep, and sleep interventions at workplaces and 
schools (Siriwardena et al., 2010).  
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6.1.1.2 Employee wellness programmes 
Employers and employees may also benefit from sleep interventions as part of an employee 
wellness programme. Sleep-related workplace productivity loss and associated costs in the United 
States have been calculated to be hundreds of dollars per employee (Rosekind et al., 2010). 
Workplace wellness programmes have been found to improve employee health in the United 
States, and for every dollar spent on such programmes medical costs drop by $3.27 and 
absenteeism costs drop by $2.73 (Baicker et al., 2010). The addition of sleep behaviour 
interventions to existing employee wellness programmes may improve sleep health, absenteeism 
and presenteeism, and have been reviewed recently (Redeker et al., 2019).  
6.1.1.3 Schools 
Sleep education programmes with subsequent sleep behaviour interventions may be offered at 
schools, at least to inform children and adolescents about the importance of sleep, and to equip 
them with tools to ensure good sleep behaviour now and at a later stage of life. Note, however, 
that two studies by the same group (one with, and one without a motivational aspect) on 
adolescents who underwent a sleep behaviour intervention programme did not find any subjective 
or objective improvements in sleep (Cain et al., 2011, Moseley and Gradisar, 2009). Moreover, a 
pilot with nine female adolescents with poor sleep quality (Pittsburgh sleep quality index (PSQI) 
score ≥9, except for one individual with a PSQI score of 5) who underwent a six-session sleep 
behaviour intervention programme showed effect size-based improvements in objective sleep 
measures (Bei et al., 2013). Since no control group was included in the latter study, it is difficult to 
comment on the true effectiveness of the programme.  
6.1.1.4 Health and life insurance providers 
Health and life insurers may benefit from sleep behaviour intervention programmes for their 
clients, as good sleep health may decrease medical costs associated with sleep deprivation and 
cardiometabolic health. For example, short sleep duration has been associated with higher CMD 
risk (Knutson, 2010, Kronholm et al., 2011), and addressing poor sleep health among clients with 
increased CMD risk may decrease morbidity, and thus cost for health insurers. Likewise, long sleep 
onset latencies, high sleep fragmentation, and short sleep duration have been associated with CMD 
and all-cause mortality (Hublin et al., 2007, Gallicchio and Kalesan, 2009, Dew et al., 2003, Heslop 
et al., 2002, Cappuccio et al., 2010), and addressing sleep disturbances of clients, may decrease the 
cost to life insurers. An incentive-based programme to increase physical activity in clients of health 
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insurer in South Africa, has already been shown to decrease hospital admission and cost (Patel et 
al., 2011). By addressing poor sleep health among clients at risk, in addition to other health-
promotion programmes, morbidity risk may be decreased, life may be prolonged and thus costs 
to health and life insurance may be saved. 
6.1.2 Identifying participants of health and wellness programmes 
Not all participants, students, clients, patients and employees of the stakeholders mentioned above 
may benefit from a sleep behaviour intervention, however. By identifying individuals who may 
benefit from a sleep behaviour intervention within an existing programme (e.g. lifestyle 
intervention programme, school education programme, or employee wellness programme), and 
only offering it to those who may, efficacy may be improved while reducing costs. Individuals may 
fall into one of four categories based on their sleep health and CMD risk. These categories will be 
discussed in the following sections.  
6.1.2.1 Healthy individuals 
Individuals without sleep or cardiometabolic impairment are the least likely to benefit from a sleep 
behaviour intervention to improve sleep and cardiometabolic health. That is, improvements in 
sleep and cardiometabolic health may both be unnecessary and unfeasible. Individuals who fall 
into this category may therefore not be offered a sleep behaviour intervention, and with that, 
relieving pressure from sleep consultants or coaches, and reduce the cost of the programme.  
6.1.2.2 Individuals with poor sleep health 
Individuals with sleep impairment but good cardiometabolic health may benefit from a sleep 
behaviour intervention for reasons other than their cardiometabolic health. For example, higher 
PSQI scores (i.e. worse subjective sleep quality) were associated with higher Cohen’s perceived 
stress scale (CPSS) scores in Chapter 3 of this thesis, and impaired sleep has been associated with 
an increased risk of anxiety under stress (Kalmbach et al., 2019) and susceptibility to the common 
cold (Prather et al., 2015). Furthermore, it is plausible that individuals in this category are at risk 
for developing future cardiometabolic impairment because of their sleep impairment. For this 
group of individuals, it may be important to monitor cardiometabolic health and include them in 
the sleep behaviour intervention programme.  
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6.1.2.3 Individuals with increased cardiometabolic risk 
In the third category are those with cardiometabolic impairment, but good sleep health. These 
individuals are more likely to benefit from traditional lifestyle intervention programmes that focus 
on diet and exercise. However, as these individuals may be at risk for developing sleep impairment, 
driven by their decreased cardiometabolic health, their sleep should be monitored closely. If a 
deterioration in sleep health occurs, they may have progressed to the fourth category. 
6.1.2.4 Individuals with increased cardiometabolic risk and poor sleep health 
Individuals in the fourth category have both cardiometabolic and sleep impairment and may 
benefit most from sleep behaviour intervention to improve cardiometabolic health. Participants 
in this category should thus always be offered to be included in a sleep behaviour intervention.  
 
Participants of the study described in Chapter 5 were recruited for their adiposity but only 25% 
of the CON group, and 40% of the SBI group had a high cardiometabolic risk. Furthermore, as 
the study was a natural experiment, the participants were recruited regardless of their sleep health, 
as long as external factors that may impair sleep (e.g. nocturnal family or work commitments, 
hypnotic medication use), or sleep-disordered breathing and previously diagnosed insomnia were 
absent. Thus, the participants in the SBI and CON groups of Chapter 5 may have been 
categorized in either of the four categories, and the effect of the sleep behaviour intervention on 
sleep and cardiometabolic outcomes may have been dependent on the category each participant 
fell under. This type of categorisation of the participants in the present study, however, was not 
possible due to the small sample size. Regardless, the findings of the present study highlight the 
importance of screening participants, patients, clients and employees for sleep health risk, to 
stratify individuals based on needs. Future research is needed to assess the precise effect of sleep 
improvement interventions on cardiometabolic health in each of these categories. Classification 
into these categories may be done with the cardiometabolic risk factors described in Section 
3.2.3.6, which were based on definitions by Grundy et al. (2005) and Lloyd-Jones et al. (2010), or 
Section 5.2.4.4, which was based on Grundy et al. (2005). Categorisation of sleep health may be 
done with the indicators of poor sleep health and the sleep health score as described in Section 
3.2.3.10, or by using cut-off values which have been proposed before (Brindle et al., 2019). 
However, more research is needed to improve and validate the criteria of poor sleep health, such 
as the work by Buysse and colleagues (Brindle et al., 2019, Buysse, 2014, Dong et al., 2019, 
DeSantis et al., 2019). 
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6.1.3 Screening for obstructive sleep apnoea 
Another consideration is the screening of participants, patients, clients and employees for OSA, 
which has been shown to exacerbate cardiometabolic risk, especially in individuals with obesity 
and the metabolic syndrome (MetS) (Drager et al., 2013). Because participants of lifestyle 
intervention programmes aimed at weight-loss are likely to be overweight or obese, and given that 
high BMI is a risk factor for OSA (Chung et al., 2008), a high prevalence of OSA among the 
participants is expected. This makes the setting of a lifestyle intervention programme specifically 
suitable for OSA screening. For example, participants may be screened for OSA with the STOP-
Bang questionnaire which has been shown to have a high sensitivity and good specificity (Chung 
et al., 2014). Those who screen positive for OSA may be referred to their general practitioner who 
may refer them for formal diagnosis and medical treatment of their condition. This is not to say, 
however, that individuals with OSA may not benefit from a sleep behaviour intervention. In fact, 
individuals with OSA were found to have poor sleep hygiene as assessed with the Sleep Hygiene 
Index (SHI), which may not aid good sleep health, especially in combination with OSA (Lee et al., 
2015). Moreover, 68.3% of patients who were on positive airway pressure treatment for OSA 
complained of insomnia symptoms before treatment, which persisted for two years after starting 
treatment (Bjornsdottir et al., 2013). For this reason, participants who screen positive for a sleep-
disordered breathing condition may specifically benefit from a sleep behaviour intervention, which 
can be tailored to the needs of these individuals. Moreover, since compliance to positive airway 
pressure treatment is often poor, sleep intervention programmes may include positive airway 
pressure treatment support if needed (Sawyer et al., 2011). 
6.1.4 Screening for psychological conditions 
The fourth and last consideration is the screening for psychological conditions that underlie poor 
sleep health. For example, the most common symptom of anxiety disorders such as generalized 
anxiety disorder and post-traumatic stress disorder is insomnia (Saletu-Zyhlarz et al., 1997, McLay 
et al., 2010). Individuals with sleep impairment that may originate from such psychological 
conditions may be referred to a psychologist, as sleep consultants may not be equipped to help 
these individuals with their psychological needs. Other psychological conditions that may be 
associated with impaired sleep, and should be considered for screening, are depression disorders 
(Riemann et al., 2001), psychotic disorders (Monti and Monti, 2004), and substance abuse disorders 
(McGregor et al., 2005, Angarita et al., 2014). Various tools are available to assess the risk for these 
psychological conditions; however, this is out of scope of this thesis.  
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A framework of the considerations discussed in this section: stakeholders, identification of 
individuals who may benefit, screening for OSA and underlying psychological conditions, and the 
sleep behaviour intervention, are depicted in Figure 6.1.  
 
 
Figure 6.1. A framework for the implementation of sleep behaviour interventions. Participants, patients, students, 
employees, and clients of various stakeholders (A) may be identified to determine if a sleep behaviour intervention 
may be beneficial to the individual (B). Those identified may be screened for OSA risk (C), for underlying 
psychological conditions that may impair sleep (D), and referred to specialists if applicable. Identified individuals 
will participate in the sleep behaviour intervention on the basis of motivational interviewing (E). The four principles 
(awareness, education, motivation and support) of the sleep behaviour intervention are tailored to fit the 
participants’ and stakeholders’ needs. CMD: cardiometabolic disease; OSA: obstructive sleep apnoea.  
6.1.5 Format of sleep behaviour interventions 
The sleep behaviour intervention in the format used in Chapter 5 may not be suitable for each of 
the stakeholders. For example, because of the personalised nature of the sleep behaviour 
intervention, a consultant can only attend to one individual per session. Thus, the sleep behaviour 
intervention of Chapter 5 is demanding to the consultants, especially with large groups of 
participants. To make implementation of a sleep behaviour intervention for any of the stakeholders 
more feasible and affordable, the intervention format may be tailored to each stakeholder.  
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Cost of the programme and pressure on the sleep consultant(s) may be reduced if sleep behaviour 
interventions are provided in group settings. Group sessions for cognitive behavioural therapy for 
insomnia have already been applied, and have been shown to be successful (Koffel et al., 2015). 
Recognizing that sleep impairment is different to clinical insomnia, these findings are promising 
and warrant further exploration of the utilisation of sleep behaviour interventions in group 
sessions in individuals with poor cardiometabolic health.  
Alternatively, parts of the sleep behaviour intervention, such as those that involve creating 
awareness, educating participants, and support to behaviour change, could be provided in group 
sessions, while the parts which require personal attention, such as intrinsic motivation, may be 
provided one-on-one. Furthermore, alternative modes-of-delivery for sleep behaviour 
interventions must also be explored, and may include online consultation sessions (e.g. chat, 
videocall) or online video courses. 
6.1.6 Content of sleep behaviour interventions 
Finally, like the intervention format, the content of the sleep behaviour intervention may also be 
tailored to the needs of the target group or stakeholders. Sleep behaviour intervention programmes 
for schools may be focused mainly on awareness and education, while intrinsic motivation and 
support to behaviour change were suggested to be important components too (Cain et al., 2011). 
Furthermore, where changes to sleep behaviour are desired in children and adolescents, educating 
teachers and parents about sleep health and cardiometabolic consequences may be an important 
part of the intervention programme.  
Sleep behaviour intervention programmes for patients may be tailored for specific groups of 
patients. For example, Li et al. (2018) developed and tested a sleep education programme for 
patients with T2DM, and observed improvements in PSQI scores and HbA1c levels (Li et al., 
2018). In that study, lectures about the importance of good sleep health for glycaemic control may 
have provided motivation for the participants to make behavioural changes for the betterment of 
their sleep. Furthermore, sleep behaviour interventions specifically tailored to the needs of patient 
groups may address sleep disturbances that are specifically common in those patients. Patients 
with T2DM, for instance, may benefit from sleep behaviour strategies to avoid thirst, 
hypoglycaemia, and frequent urination during night-time. 
A sleep intervention programme tailored for clients of health and life insurers may have little or 
no face-to-face interaction with a consultant, but rather be entirely electronic, for scalability and 
cost reduction. Recently, a self-help web-based intervention for improving sleep in workers was 
 
 132 
found to improve Insomnia Severity Index scores in 88 men and women (Behrendt et al., 2020). 
Participants had access to an online learning platform, with modules on sleep in general, sleep 
hygiene, sleep restriction and stimulus control, monitoring progress, and included elements to 
reduce work-related stress. Although developed for the workplace, health and life insurers may 
offer a similar self-help sleep behaviour intervention programme to their clients, for sleep 
improvement.   
6.1.7 Example: the healthy weight programme 
The lifestyle intervention programme named the ‘Healthy Weight Programme’ that served as the 
setting of the studies in Chapter 4 and Chapter 5, has since included sleep health as one of its 
pillars for weight-loss and healthy living. To reduce costs, the purpose of the sleep intervention in 
this context was to screen the participants for common sleep disorders and refer on if necessary, 
to educate about sleep in general, and to help with sleep hygiene-related behaviour change. This 
sleep intervention programme was thus not as individualised and labour-intensive as the one 
described in Chapter 5. In short, during the first week of the programme, the participants attend 
a lecture about the importance of sleep for (cardiometabolic) health, receive general sleep hygiene 
tips and receive information about OSA, because of the high prevalence of OSA among 
individuals with overweight and obesity. The participants also complete an online sleep 
questionnaire, where information about their sleep habits is captured and their risk for sleep 
problems can be assessed. Then, during a 20-min one-on-one consultation session, each 
participant and the sleep consultant (one of the sleep scientists at the University of Cape Town) 
go over the results from the questionnaire and discuss challenges the participant may have with 
their sleep. At the end of this session, recommendations are made by the sleep consultant, which 
the participant may implement at home over the following weeks. Half-way through the 
programme, participants are asked to keep a two-week sleep diary, of which the interpretation is 
discussed during a group workshop with the sleep consultant. This exercise helps the participants 
to become aware of their habitual sleep patterns and to identify unhealthy sleep habits. Over the 
course of the programme, the sleep consultants are available to answer sleep-related questions 
from the participants via phone or email. Participants with suspected sleep disorders (e.g. OSA, 
narcolepsy, chronic insomnia) are referred on for further investigation and appropriate treatment. 
Although no data are yet available on the efficacy of this sleep behaviour intervention format, it is 




6.2 Final remarks 
6.2.1 Healthy nature of study participants 
As mentioned in Chapter 5, despite changes in sleep timing, the sleep behaviour intervention did 
not have any effect on other aspects of sleep that have been associated with cardiometabolic 
health, and especially obesity. The generally good sleep health of the intervention participants was 
discussed in Chapter 5 as one of the reasons why no change was observed in sleep duration and 
sleep fragmentation. The participants with overweight or obesity of the HWP group in Chapter 
4, and the SBI and CON groups in Chapter 5 took the initiative to sign up for a lifestyle 
intervention programme, but also agreed to participate in the research study. As such, they were 
presumably willing to make changes to their lifestyle and improve their cardiometabolic health 
(although the latter objective may be secondary to weight-loss). In one way or another, these 
participants may have been more motivated to change their lifestyle behaviour than individuals 
who did not sign-up to the lifestyle intervention programme or who chose not to participate in 
the present studies. Individuals with significant daytime sleepiness, which may be caused by sleep 
impairment or a sleep disorder, take less initiative and experience less intrinsic motivation, as 
assessed with the checklist individual strength (Worm-Smeitink et al., 2017), compared to 
individuals with no sleepiness symptoms (van der Werf et al., 2003). As such, the generally good 
sleep health of most participants of the present studies, may have been the result of a selection 
bias, and may not be translatable to the general overweight-obese population.  
Furthermore, the participants of Chapter 5 were overweight-obese, but were not otherwise 
cardiometabolically impaired, which may have contributed to the lack of improvement in 
cardiometabolic outcomes other than HbA1c and RMR. It must be noted that the participants of 
the lifestyle intervention programme may have been of higher socioeconomic status than 
individuals with overweight and obesity who did not participate in the programme, since a 
considerable fee had to be paid. The association between higher socioeconomic status and better 
cardiometabolic health, sometimes referred to as the ‘social causation hypothesis’, is well-known 
(Elovainio et al., 2011, Ogunsina et al., 2018). It must be explored if individuals with overweight 
and obesity who do not voluntarily sign-up to a lifestyle intervention programme have different 
cardiometabolic health profiles than those in the present study, and whether they may benefit from 
a sleep behaviour intervention differently.  
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6.2.2 On the association between sleep and cardiometabolic health 
Current belief indicates that overweight and obesity are associated with poor sleep health (Rao et 
al., 2009, Cappuccio et al., 2008). While this association was confirmed in the men and women 
with overweight and obesity in Chapter 3 of this thesis, the results also suggest that not all 
individuals with overweight or obesity had poor sleep health. In fact, the majority of participants 
in that group had (independently of the other sleep health indicators) sufficient sleep duration, 
minimal sleep fragmentation, normal sSRI, no social jet lag and did not suffer from EDS.  
Other markers of poor cardiometabolic health, rather than obesity, may have a stronger association 
with poor sleep health. Based on the model by Lucassen et al. (2012), such markers may be that 
of inflammatory state, which may be identified with inflammatory markers such as interleukin (IL)-
6, C-reactive protein (CRP) and tumour necrosis factor (TNF)-⍺, and physical stress, which may 
be identified by measures of increased sympathetic nervous system activation, such as cortisol and 
decreased heart rate variability. These markers may be more suitable to identify participants who 
may benefit from sleep behaviour interventions than the ones used in the present study, namely 
overweight and obesity. Future research should explore which cardiometabolic health markers may 
be appropriate for identifying individuals who benefit from sleep behaviour interventions, and 
what the effect of sleep behaviour interventions on the cardiometabolic health of these individuals 
may be.  
The definition of indicators of poor sleep health in this thesis was based on recommendations and 
a consensus statement from the United States National Sleep Foundation (Hirshkowitz et al., 2015, 
Ohayon et al., 2017). However, these indicators do not define poor sleep health itself. While the 
indicators of poor sleep health used in this thesis may be used as a starting point, it must be 
explored whether these criteria may sufficiently stratify individuals based on their sleep health and 
consequences on overall health.  
Furthermore, more research is needed to better understand the causative relationship between 
poor sleep health and cardiometabolic impairment or adiposity. For example, it is not known 
whether the individuals with poor sleep in the OBII group of Chapter 3 had poor sleep before 
becoming overweight or obese, or whether these individuals had poor sleep because they had class 
II obesity. Likewise, it is not known whether those with poor sleep health in the OW-OBI are at 
risk for further weight gain and progression into class II obesity, or whether those with good sleep 
health in the OW-OBI group are protected against progression to class II obesity. By better 
understanding the causative relationship between cardiometabolic and sleep health, individuals 
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who may benefit from a sleep behaviour intervention may be identified at an earlier stage, before 
further deterioration of cardiometabolic or sleep health occurs.  
6.3 Conclusion 
In conclusion, preliminary evidence to suggest that a sleep behaviour intervention may improve 
cardiometabolic health in individuals who are at risk for CMD is available. Considerations for 
implementation of such interventions are 1) tailoring the format and content of the intervention 
for different target groups, 2) identifying individuals who may benefit from a sleep behaviour 
intervention, 3) screening for sleep disorders such as OSA, and 4) screening for psychological 
conditions that are precursors for poor sleep. Further research in this field is needed to determine 
how individuals who are at risk for CMD and who may benefit from a sleep behaviour intervention 
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